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Abstract 
 
 
Epstein-Barr virus (EBV) establishes lifelong latent infections in humans. EBV isolates 
worldwide are classified as type 1 or type 2 based on their EBNA-2 gene sequence. Type 1 
EBV is more efficient at B cell transformation, a property previously mapped to the EBNA-2 
locus. Previous work using EREB2.5 cells in a trans-complementation assay showed that the 
superior ability of type 1 EBNA-2 to sustain B cell proliferation is mostly determined by its 
C-terminal region. In this study, conversion of a single amino acid in the transactivation 
domain (TAD), from serine in type 2 EBNA-2 to the aspartate residue in the type 1 protein 
(S442D), was remarkably found to confer the type 1 growth-promoting phenotype in the 
EREB2.5 growth assay. The mechanism of the greater transformation efficiency of type 1 
EBV appears to involve differential regulation of EBNA-2 target genes. The superior growth 
properties of type 1 EBNA-2 correlate with the greater induction and activation of viral LMP-
1 and cellular CXCR7, compared to type 2 EBNA-2. 5 RACE was used to identify the 
transcription start site (TSS) of the CXCR7 promoter transcribed in response to EBNA-2. In 
chromatin immunoprecipitation (ChIP) assays, type 1 EBNA-2 was found to associate more 
strongly than the type 2 protein with EBNA-2 binding sites near the LMP-1 and CXCR7 
genes. D442 was shown to increase binding of type 2 EBNA-2 to some sites at differentially 
regulated genes. Unbiased motif searching identified an ETS-interferon regulatory factor 
(IRF) composite element (EICE) that closely resembles the sequence known to mediate 
EBNA-2 regulation of the LMP-1 promoter. This element may therefore confer the 
differential effects of type 1 and type 2 EBNA-2 on both LMP-1 and cell gene activation 
resulting in superior immortalisation by type 1 EBV. 
 
 
(287 words) 
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ICAM  intercellular adhesion molecule 
IF  immunofluorescence 
IFN  interferon 
Ig  immunoglobulin 
IL  interleukin 
IM  infectious mononucleosis 
IR  internal repeat 
IRF  interferon regulatory factor 
I-TAC  interferon-inducible T cell α-chemoattractant 
JNK  c-Jun N-terminal kinase 
K  lysine 
κ  kappa 
kb  kilobases 
KCl  potassium chloride 
kDa  kilo-Dalton 
KPB  potassium phosphate buffer 
KS  Kaposi’s sarcoma 
KSHV  Kaposi’s sarcoma-associated herpesvirus 
l  litre 
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LB  Luria Bertani 
LCL  lymphoblastoid cell line 
LCV  lymphocryptovirus 
LFA  lymphocyte function-associated antigen 
LiCl   lithium chloride 
LMP  latent membrane protein 
LP  leader protein 
M  marker 
M  molar 
μ  micro 
MACS  model-based analysis of ChIP-seq 
MAP  mitogen-activated protein 
MAPK  MAP kinase 
MCS  multiple cloning site 
μg  microgram 
MHC  major histocompatibility complex 
μl  microlitre 
MgCl2  magnesium chloride 
MgSO4 magnesium sulphate 
min  minute 
miRNA micro RNA 
ml  millilitre 
μl  microlitre 
mM  millimolar 
μM  micomolar 
mRNA  messenger RNA 
ms  millisecond 
MT  metallothionein 
N  glutamine 
N-terminus amino terminus 
NaCl  sodium chloride 
NaOH  sodium hydroxide 
NF-κB  nuclear factor kappa B 
(NH4)2SO4 ammonium sulphate 
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NK  natural killer 
NLS  nuclear localisation signal 
nm  nanometer 
NMR  nuclear magnetic resonance 
NPC  nasopharyngeal carcinoma 
nt  nucleotide 
o/n  overnight 
oct  octamer 
ORF  open reading frame 
OriLyt  origin of lytic replication 
OriP  origin of latent replication 
P  proline 
p/s  penicillin/streptomycin 
PBMC  peripheral blood mononuclear cell 
PBS  phosphate-buffered saline 
pBS  pBluescript plasmid 
PBS-T  PBS-Tween20 
PCR  polymerase chain reaction 
PFA  paraformaldehyde 
PI3K  phosphatidylinositol 3-kinase 
PMSF  phenol methyl sulfonyl fluoride 
PPIA  peptidylprolyl isomerise A 
PPR  poly-proline repeat 
PTCL  peripheral T cell lymphoma 
PTLD  post-transplant lymphoproliferative disease 
Qp  Q promoter 
qPCR  quantitative PCR 
R  arginine  
RACE  rapid amplification of cDNA ends 
RBP-Jκ recombination signal-binding protein J kappa 
RDV  rhadinovirus 
RG  arginine-glycine repeat 
RNA  ribonucleic acid 
RNAPII host cell RNA polymerase II 
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rpm  revolutions per minute 
RPMI  Roswell Park Memorial Institute 
RT  reverse transcription 
RT  room temperature 
RT-PCR reverse transcription-PCR 
RUNX  Runt-related protein 
s  second 
S  serine 
SAD  self-association domain 
sBL  sporadic BL 
SCID  severe combined immunodeficiency 
SDM  site-directed mutagenesis 
sDMA  symmetrically dimethylated arginine 
SDS  sodium dodecyl sulphate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SKIP  SKI-interacting protein 
SMN  survival motor neuron 
Stp  Saimiri transformation protein 
T  deoxythymidine 
T  threonine 
t  translocation 
T1  type 1 
T2  type 2 
TAD  transactivation domain 
TAF  TBP-associated factors 
TALEN transcription activator-like effector nuclease 
TBE  Tris-borate EDTA 
TBP  TATA-binding protein 
TBS  Tris-buffered saline 
TCID50 50% tissue culture infective dose 
TdT  terminal deoxynucleotidyl transferase 
TE  Tris-EDTA 
TEMED NNN’N’-tetramethylethylenediamine 
TF  transcription factor 
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TFII  transcription factor for polymerase II 
TNF  tumour necrosis factor 
TR  tandem repeat 
TRADD TNF receptor-associated death domain 
TRAF  TNF receptor-associated factor 
TRITC  tetramethylrhodamine isothiocyanate 
TSS  transcription start site 
U  unit 
UCSC  University of California Santa Cruz 
UL  unique long sequence 
US  unique short sequence 
UTR  untranslated region 
UV  ultraviolet 
V  volt 
v/v  volume:volume ratio 
VP  viral protein 
VZV  Varicella-zoster virus 
W  tryptophan 
WB  Western blotting 
Wp  W promoter 
w/v  weight:volume ratio 
XLPD  X-linked lymphoproliferative disease 
Y  tyrosine 
Zp  BZLF1 promoter 
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1 Introduction 
 
1.1 The Epstein-Barr virus 
 
1.1.1 The Epstein-Barr virus: discovery and the first candidate human 
tumour virus 
 
Denis Burkitt first described an endemic malignant lymphoma, which he suspected to be 
viral-associated, affecting children in equatorial Africa in 1958 [1, 2]. Anthony Epstein, 
Yvonne Barr and Bert Achong later used these tumour biopsies and successfully cultured 
lymphoma cells from them in 1964. Electron microscopy revealed the presence of 
herpesvirus-like particles in these lymphoma cells [3]. The Epstein-Barr virus (EBV) had 
been discovered and, due to its distinct characteristics, identified as a new member of the 
herpesvirus family [4]. Importantly, EBV from Burkitt’s lymphoma (BL)-cultured cells 
transformed resting B lymphocytes in vitro causing infected cells to continuously proliferate. 
The observation that EBV generated lymphoblastoid cell lines (LCLs) led to it being defined 
as a B lymphotropic oncogenic virus [5, 6].  
 
Due to its association with malignancy and Burkitt’s lymphoma (BL), EBV was classified as 
the first candidate human tumour virus. EBV has since been associated with a number of 
human malignancies which include Hodgkin’s lymphoma (HL), post-transplant 
lymphoproliferative disease (PTLD), X-linked lymphoproliferative disease (XLPD), 
peripheral T cell lymphoma (PTCL), nasal T or natural killer (NK) cell lymphoma, gastric 
carcinoma (GC) and nasopharyngeal carcinoma (NPC). These EBV-associated carcinomas 
demonstrate the ability of EBV to infect other cell types in addition to B lymphocytes, since 
they have been identified in T, NK and epithelial cells [7]. Overall, EBV is linked to 
approximately 1.5% of malignancies worldwide [8] and has also been associated with the 
benign disease infectious mononucleosis [9]. 
 
Despite a particular prevalence of BL in young children in equatorial Africa and New Guinea 
(endemic BL) where it is closely associated geographically with malaria and AIDS, BL also 
occurs in lower incidences throughout the world (sporadic BL) [10]. Similarly, EBV is not 
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restricted to the geographical region of its initial discovery. Rather, it has since been 
characterised as a ubiquitous gammaherpesvirus which infects virtually the whole human 
population (>95%). As EBV establishes a lifelong latent infection in the host B cell 
compartment, it is considered one of the most successful human pathogens. However, EBV 
remains benign in the majority of infected humans and tumour development is 
epidemiologically rare despite the association of EBV with many forms of cancer and its 
potent B lymphocyte transformation ability in vitro. 
 
The general mechanism by which EBV causes B lymphocyte growth involves the activation 
of proliferation pathways normally used by B cells in response to foreign antigens. Several 
EBV-encoded proteins, including EBNA-2, EBNA-3A and -3C and LMP-1, contribute to B 
cell transformation (reviewed in sections 1.3.1 and 1.2.4.3.2). In fact, EBNA-2 acts as a 
promiscuous transcriptional activator of viral and cellular genes that cause cell proliferation. 
The potential contribution of EBV and its genes to EBV-related cancers will be discussed in 
section 1.2.5. 
 
 
1.1.2 The Herpesviridae family  
 
EBV, also called human herpesvirus 4 (HHV-4), belongs to the Herpesviridae family. 
Together with Alloherpesviridae and Malacoherpesviridae families, Herpesviridae makes up 
the Herpesvirales order [11]. Herpesviridae infect mammals, reptiles and birds, while the 
relatively new Alloherpesviridae and Malacoherpesviridae infect fish and frogs, respectively 
[11]. 
 
Herpesviridae are a broad family of large, double-stranded DNA viruses that are further 
divided into three subfamilies (Alpha-, Beta- and Gamma-herpesvirinae) according to DNA 
sequence and biological properties (Figure 1.1). The Alphaherpesvirinae subfamily is 
characterised by a short reproductive cycle, a variable host range and a rapid spread in cell 
culture. Herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) and Varicella-zoster virus 
(VZV) are examples of human alphaherpesviruses. The Betaherpesvirinae subfamily has a 
host range restricted to mammalian hosts, a long reproductive cycle and slow infection in 
culture. Cytomegalovirus (CMV) and human herpesviruses 6 and 7 (HHV-6 and HHV-7) are 
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examples of betaherpesviruses that infect humans. The Gammaherpesvirinae subfamily is 
defined by a host range that is limited to the family or order to which the natural host 
belongs. These viruses replicate in lymphoblastoid cells in vitro, but can also do so in 
epithelial and fibroblast cells. Most gammaherpesviruses establish lifelong infections in their 
hosts and may have oncogenic effects resulting in the development of malignancies, although 
this is epidemiologically rare [12]. This subfamily is classified further into four genera: 
Lymphocryptovirus (LCV), Rhadinovirus (RDV), Macavirus and Percavirus. EBV is an LCV 
and is the only known human pathogen of this genus, whereas Kaposi’s sarcoma-associated 
herpesvirus (KSHV) is the only known human RDV [12, 13]. EBV strains are further 
subdivided into two broad families known as type 1 and type 2 (reviewed in section 1.4). 
 
The Herpesviridae family is known to contain approximately 140 herpesviruses [14], of 
which only 8 can infect humans (Figure 1.1). The majority of herpesviruses display narrow 
host specificity due to co-evolution of viruses with their hosts and some are even 
asymptomatic in their natural host [15]. For example, human herpesviruses can be 
asymptomatic in their natural host but can also cause cancer and life-threatening infections. 
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Figure 1.1. Herpesviridae taxonomy. Based on the classification of viruses by the International Committee on 
Taxonomy of Viruses (ICTV). 
 
 
1.1.3 The EBV particle and genome 
 
The EBV viral particle shares its overall general structure with all other herpesviruses. The 
linear double-stranded DNA (dsDNA) genome surrounds a protein core. This is enclosed by 
an icosahedral capsid, approximately 100-110 nm in diameter, formed by 12 pentavalent and 
150 hexavalent capsomeres. The nucleocapsid is surrounded by a protein tegument which 
includes viral and cellular proteins, such as actin, tubulin and heat shock proteins [13]. The 
EBV viral particle is completed by a lipid envelope which displays several viral 
glycoproteins (gp) on the outer surface. These are important for cell tropism and receptor 
recognition and include gp350/220, gH (gp85), gB (gp110), gp42 and gp150 [16]. 
 
Herpesviruses have large dsDNA genomes of between 125 and 290 kb [13]. The EBV 
genome consists of a single, linear, 172 kb dsDNA molecule that encodes approximately 85 
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protein-coding genes (including Epstein-Barr nuclear antigen 2, EBNA-2) [17] and several 
non-coding functional RNAs (EBER RNAs, BART miRNAs and BHRF1 miRNAs) (see 
section 1.2.4.3.1, Figure 1.3). It contains several identical 0.5 kb tandem terminal repeat (TR) 
sequences at both termini of the genome [18], a feature typical of gammaherpesviruses. 
Similar to other LCVs, the EBV genome also contains 4 to 8 major internal repeat (IR) 
sequences (unpublished data, PJ Farrell) of 3 kb which include the Wp latency promoters, 
and long and short unique sequences (UL and US) which contain almost the entire coding 
content of the genome [12]. The viral genome is present in a linear form in the virus particle 
but, upon EBV infection of B cells, it circularises in the cell nucleus via the TRs and becomes 
an episome [18]. 
 
The EBV genome was the first of all herpesviruses to be sequenced completely [17]. The 
B95-8 EBV strain was derived from a patient with infectious mononucleosis [19] and was 
later discovered to contain a 13.6 kb deletion which includes parts of the BamHI rightward 
transcript (BART) miRNAs. This region was sequenced from the Raji strain in 1990 [20] and 
additional minor corrections were reported more recently in 2003 [21]. Sequencing of the 
B95-8 strain was from a library of EcoRI and BamHI-digested fragments. Overlapping EcoRI 
and BamHI fragments were sequenced and assembled. The cloned restriction fragments were 
labelled alphabetically in order of their size, with A being the largest fragment. EBV genes 
were designated based on their BamHI fragment position and orientation of the reading 
frame. Therefore, EBV gene BARF1 is the first rightward open reading frame (ORF) starting 
in the largest BamHI (A) fragment. More recently, additional EBV strains have been 
sequenced. These include AG876, derived from an African BL cell line [22, 23], GD1, 
derived from LCLs made with the saliva of an NPC patient in China [24], GD2, a direct 
determination of EBV sequence from an NPC biopsy in China [25] and HKNPC1, another 
NPC biopsy in Hong Kong [26]. A further eight EBV genomes from NPC biopsies of the 
same geographic location (HKNPC2 to HKNPC9) have been determined using target 
enrichment of EBV DNA by hybridisation, followed by next-generation sequencing 
techniques, de novo assembly and conventional Sanger sequencing to join contigs [27]. 
 
Several EBV genes show a high degree of sequence homology with genes of other 
herpesviruses, including genes encoding lytic cycle proteins involved in viral DNA 
replication and packaging, and viral particle structure [12]. Other EBV genes are conserved 
in gammaherpesviruses only, such as those that encode the latent proteins LMP-1 and LMP-
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2A, and the immediate early regulators of lytic viral gene expression BZLF1 and BRLF1 
[12]. Some EBV genes even show similarities to cell genes. For example, BHRF1, BCRF1 
and BZLF1 are similar to BCL-2, IL-10 and c-FOS respectively [28-30], and EBNA-2 is to 
some extent a functional homolog of the intracellular part of the Notch receptor [31,32]. 
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1.2 The EBV life cycle 
 
1.2.1 Primary infection 
 
EBV infection usually occurs in early childhood leading to a lifelong, and in most cases, 
asymptomatic latent infection where the virus persists in the host memory B lymphocyte pool 
in 1 out of 10
5
-10
6
 cells [7]. Persistent infection is not exclusively limited to B cells; some T, 
NK and epithelial cells can also be infected by EBV. Although usually sub-clinical, primary 
EBV infection may cause the benign self-limiting lymphoproliferative disease infectious 
mononucleosis (IM) [33] if it is delayed until adolescence or adulthood [9]. Symptoms 
include pharyngitis, fever and lymphoadenopathy due to a strong host T cell response to the 
viral infection [9]. Furthermore, different NK activity against EBV may determine why adults 
get IM but children do not [34]. 
 
B cells and epithelial cells are important targets in the EBV life cycle. The virus is primarily 
transmitted through saliva although it can also be acquired from blood and transplanted 
hematopoietic cells or organs [35]. Primary EBV infection occurs in the mucosal tissues of 
the oropharynx where virus, transmitted orally, establishes lytic replication in the epithelial 
cells. At the same time, a latent infection is also established as virus begins to colonise the B 
cell compartment. It is still unclear whether the initial target of infection is an epithelial cell 
or a naive B cell of the Waldeyer’s ring of the tonsils. Faulkner and colleagues proposed a 
dual tropism model for the mechanism of primary EBV infection at oropharyngeal sites [36]. 
According to this model, EBV initially infects resting naive B cells in the Waldeyer’s rings. 
As the lymphoepithelium forms crypts which penetrate into the lymphoid tissue beneath, the 
infected B cells come into close proximity with, and can therefore transfer virus to, squamous 
epithelial cells. Here, the virus can replicate further and new viral progeny are released to 
infect new naive B cells of the same carrier or a new host. Alternatively, EBV could initially 
infect epithelial cells of the oropharynx, from which the viral population is amplified and 
establish a persistent infection in the nearby naive B cells [36]. This dual tropism model of 
EBV infection is supported by in vitro studies which showed that EBV particles shed from 
epithelial cells infect B cells more efficiently, and EBV released from B cells infects 
epithelial cells more efficiently [37]. 
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Other studies have shown that EBV infection of epithelial cells in vitro is inefficient and that 
EBV is rarely detected in epithelial cells of IM patients and healthy carriers [38-41]. 
Furthermore, epithelial cells were found to be infected in vitro more efficiently by virus-
producing B cell lines than by cell-free virus particles [38]. Patients with X-linked 
agammaglobulinaemia who lack mature B cells were not infected with EBV, further 
indicating the B cell requirement for productive EBV infections [42]. These findings suggest 
that B cells may be the initial site of EBV infection. However, B cells can dramatically 
enhance epithelial cell infection in vitro. Experiments demonstrated that epithelial cells could 
be infected with virions that were bound to the B cell surface and that gp42 was not required 
for B cell entry [42]. EBV remained attached to the B cell surface for up to 2 days and could 
form B cell-epithelial conjugates by infecting epithelial cells within 10 minutes. B cells were 
proposed to act as a transfer vehicle for EBV infection of epithelial cells that was dependent 
on EBV gH and gB, involved in epithelial fusion and penetration [42], and restricted to the 
basolateral surface of the epithelial cells [43]. However, recent characterisation of M81 EBV 
from an NPC biopsy found it was more efficient at infecting epithelial cells than the B95-8 
strain [44] and this type of variation may affect interpretation of some of the experiments 
described above. 
 
Although the role of the oropharyngeal epithelium in primary EBV infection remains unclear, 
EBV is clearly important in several epithelial malignancies as the virus is consistently 
detected in malignant epithelial cells of NPC, gastric carcinoma (GC) and oral hairy 
leukoplakia AIDS patients [39, 45, 46]. 
 
 
1.2.2 Attachment and cell entry 
 
B lymphocyte infection with EBV is initiated by attachment of the major viral envelope 
glycoprotein gp350/220 to the CD21 surface receptor, also known as complement receptor 2 
(CR2) [47, 48]. The interaction between CD21 and gp350/220 is followed by CD21 receptor 
aggregation in the plasma membrane of B cells resulting in CD19 tyrosine phosphorylation. 
In turn, the signal-transducing enzyme phosphatidylinositol 3-kinase (PI3K) is recruited and 
NF-κB activated [49]. This culminates in B cell activation and cell cycle entry [49, 50]. A 
complex of many glycoproteins (including gH, gL and gp42) is required for virion entry into 
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B cells [51]. The EBV gHgL complex is essential for B cell penetration as they mediate viral 
envelope and cell membrane fusion, and gB is thought to be involved in these processes [51, 
52]. 
 
Virus internalisation and cell entry is also triggered by the interaction between the EBV 
envelope glycoprotein gp42 and the human leukocyte antigen (HLA) class II, which acts as a 
co-receptor for EBV [53]. Viral capsids are subsequently released into the cytoplasm and 
transported to nuclear pores on microtubules [54]. Although linear in the virion, the viral 
genome circularises when translocated to the nucleus and is maintained as a covalently-
closed extrachromosomal episome [12]. 
 
In contrast to B cells, epithelial cells do not express the CD21 receptor and HLA class II 
molecules and therefore gp350/220 and gp42 are not required for viral entry [55]. EBV 
infection of epithelial cells is instead mediated by gHgL heterodimers, which interact with 
integrins and are required for attachment and entry [56]. Although the epithelial cell EBV 
receptor has not yet been identified [57] it is known that gB is also required and mediates the 
fusion process [58]. This mechanism of viral entry into epithelial cells is further supported by 
the observation that virions lacking gp350/220 have improved epithelial cell infection 
efficiency [42]. Recently, EBV was reported to be able to infect organotypic cultures of 
epithelial cells in vitro, establishing a predominantly productive infection [59], and this will 
enable a mechanistic investigation of EBV infection in the stratified epithelium. 
 
EBV virions express three-part gHgLgp42 and two-part gHgL complexes, enabling them to 
infect B cells and epithelial cells [57]. The ratio of these complexes defines the tropism of the 
virus. For example, EBV particles originating from epithelial cells express more three-part 
gp42-containing complexes and favour infection of HLA class II-positive B cells, whereas 
those that originate from B cells preferentially express the two-part gHgL complexes, 
enabling infection of HLA class II-negative epithelial cells. This modification of glycoprotein 
complex ratios explains the switch in EBV tropism [37] and further supports the dual tropism 
model of EBV [36] (reviewed in section 1.2.1). 
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1.2.3 Lytic infection 
 
Like all herpesviruses, EBV has a life cycle characterised by lytic and latent phases. EBV 
persists in a latent state, where viral replication is suppressed and the virus is dormant, but 
can reactivate to enter the lytic phase. During lytic infection, the virus replicates which results 
in the production of new infectious viral particles and completion of the viral life cycle. New 
viral progeny can infect other naive B cells in the same host, or be shed through the saliva to 
infect a new host and ensure viral spread and survival. Reactivation of EBV from the latency 
phase has been observed in antibody-secreting plasma cells of healthy carriers [60, 61], 
indicating that lytic cycle induction is coupled to the B cell maturation pathway of memory 
cells into terminally-differentiated plasma cells upon antigen recognition. These plasma cells 
are located in the tonsil epithelia which allow for easy access and transmission of new EBV 
virions to new hosts [62]. The observation that some healthy carriers shed virus continuously 
[63] could be explained by virus release from B cells which then infects epithelial cells 
resulting in plaques of EBV-infected epithelia. 
 
Genes expressed during the lytic cycle are defined as immediate early, early and late lytic 
genes [12]. The major immediate early genes that are involved in lytic cycle induction are 
BZLF1 and BRLF1. BZLF1 is the master regulator of this process as it can induce the switch 
from latency to lytic phase alone [64]. BZLF1 codes for a bZIP sequence-specific 
transcription factor (TF) which has some sequence similarity to c-FOS and C/EBP [30], and 
transactivates several viral and cellular genes in addition to its own expression [65]. BZLF1 
also activates expression of BRLF1, another TF which functions as the second major 
regulator of lytic cycle initiation [66]. 
 
In vitro models of EBV reactivation from latency indicate that BZLF1 and BRLF1 expression 
is triggered by signal transduction through the B cell antigen receptor (BCR) [65, 67]. Only 
BZLF1 responds directly to BCR signal transduction, thus initiating BRLF1 expression and 
early lytic genes [68]. In vivo, the signals that normally drive B cell maturation from memory 
into plasma cells, such as specific antigen recognition which induces an immune response, 
are also thought to cause EBV reactivation from latency. This model is supported by the cell 
transcription factor XBP-1 which plays a key role in memory B cell differentiation into 
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plasma cells [69] and also contributes to Zp promoter regulation from which BZLF1 is 
expressed [70]. 
 
BZLF1 and BRLF1 trigger other immediate early and early genes to drive viral DNA 
replication. This process is mediated by BZLF1 and requires the lytic origin of replication 
(oriLyt) [12]. Late genes are subsequently expressed leading to synthesis of viral structural 
proteins (capsid, tegument and glycoproteins). Replicated viral DNA is packaged into capsids 
in the cell nucleus which bud through the nuclear membrane to form cytoplasmic vesicles 
that contain enveloped virus. These vesicles fuse with the cell plasma membrane and newly-
formed viral particles are released by exocytosis [12]. 
 
 
1.2.4 Latent infection 
 
1.2.4.1 EBV latent infection in vivo 
 
A characteristic of all herpesviruses is their ability to establish and maintain latent infection. 
The primary target for EBV latency in vivo and the long-term reservoir for the virus in the 
host is the B cell pool. EBV persists in a quiescent state in (approximately 1 of every 10
5
-10
6
) 
resting memory B cells circulating in the blood. A model for the colonisation of the B 
lymphocyte system by EBV in vivo was proposed by Thorley-Lawson [71]. EBV is thought 
to gain access to and persist in the long-term memory B cell compartment by following the 
normal differentiation route of B cells (Figure 1.2). 
 
In normal immune responses, naive B cells are efficiently activated to become B blasts when 
the B cell receptor (BCR) binds to antigen, and CD40L, on the surface of antigen-specific T 
helper cells, binds to B cell CD40 [72]. Once activated, B blasts migrate to germinal centres 
(GCs) of lymph follicles where they undergo strong proliferation, class switch recombination 
and hypermutation of the immunoglobulin (Ig) chain and clonal selection [73]. B cells that 
produce high affinity antibodies differentiate into memory B and plasma cells in the 
peripheral circulation [72]. According to the Thorley-Lawson model, this B cell 
differentiation pathway is exploited by EBV to gain access to the memory B cell pool and 
persist lifelong [71]. 
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In this model, EBV latently infects resting naive B cells found in the Waldeyer’s ring of the 
tonsils and drives their proliferation as activated B blasts that have a cell surface phenotype 
and morphology similar to those of antigen-activated B cells [74]. These B blasts express all 
EBV latent genes and display latency III infection or growth programme (Table 1.1). EBV 
mimics the normal immune response by expressing two latent membrane proteins (LMPs). 
LMP-1 acts as a functional homologue of CD40 and binds to T helper cell CD40L, and LMP-
2A mimics a constitutively-active BCR [75, 76]. Latent EBV gene expression causes 
activation of B cells that subsequently proliferate to expand the number of infected B blasts 
[74, 77] (Figure 1.2). This expansion time is only short, given that the virus must establish 
latent infection to avoid a strong cytotoxic T cell response. Virus-activated B blasts then 
migrate to the germinal centres (GCs) where a more restricted latent gene expression 
programme is established (latency II infection or default programme; Table 1.1) (Figure 1.2). 
EBV-infected B blasts in the GC only express the LMPs and the EBNA-1 protein to provide 
cell survival signals and to maintain the viral genome respectively [78-80] (Figure 1.2). 
Consistent with physiological maturation of B cells from centroblasts to centrocytes, EBV-
infected B blasts undergo further clonal expansion to increase the infected cell pool size and 
Ig gene rearrangement via somatic hypermutation and isotype switching. The LMPs further 
mimic foreign antigens to drive differentiation and migration of B cells in the GC to the 
memory compartment [75, 76]. EBV-infected memory B cells undergo a further shutdown of 
viral gene expression, such that none of the latent viral proteins are expressed (latency 0 
infection or latency programme; Table 1.1) (Figure 1.2). This expression pattern is thought to 
enable EBV-infected memory B cells to evade detection by the immune system and allow 
lifelong persistence of the virus in the host [71, 81]. The EBV genome is not transcriptionally 
silent in the latency programme however as multiple viral transcripts including BART 
miRNAs and EBERs are expressed in the memory B cells [81, 82] (Figure 1.2). Although 
occasional division of latently-infected memory B cells is driven by normal memory B cell 
homeostasis and not the virus [71], EBNA-1 is expressed to allow viral DNA replication 
(latency I infection or EBNA-1 only transcription progamme; Table 1.1) [81] (Figure 1.2). 
Occasionally, memory B cells return to the Waldeyer’s ring of the tonsils and are 
differentiated into plasma cells, thought to signal initiation of the lytic cycle [61]. New viral 
particles can then infect new naive B cells or be shed in the saliva and transmitted to a new 
host [61, 71] (Figure 1.2). 
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Figure 1.2. EBV latent infection in vivo exploits the normal B cell differentiation pathway. EBV acts as a 
benign parasite of B cells. It is transmitted through saliva and crosses the epithelial barrier to infect naive B cells 
in the Waldeyer’s ring of tonsils. Expression of the growth programme (latency III) enables EBV to activate 
infected B cells and drive them to proliferate strongly and differentiate into B blasts. These cells migrate to the 
germinal centre (GC) before differentiating further into memory B cells. The B cell differentiation process 
occurs with a successive shutdown of latent EBV gene expression – from growth programme (latency III) in 
activated B blasts, to default programme (latency II) in GC B cells and finally latency programme (latency 0) in 
memory B cells. No viral proteins are expressed in latency 0 but EBNA-1 is expressed when memory B cells, 
although rare, divide (latency 1). EBV finds the perfect niche in resting memory B cells as it can evade immune 
system detection and persist lifelong in the host. Memory B cells can re-enter the tonsils and differentiate into 
plasma cells to initiate the lytic cycle. New viral particles are produced and shed into the saliva ready for 
transmission to a new host. Adapted figure from [83] and redrawn with all EBV latency genes shown. 
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Table 1.1. Latency stages and transcription programmes during latent EBV infection in vivo and their 
EBV-associated lymphomas. 
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1.2.4.2 Latent gene expression patterns in vivo 
 
EBV can establish a number of alternative forms of latent infection in B cells, termed latency 
0, I, II and III [84, 85] (Table 1.1). Other cell types, however, usually support only the more 
restricted latent gene expression patterns seen in latency I and II [85, 86]. Each latency type is 
characterised by a specific gene expression pattern which is observed in the different stages 
of EBV infection in vivo and in several EBV-associated malignancies. These observations 
support the view that EBV-linked malignancies are tightly coupled to a specific stage of the 
pathway for normal B cell differentiation. 
 
In latency III, also termed the growth programme, all six nuclear antigens (EBNA-1, -2, -3A, 
-3B, -3C and -LP) are expressed from the EBV W and C promoters. The three latent 
membrane proteins (LMP-1, -2A and -2B), the family of spliced polyadenylated BamHI A 
rightward transcripts (BARTs), several miRNAs and two small non-polyadenylated and non-
coding RNAs, termed EBERs, are also expressed (Table 1.1) (Figure 1.3). Although 
previously regarded as a gene product of the lytic cycle, low-level expression of the BCL-2 
homologue BHRF1 has recently been associated with latency III infection [87]. Latency III 
expression pattern is displayed in EBV-transformed LCLs in vitro (see section 1.2.4.3), in 
newly-infected naive B cells in vivo [74, 77] and in EBV-associated lymphomas of 
immunocompromised patients [71, 88] (Table 1.1). 
 
In latency II, also termed the default programme, EBNA-1, LMPs, EBERs and BARTs are 
expressed [71, 85, 86]. Interestingly, the genome maintenance protein EBNA-1 is expressed 
from the Q promoter (Qp) as Wp and Cp are transcriptionally silenced resulting in no other 
EBNA expression [71, 81, 84, 85, 89-91]. The expression pattern of latency II is found in 
Hodgkin’s lymphoma (HL) and in undifferentiated nasopharyngeal carcinoma (NPC), T-cell 
lymphomas and gastric carcinomas (GC). This expression profile is also seen in germinal 
centre B cells of the host [78, 81, 85] (Table 1.1). 
 
Other EBV-associated malignancies have been detected in more restrictive forms of EBV 
latency. For example, EBV-positive Burkitt’s lymphoma (BL) displays a latency I pattern of 
gene expression, where only EBERs and BARTs are transcribed, together with EBNA-1 from 
the Qp. This latent gene expression profile is observed in memory B cells that divide in the 
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host [78, 81, 85] (Table 1.1) and is also referred to as the EBNA-1-only transcription 
programme. 
 
Another form of restricted viral latency associated with over 15% of endemic BL (eBL) cases 
has recently been identified [92]. In this latency type, all EBV latent proteins are expressed 
with the exception of EBNA-2 and the LMPs. Lack of EBNA-2 expression is due to deletion 
of the gene from the viral genome. All other EBNAs are expressed from the Wp, not the Qp, 
so that this latency type is termed “Wp restricted” and cannot therefore drive transcription at 
the LMP promoters. Importantly, the viral homologue of cellular anti-apoptotic BCL-2, 
BHRF1, is also expressed and confers a survival advantage to these tumour cells [92]. All 
three types of latent infection can be established in B cells but other cell types support only 
the more restricted latent gene expression patterns (latency I or II) [49]. In order to initiate the 
latency III expression profile in a cell type specific way, EBV exploits the B cell-specific 
transcription factor BSAP/Pax5 for activation of the Wp promoter, driving the expression of 
all EBNA and LMP proteins in B lymphocytes [93]. 
 
1.2.4.3 EBV latent infection in vitro 
 
1.2.4.3.1 Primary B lymphocytes are transformed into lymphoblastoid cell lines (LCLs) 
upon latent EBV infection in vitro 
 
EBV has the unique ability to infect primary B lymphocytes in vitro and transform them into 
latently-infected, continuously-proliferating lymphoblastoid cell lines (LCLs) [5]. LCLs are 
the in vitro model system most widely used to study EBV infection and the functions of latent 
viral proteins. EBV infection of primary B lymphocytes in vitro results in 3-10% of cells 
being transformed into LCLs [12]. Although viral replication is not detectable in LCLs, the 
virus retains the ability to replicate upon reactivation [12]. EBV-transformed LCLs carry 
multiple copies of the viral genome as episomes and display a latency III pattern of gene 
expression [85] (Table 1.1) which maintains latent infection and induces continuous 
proliferation of cells [12]. They are characterised by the expression of six EBV nuclear 
antigens (EBNA-1, EBNA-2, EBNAs-3A, -3B and -3C and EBNA-LP) [94, 95] as well as 
three latent membrane proteins (LMP-1, LMP-2A and LMP-2B). EBV-LCLs also express 
BART and BHRF1 miRNAs and EBERs [12, 96]. 
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Initial events of viral infection, including virus attachment, penetration and host cell entry 
(see section 1.2.2), are followed by uncoating and delivery of the viral episome to the host 
nucleus where the EBV genome circularises 12-16 h post-infection [12]. Host cell RNA 
polymerase II (RNAPII) drives transcription from the W promoter (Wp) (Figure 1.3) 
generating transcripts of the first latent gene products EBNA-2 and EBNA-LP [96-98]. 
EBNA-2 and EBNA-LP proteins are detected within 12-24 hours of infection and EBNA-2 
reaches a maintained expression level in LCLs by 24-32 hours post-infection [96]. In 
cooperation with EBNA-LP, EBNA-2 then acts as a potent transcriptional activator of the 
upstream C promoter (Cp) (Figure 1.3), leading to the expression of a single transcript that is 
alternatively spliced to generate mRNAs for all other EBNAs [12, 99-103]. Promoter 
switching occurs as Cp assumes transcriptional control of the viral genome by shutting down 
the Wp [104, 105]. EBNA-2 also activates two other viral promoters, LMP-2A and the 
bidirectional LMP-1/-2B promoter [106-110] (Figure 1.3) in addition to many cellular genes 
involved in B cell survival and proliferation [111-113]. EBNA-LP cooperates with EBNA-2 
to enhance promoter activation of some of these genes [114-120]. EBNA-1, -3A, -3B and -3C 
and LMP-1, -2A and -2B reach steady state levels of expression in LCLs between 48 and 72 
hours after infection [96]. EBNA-1 binds to the plasmid origin of replication (OriP) (Figure 
1.3) and to chromosomes to ensure that progeny cells receive a viral episome. EBNA-1 also 
regulates enhancer elements within the OriP region (Figure 1.3) to activate Cp and LMP-1 
promoters with EBNA-2 and EBNA-LP and increases transcription of the latent proteins 
[104, 121, 122]. In fact, mutational analysis demonstrated that Cp is activated by EBNA-1 
[123]. EBNA-3s, however, compete with EBNA-2 for RBP-Jκ, the host EBNA-2-Cp 
tethering factor, to limit EBNA-2-induced Cp transcription [124, 125]. The LMP-2A 
promoter is stringently controlled by EBNA-2 [110, 126], whereas the LMP-1/-2B 
bidirectional promoter is regulated by EBNA-2, EBNA-LP and EBNA-3A [107, 108, 115, 
116, 127]. Expression of two small, non-polyadenylated RNAs (EBERs) is delayed relative 
to other latency genes, only beginning 36 hours post-infection before reaching constant 
expression levels at approximately 70 hours after infection [96]. 
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Figure 1.3. The EBV genome showing genes important in latency. The locations of the six nuclear antigens 
(EBNA-1, -2, -3A, -3B, -3C and -LP), the viral BCL-2 homologue (BHRF1), the BART cluster and the three 
latent membrane proteins (LMP-1, -2A and -2B) coding exons are shown. The repeated W0, W1’, W1 and W2 
EBNA-LP coding exons are located within the BamHI W internal repeat (IR1) region marked by the grey box 
and the unique Y1 and T2 EBNA-LP exons are downstream. The latent origin of replication (OriP) and the 
joined terminal repeats (TR) are also displayed at the terminus. Arrows indicate the direction of Cp, Wp, Qp, 
LMP2Ap and LMP1p/LMP2Bp bidirectional promoters. 
 
 
Viral protein expression rapidly triggers cells to enter the cell cycle and proliferate. EBNA-2, 
in cooperation with EBNA-LP, induces the G0 to G1 cell cycle transition, marked by cyclin 
D2 upregulation [114]. DNA synthesis begins at between 48 and 72 hours post-infection and 
this is followed by continuous proliferation with a doubling every 20-30 hours [12]. 
Telomeres progressively shorten with each cell division and reach a critical length when, 
after approximately 100-150 doublings, cells undergo a crisis and many die. Cells that 
stabilise their telomeres and upregulate telomerase activity however grow out as 
immortalised cell lines [128, 129]. The previously small-sized resting primary B cells 
undergo dramatic phenotypic changes upon EBV infection in vitro, becoming large and 
irregularly-shaped. The established LCLs express high levels of B cell activation markers, 
such as CD23, CD30, CD39 and CD70, and the cell adhesion molecules LFA1, LFA3 and 
ICAM1 [12, 84, 89, 130] which are typical for activated B cells [12, 84]. These markers 
explain the clustering phenotype of LCLs in tissue culture which closely resembles that of 
naive B cells stimulated with IL-4, anti-CD40 or antigen [12]. Since LCLs and B blasts both 
express the growth programme (latency III) and proliferate rapidly, it is clear that B cell 
infection in vitro closely resembles the early stages of infection of B cells in vivo. LCLs are 
therefore a very useful in vitro model to investigate the initial stages of B cell infection and 
transformation. 
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1.2.4.3.2 Latent EBV genes involved in B cell immortalisation in vitro 
 
Recombinant EBV viruses lacking specific latent genes have made it possible to study the 
role of individual latent EBV genes in B cell transformation in vitro (summarised in table 
1.2). EBNA-2, LMP-1 and EBNA-3C are absolutely required for B cell transformation by 
EBV [75, 131-135]. Recombinant EBVs with translation stop codons inserted by second-site 
homologous recombination in the P3HR1 genetic background have shown EBNA-3A to be 
essential [135]. However, a bacterial artificial chromosome (BAC)-derived B95-8 EBV strain 
with a EBNA-3A deletion was demonstrated to transform B lymphocytes into LCLs in vitro, 
albeit with a reduced efficiency relative to wildtype [136]. In contrast, EBNA-3B is 
dispensable for EBV infection and transformation of B lymphocytes [135, 137, 138] and 
functions as a tumour suppressor gene [139]. EBNA-3C plays a key role in repression of 
p16(INK4a) [140] which allows primary B lymphocyte proliferation upon EBV infection and 
transformation into LCLs [141]. Indeed, in cells that are p16(INK4a)-null, EBNA-3C is 
dispensable for LCL outgrowth [141], indicating that p16(INK4a) is the target of EBNA-3C. 
A recent report has shown that EBNA-3C-mediated BIM repression is also likely to be 
important for B cell immortalisation and LCL establishment [142]. EBNA-1 mediates the 
binding of EBV OriP to mitotic chromosomes, enabling the maintenance of the viral genome 
as an episome in proliferating cells [143, 144]. EBNA-LP, although not absolutely required, 
can improve the outgrowth of virus-infected B cells [131, 145]. LMP-2 is also non-essential 
as recombinant EBV viruses which lacked the LMP-2 genes (due to marker gene insertion) 
were demonstrated to be as efficient as wildtype in B cell immortalisation in vitro [146-150]. 
This has been challenged by two reports which used mini-EBV plasmids (E. coli constructs 
that contain the minimal EBV sequences sufficient for B cell transformation), and BAC-
derived EBV recombinant viruses to show that LMP-2 improves efficiency of B cell 
immortalisation [151, 152]. Similarly, EBER2 was reported as required for B cell 
transformation and LCL outgrowth in the recombinant Akata EBV background [153], but 
other studies performed in the P3HR1 and B95-8 EBV genetic backgrounds have shown 
EBER2 not to contribute to B cell transformation [154, 155]. Another RNA species, the 
BHRF1 miRNA cluster, was knocked out in a recombinant virus which was found to display 
a 20-fold decrease in transformation ability compared to the wildtype, indicating its 
importance to B cell immortalisation by EBV [156]. 
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Therefore, EBNA-2, LMP-1, EBNA-3A and EBNA-3C are also essential for the maintenance 
of the continuously-proliferating EBV-LCLs. This was also demonstrated in B cell lines 
using mini-EBV plasmids with EBNA-2 or LMP-1 genes, or by primary B cell 
transformation assays with recombinant viruses that expressed conditionally-active EBNA-
3A or -3C proteins [75, 134, 157, 158]. However, earlier EBNA-3A studies used primary B 
cell transformation assays with mini-EBV plasmids and showed that it is not required for 
maintenance of cell proliferation although it provides a selective advantage to proliferating 
cells [159]. Therefore, the exact role of the latent EBV genes EBNA-3A, LMP-2A and -2B, 
and EBERs in B cell transformation and cell proliferation maintenance is yet to be 
determined. The use of different systems for recombinant EBV genetic analysis may explain 
the contradictory results previously reported in these studies. The role of EBNA-2 in B cell 
transformation will be discussed further in section 1.3.1. 
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Table 1.2. Latent EBV genes and their role in B cell immortalisation. 
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1.2.5 The role of EBV in human cancers 
 
Consistent with its growth-transforming properties, EBV is associated with approximately 
1.5% of all human cancer cases worldwide and contributes to the development of a number of 
lymphoid and epithelial malignancies. These include Burkitt’s lymphoma (BL), Hogkin’s 
lymphoma (HL), post-transplant lymphoproliferative disease (PTLD), X-linked 
lymphoproliferative disease (XLPD), peripheral T cell lymphoma (PTCL), nasal T or natural 
killer (NK) cell lymphoma and the epithelial malignancies gastric carcinoma (GC) and 
nasopharyngeal carcinoma (NPC) [8, 12, 160, 161]. Moreover, these EBV-associated 
malignancies occur in specific stages of the B cell differentiation pathway further supporting 
the model of EBV persistence in vivo proposed by Thorley-Lawson [71] (Table 1.1). 
 
PTLD arises in immunosuppressed patients after transplantation and 90% of these 
lymphomas are EBV-positive. Since they express the EBV growth programme (latency III) 
and therefore closely resemble in vitro EBV-LCLs, PTLD lymphomas are thought to arise 
from EBV infection of naive B cells causing them to proliferate under the influence of the 
growth programme [88]. Due to the impaired cytotoxic T lymphocyte (CTL) response in the 
immunosuppressed host, the EBV-infected lymphoblasts grow uninhibited and do not 
differentiate into resting memory B cells. To become more tumourigenic than EBV-LCLs 
and give rise to a lymphoma, proliferating lymphoma cells must acquire additional mutations 
[71]. Alternatively, non-naive bystander B cells, such as germinal centre or memory B cells 
that become infected with EBV, have also been suggested as the source of PTLD if the CTL 
response is suppressed [71, 162]. 
 
The role of EBV in tumours such as BL and HL that arise in immunocompetent hosts is less 
clear since many of the viral genes essential for LCL proliferation in vitro (see section 
1.2.4.3.2) are not expressed in malignant cells. In some regions worldwide, EBV-positive BL 
tumours are extremely common, reaching up to 98% in endemic areas [163]. However, EBV-
positive BL cells lack expression of the growth-promoting latent proteins as they display the 
latency I programme of gene expression and so the role of EBV in the development of BL is 
not well understood. A feature common to all BL malignancies is the chromosomal 
translocation of the c-MYC proto-oncogene into the Ig gene loci, believed to occur during Ig 
class switching in the germinal centre (GC) B cell, mediated by the RNA editing enzyme 
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activation-induced cytidine deaminase (AID) [164]. This results in constitutive increased 
expression of the c-MYC protein typically found in BL cells and contributes to their high 
level of proliferation [165-167]. Despite this normally leading to apoptotic cell death, it is 
thought that exposure to the EBV growth programme prior to GC entry [71, 142] or to the 
EBV default transcription programme in the GC [168, 169], is sufficient to convey resistance 
to c-MYC-induced apoptosis. The EBV-positive BL cells that display the latency programme 
(latency I) are similar to rarely-dividing memory B cells in the peripheral circulation. EBV-
positive BL cells also have the same Ig gene hypermutations found in memory B cells [170] 
but have the cellular phenotype of GC B cells [171]. Taken together, these observations 
suggest that BL might arise when c-MYC gene translocation in an EBV-infected GC B cell 
causes it to proliferate uncontrollably rather than differentiate into a memory B cell [71]. In 
addition to c-MYC translocation, BL cells sometimes contain genetic mutations of the p53 
and RB pathways [172, 173] which may contribute to BL pathogenesis. In fact, in a recent 
study in which over 40 BL patient biopsies were sequenced, mutations in the TCF3 and its 
negative regulator ID3 genes were identified in 70% and 40% of sporadic BL (sBL) and 
endemic BL (eBL) cases respectively [160]. The TCF3 direct target CCND3 which encodes 
cyclin D3 was also found to be mutated frequently increasing protein stability in sBL (38%) 
but not in EBV-associated eBL (just 1.8%) [160]. These data suggest a central role for Akt 
phosphorylation and the mTOR pathway in BL pathogenesis. Therefore, EBV may expand 
the pool of EBV-infected lymphoblasts (which initially express EBNAs and LMPs in latency 
III) and are at risk of c-MYC translocation, and subsequently ensure survival and 
proliferation of translocation-positive cells. Rather than promote proliferation, EBV might 
protect BL cells from deregulated c-MYC-induced apoptosis. As described above (see section 
1.2.4.3.2), EBNA-3C represses BIM [142] which is otherwise activated by the c-MYC 
translocation to induce apoptosis. The mechanism of this protection might also involve a 
more restricted form of EBV latency as some EBV-positive clones that express a restricted 
EBV gene profile have a slight protection against apoptotic triggers when compared to EBV-
negative BL clones [174, 175]. Moreover, when transfected into BL cell lines, EBNA-1 and 
EBERs confer resistance to apoptosis [176, 177]. In addition, BHRF1 and EBNA-3s have 
been shown to elicit an anti-apoptotic effect in Wp-restricted BL cells [87, 175, 178]. The 
incidence of P. falciparum malaria and eBL are closely linked geographically and this 
association has recently been investigated. P. falciparum has been shown to deregulate AID 
expression enhancing the risk of c-MYC translocation, and to increase the number of B cells 
that transit the GC and that are infected with EBV protecting them from c-MYC-induced 
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apoptosis [179]. Therefore, the immunosuppressive effect of P. falciparum malaria [180] may 
lead to a higher viral burden of EBV in the eBL population [179, 181, 182]. 
 
Approximately 40% of all HL cases are EBV-positive. Similar to latently-infected GC B 
cells, Reed-Sternberg tumour cells express the latency II programme [183] and have 
extensively hypermutated Ig genes [184] indicating that these EBV-positive HL cells arise 
from an EBV-infected GC B cell. The viral membrane proteins LMP-1 and LMP-2 are 
thought to have a critical role in the survival of Reed-Sternberg tumour cells where they are 
highly expressed. In addition, it is believed that further mutations that block GC B cell 
differentiation into memory B cells must also accumulate for a HL tumour to develop from 
an EBV-infected GC B cell [71]. Furthermore, it was also reported that genomic translocation 
of the MHC class II transactivator (CIITA) occurs with high frequency in HL [185]. A role 
for the B cell receptor (BCR) which supplies cell survival signals has recently been proposed. 
BCR-less or crippled GC B cells that were infected with EBV were found to establish LCLs, 
approximately 50% of which did not express surface Ig mainly due to posttranscriptional 
defects [186]. Also, very few BCR-crippled GC-LCLs showed significant hypermutation 
activity [187]. These data strongly support the idea that EBV infection rescues BCR-deficient 
GC B cells from apoptosis, silences hypermutation and renders the cells independent from 
survival signals normally supplied by BCR [186, 187]. 
 
EBV is also associated with epithelial malignancies and is present in almost all cases of NPC. 
In 80% of NPC cases, LMP-1 is detected and found to support EBV-mediated transformation 
in NPC pathogenesis [188]. When LMP-1 and -2 were specifically expressed in the epithelial 
cells of transgenic mice, LMP-1 increased papilloma and carcinoma formation and LMP-2 
contributed to tumour progression but not by initiating malignant growth [189]. Although 
expression of LMPs varies between NPC tumours, LMP-1-upregulated anti-apoptotic B cell 
lymphoma 2 (BCL-2) is consistently overexpressed in malignant NPC cells [188]. EBERs 
have also been observed to upregulate BCL-2 in BL and NPC cells, and have been implicated 
in LMP-1 induction in NPC tumours [190, 191]. In addition, EBV microRNAs are also 
strongly expressed in NPC tumours and involved in their tumourigenicity [192, 193]. Recent 
whole-exome and targeted deep sequencing as well as SNP array analysis of 128 NPC cases 
revealed a distinct mutational signature [161] of host DNA which included the previously 
implicated PIK3CA gene [194, 195]. ARID1A, a component of the SWI/SNF complex, was 
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also frequently deleted or mutated in NPC cells [161] indicating a role for chromatin 
remodelling in NPC malignancy. 
 
9% of GC cases are EBV-positive [196]. Although little is known about the role of EBV in 
GC malignancies, outgrowth of these tumours may be supported by the induction of autocrine 
insulin-like growth factor 1 (IGF1) which is detected in EBV-positive, but not negative, 
biopsies [197]. In addition, 295 GC patients were recently sequenced and, similar to NPC, a 
high frequency of PIK3CA and ARID1A gene mutations was observed in the EBV-positive 
subset [8]. 
 
EBV-associated BL and NPC both have distinct geographical patterns of incidence, where 
BL is endemic in Central Africa and NPC is especially prevalent in Southern China [7]. This 
suggests that environmental and genetic factors contribute to malignancy, in addition to EBV 
infection. For example, parasitic infections (like malaria), nutrition, immune system status 
and c-MYC translocation are all thought to contribute to endemic BL development [198-200]. 
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1.3 The Epstein-Barr Nuclear Antigen 2 (EBNA-2) 
 
1.3.1 The role of EBNA-2 in B cell transformation 
 
EBV strains are classified as type 1 or type 2 based on the sequence of the EBNA-2 gene. 
EBV types will be reviewed in section 1.4. EBNA-2 is essential for transformation of primary 
B lymphocytes in vitro. The type 2 EBV strain P3HR1 which has a deletion of the EBNA-2 
ORF (and part of EBNA-LP) cannot immortalise B cells [201-205]. If the deletion is 
complemented by recombination with a type 1 virus or cloned fragments of the type 1 
EBNA-2 gene, the immortalisation capacity of the virus is rescued [131, 132]. The 
development of the EREB2.5 system further illustrated the key role of EBNA-2 in EBV-
induced B lymphocyte transformation [134]. The EREB2.5 cell line, an LCL, contains the 
type 2 P3HR1 EBV genome and an OriP plasmid which carries the type 1 sequence of the 
deleted region of P3HR1. This deleted genome region is modified with part of the oestrogen 
receptor (ER) such that the fusion protein ER-EBNA-2 is conditionally expressed from the 
EBV Wp. The OriP plasmid also expresses full-length EBNA-LP which is missing from the 
P3HR1 genome. Conditional ER-EBNA-2 translocates to the nucleus where it activates target 
genes and drives cell proliferation but only when oestrogen is present in the cell culture 
medium and binds to the ER. ER-EBNA-2 is sequestered in the cytoplasm and rendered 
inactive upon oestrogen withdrawal from the culture medium as heat-shock proteins bind to 
the ER binding domain [206]. As a result, approximately half of the EREB2.5 cells undergo 
growth arrest entering a quiescent state and others die by apoptosis. Therefore, EBNA-2 is 
absolutely essential for the maintenance of EREB2.5 cell proliferation. Proliferation arrest 
occurs at G1 and G2 cell cycle stages but oestrogen re-addition can stimulate cells blocked in 
G0/G1. This indicates that EBNA-2 is required for G1 cell cycle progression and is consistent 
with the finding that EBNA-2, during EBV infection of B cells in vitro, cooperates with 
EBNA-LP to induce G1-specific cyclin D2 expression [114]. Experiments performed in 
EREB2.5 cells have revealed the EBNA-2 requirement for both initiation of B cell 
transformation into LCLs and maintenance of the EBV-LCL immortalised state [134]. 
Therefore, EBNA-2 functions as a transcriptional activator to regulate cell and latency III 
viral gene expression, driving cell cycle progression into G1 and maintaining continuous LCL 
proliferation. The EREB2.5 cell line has been used extensively to identify and investigate 
functions and types of EBNA-2 [207-211]. 
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1.3.2 EBNA-2 structure and functional domains 
 
The functions of the EBNA-2 protein have been investigated in many genetic and 
biochemical studies. Most investigations however have focussed on type 1 EBNA-2 with the 
consequence that little is known about the type 2 protein. The prototype type 1 EBV (B95-8) 
strain carries an EBNA-2 gene that encodes a 487-amino acid-long protein whereas the 
EBNA-2 protein of the prototype type 2 EBV (AG876) strain is 455 amino acids in length. 
Type 1 and type 2 EBNA-2 proteins share just 56% sequence identity [212, 213]. Since 
EBNA-2 does not share significant sequence similarity with any cellular protein, determining 
its function was initially difficult. However, a sequence comparison of EBNA-2 alleles from 
four lymphocryptoviruses (LCVs) (type 1 and type 2 EBV, baboon Herpesvirus Papio (HVP) 
and rhesus macaque LCV [214]) identified nine evolutionary-conserved regions (CR1-9) 
(Figure 1.4). These CRs represent most of the type 1 and type 2 EBV EBNA-2 sequence 
homology, and define some functional domains of EBNA-2 [212, 214] (Figure 1.5). The CRs 
are clustered at the amino (N)-terminus (CR1-4) and the carboxyl (C)-terminus (CR5-9) and 
are separated by a diversity region which varies in length and sequence based on EBNA-2 
types and homologues [215]. The poly-proline repeat (PPR) region, a long sequence of 
proline residues between CRs 2 and 3, provides an additional region of variability as its 
length varies in EBV isolates [212]. Two self-association domains (SAD1 and SAD2) are 
found either side of the PPR and are important for homotypical self-association of EBNA-2 
[216, 217]. The cell DNA-binding protein and EBNA-2 cofactor RBP-Jκ interacts with CR5 
of EBNA-2 through the conserved tryptophan residues at position 323 and 324 [218-222]. 
CR6 is bound by the cell protein SKIP, a RBP-Jκ cofactor, and therefore facilitates formation 
of the EBNA-2/RBP-Jκ complex [223]. The acidic transactivation domain (TAD), which 
mediates activation of target gene transcription, is found in CR8 [212]. Karyophilic signals 
are provided by the nuclear localisation signal (NLS) at CR9 of the C-terminus [212, 224] 
and the RG sequence, an 18-amino acid-long domain rich in arginine and glycine residues, 
which lies between CRs 6 and 7 [212]. Gal4 DNA-binding domain fusions and Cp promoter-
reporter assays have shown that the TAD, CR7, RG and SAD1 motifs are involved in EBNA-
LP cooperation. SAD1 is often referred to as the second activation domain (AD2) and, 
together with the TAD, is specifically bound by EBNA-LP [117, 225]. EBNA-2 structure and 
functional domains are represented in Figure 1.5. The EBNA-2 protein is very stable with a 
half-life of over 24 hours but it also interacts with nucleoplasm, chromatin and nuclear matrix 
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fractions and localises to large nuclear granules [226, 227]. EBNA-2 is phosphorylated at 
some serine and threonine residues, but the size of the nascent protein in comparison to the 
stable intranuclear EBNA-2 [226, 228] suggests additional post-translational modifications 
such as methylation [229]. 
 
 
 
Figure 1.4. Alignment of type 1 (B95-8) and type 2 EBV (AG876) EBNA-2 sequences. Amino acids in red 
and highlighted in yellow are identical. Amino acid residues highlighted in green indicate those with similar side 
chain chemistry. Conserved regions (CRs 1-9) are shown in boxes and are based on sequence homology with 
the EBNA-2 sequences of baboon and rhesus LCV also [214]. The alignment was performed in Vector NTI and 
some gaps were introduced. The alignment length is indicated at the beginning and end of each line. 
56 
 
 
 
 
Figure 1.5. Cartoon structure of the type 1 EBNA-2 protein. Light grey boxes indicate conserved regions 
(CR1-9) of EBNA-2 at either terminus which are separated by a variable (diversity) region. Dark grey boxes 
specify regions shown to be important for B cell immortalisation. SAD1 and 2: self-association domains; PPR: 
poly-proline region; RBP-Jκ: RBP-Jκ-interacting domain; RG: arginine-glycine-rich region; TAD: 
transactivation domain; NLS: nuclear localisation signal. The two sites of interaction with the leader protein 
(EBNA-LP) are also indicated. Adapted from [211]. 
 
 
1.3.3 Regions of EBNA-2 important for B cell transformation 
 
Extensive mutational analysis using recombinant viruses and the EREB2.5 trans-
complementation system has mapped the domains of type 1 EBNA-2 that are essential for 
transforming ability (Figure 1.5). Four EBNA-2 regions essential for both B lymphocyte 
transformation and LMP-1 promoter activation in transient assays were identified, indicating 
that EBNA-2 transformation and transactivation functions are closely-related [238]. These 
four regions and the importance of possible subdomains to LCL outgrowth were 
characterised further in numerous subsequent reports. In the N-terminus, the two self-
association domains (SAD1 1-58 a.a and SAD2 97-210 a.a) are essential for EBNA-2 
transformation [216, 217, 230]. The EREB2.5 system revealed the requirement of residues 3 
to 30 for induction of LMP-1 expression and consequently the immortalisation phenotype. 
While the EREB2.5 system showed that the whole of the EBNA-2 PPR was dispensable for 
B cell immortalisation, B cell infection experiments with recombinant EBV viruses revealed 
that at least seven proline residues in the PPR were required for transformation [207, 231]. In 
other infection experiments which used a mutant virus with a deletion of EBNA-2 CR4, B 
cell transformation was drastically decreased [232], indicating the contribution of CR4 to 
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EBNA-2-mediated B cell immortalisation. In the C-terminus, the entire RBP-Jκ binding 
domain and the TAD are essential for LMP-1 induction and B cell transformation [224, 230, 
233]. Even when the amino acid sequence of the TAD was randomised, the mutant virus had 
markedly reduced transcriptional and transformation activity demonstrating that TAD 
activation of transcription is a requirement of EBNA-2-induced B cell transformation [234]. 
The RG motif has also been studied to determine its role in B lymphocyte transformation 
efficiency [235]. In fact, the RG motif might negatively regulate EBNA-2 transactivation of 
LMP-1 since LMP-1 promoter activation increases four-fold in reporter assays using a 
deletion mutant of EBNA-2 which lacks the RG domain [235]. Although the CR7 domain is 
important for EBNA-2 co-activation by EBNA-LP [225], it has been shown to be non-
essential for B cell transformation [235]. In addition, when the CKII phosphorylation site 
SS469 between CRs 8 and 9 is mutated, EBNA-2 binding to hSNF5/Ini1, a component of  the 
SWI/SNF chromatin remodelling complex, is abolished and leads to severely-impaired 
EBNA-2-promoted B cell growth [236, 237]. 
 
 
1.3.4 Mechanisms of transactivation of EBNA-2 target genes 
 
1.3.4.1 EBNA-2 requires cofactors to bind to gene promoters 
 
EBNA-2 lacks intrinsic DNA-binding ability and instead uses various host DNA-binding 
proteins to tether itself to viral and cellular EBNA-2-responsive promoters. The most studied 
of these is RBP-Jκ, or CBF1, a cell transcriptional repressor [220, 221, 238, 239]. RBP-Jκ is 
an important feature of EBNA-2 transactivation of the viral LMP-1/-2B, LMP-2A and Cp 
promoters and the cellular CD21 and CD23 promoters [126, 240-243]. At the LMP-1 
promoter, many other cell factors such as PU.1/Spi-1, Spi-B, AP-2 and POU domain protein 
bind to confer EBNA-2-responsiveness [108, 240, 244]. Similarly, Cp and CD21 promoters 
are also regulated by hnRNP AUF1 binding [245, 246]. 
 
1.3.4.2 EBNA-2 is similar to the intracellular domain of Notch 
 
The ubiquitously expressed transcription factor RBP-Jκ is highly conserved in evolution and 
is important in the Notch signalling pathway. EBNA-2 and the intracellular domain of Notch 
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(Notch-IC) both interact with RBP-Jκ to modulate gene expression and therefore EBNA-2 is 
considered to have a similar function to a constitutively active Notch receptor [31, 32]. RBP-
Jκ recruits histone deacetylases (HDACs) to target promoters acting as a transcriptional 
repressor [247]. EBNA-2 and Notch-IC are thought to induce target gene expression by 
binding to the same minimal repression domain of RBP-Jκ and replacing the HDAC 
repression complex with their own transactivation domains. EBNA-2 binds to RBP-Jκ using 
the WWP sequence in CR6 (Figure 1.4 and 1.5), similar to the WFP sequence in Notch-IC 
[12]. When the WW residues in EBNA-2 were mutated to SS, EBNA-2 upregulation of the 
Cp was abolished, LMP-1 promoter activation was reduced and the recombinant EBV failed 
to transform primary B lymphocytes [233]. 
 
Many developmental processes including lineage commitment of lymphocytes are regulated 
by the Notch signalling pathway. Several human malignancies and oncogenic animal model 
systems are associated with deregulated Notch expression [215], suggesting that EBNA-2 can 
contribute to B cell immortalisation by constitutively activating the Notch signalling 
pathway. However, Notch cannot maintain continuous proliferation of EBV-LCLs, unlike 
EBNA-2 [209, 248]. Partial rescue of LCL proliferation only occurs with very high levels of 
Notch-IC expression or when LMP-1 expression is EBNA-2-independent [209, 248]. This 
biological difference of EBNA-2 and Notch was probed by comparative genome-wide 
expression analysis which revealed differences in target genes of EBNA-2 and Notch 
regulation [249]. Notch was found to be more closely associated with regulation of 
differentiation and developmental genes whereas EBNA-2 was more efficient at inducing 
genes involved in cell proliferation and survival [249]. Previous investigations carried out in 
B cells also showed that Notch can only regulate the expression of some EBNA-2 viral target 
genes that contain RBP-Jκ binding sites (Cp and LMP-2A but not LMP-1) and their induction 
is lower than with EBNA-2 [32, 250]. Therefore, it has been proposed that EBNA-2 promotes 
B cell proliferation by mechanisms that involve both usurping part of the Notch signalling 
pathway and transactivating genes independently of RBP-Jκ. This is consistent with the 
finding that EBNA-2/RBP-Jκ interaction is necessary but not sufficient for the expression of 
some target genes [251]. In addition, other target genes become EBNA-2-responsive only 
when additional factors bind to promoter elements, such as in the EBNA-2-mediated 
transactivation of the LMP-1 promoter upon PU.1-binding [240, 241, 252]. Therefore, 
regulation of the LMP-1 promoter, and perhaps others, involves more than just RBP-Jκ-
tethering which might explain the inability of Notch-IC to activate LMP-1 expression in 
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EBV-LCLs. Indeed, counteracting effects of cellular Notch and EBNA-2 at the LMP-1 ED-
L1 promoter have recently been reported [253]. EBNA-2-mediated initiation of LMP-1 
transcription was inhibited upon Delta-like ligand 1 activation of Notch-2 [253]. 
 
1.3.4.3 Co-activating proteins that interact with EBNA-2 
 
When EBNA-2 is bound at target promoters, EBNA-2-mediated transcription can be 
activated by the TAD which interacts with histone acetyltransferases (HATs) p300/CBP and 
PCAF [254, 255] and several cell transcription machinery components. These include TFIIH, 
TAF40, TFIIB, p100 and TFIIE [256, 257]. These protein factors are also bound by the acidic 
domain of Herpes Simplex virus VP16 [255], to which EBNA-2 is similar [212, 234]. 
Moreover, a core hydrophobic 14-amino acid sequence of the VP16 activation domain can 
substitute for the homologous region of the EBNA-2 TAD in transactivation assays [212, 
234]. Furthermore, a chimeric EBV virus containing this 14-amino acid sequence of VP16 
was found to transform primary B lymphocytes with the efficiency of wildtype virus [234]. 
 
EBNA-LP mainly interacts with the EBNA-2 TAD and SAD1 [117, 225] to enhance EBNA-
2-mediated transcription [114-116]. EBNA-LP can further cooperate with EBNA-2 by 
interacting with the RG and CR7 motifs [225]. EBNA-LP modulation of EBNA-2 
transcriptional activity is thought to occur through its effect on RBP-Jκ interaction. EBNA-
LP has been shown to remove the transcriptional repressors NCoR and RBP-Jκ from cell 
promoters thus augmenting EBNA-2 binding and transactivation [258]. Furthermore, recent 
ChIP-sequencing (ChIP-seq) analyses revealed that EBNA-2 and EBNA-LP associated with 
similar regions of the genome and that EBNA-2 sites were enriched for EBNA-LP-associated 
cell TFs as well as RBP-Jκ and EBF [259]. Taken together, these data indicate that EBNA-2 
and EBNA-LP interact, together with TFs, at promoters and enhancers to stimulate gene 
expression. In contrast, the EBNA-3 family of viral proteins compete with EBNA-2 for RBP-
Jκ-binding and therefore negatively regulate EBNA-2-mediated transactivation [124, 260]. 
 
EBNA-2 also interacts with the SWI/SNF chromatin remodelling complex component 
hSNF5/Ini1 to regulate gene expression as this converts the chromatin structure to a more 
‘open’, transcriptionally-active form [237, 261]. This interaction involves the IPP motif of 
EBNA-2 (aa 286-288), found just upstream of CR5 in the diversity region, and DQQ (aa 313-
315) in the RBP-Jκ-binding domain (Figure 1.4). The CKII phosphorylation site SS469 has 
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also been shown to be important for EBNA-2/hSNF5/Ini1-binding [236], an interaction that 
is stabilised by the poly-proline region of EBNA-2 [237]. 
 
In addition, EBNA-2 can bind to the DEAD-box protein DP103/Geminin3, considered a 
putative RNA helicase, through its N-terminus (aa 121-216) [262]. A methylated RG motif is 
required for EBNA-2 to interact with survival motor neuron (SMN) protein, which co-
activates RNAPII transcription and is involved in RNA metabolism [263, 264]. Finally, in 
order to block Nur77-mediated apoptosis, EBNA-2 can interact with the transcription factor 
and mediator of apoptosis, cell protein Nur77 [265]. 
 
 
1.3.5 EBNA-2 target genes 
 
1.3.5.1 EBNA-2 microarray studies 
 
As EBNA-2 is such a potent transcriptional activator, it is able to regulate viral Cp and LMP 
promoters in addition to approximately 300 cellular target genes in order to control B 
lymphocyte transformation. In initial studies, individual target genes of type 1 EBNA-2 were 
investigated. These genes were often involved in cell growth and development, cycle and 
survival, such as the proto-oncogenes c-FGR and c-MYC [266, 267], the Notch family 
member HES-1 [118], cyclin D2 [114], and the transcription factor RUNX3 [268]. Other 
EBNA-2 target genes encode cell surface proteins like the B cell activation markers CD21 
and CD23 [269, 270], IL-18R [271] and the chemokine receptor CCR7 involved in B cell 
maturation [272], as well as soluble proteins such as the cytokines TNFα, LTα and IL-16 
[268, 273] that are all involved in cell-environment interactions. EBNA-2 may also interfere 
with germinal centre (GC) phenotype as it has also been shown to downregulate the GC 
proteins TCL1 and BCL6 [274]. In contrast to other EBNA-2 target genes, the AP-1 
transcription factor BATF antagonises cell growth and is thought to promote viral latency and 
prevent lytic cycle entry [275]. EBNA-2 also acts as a transcriptional repressor of the Ig μ 
gene via a RBP-Jκ-independent mechanism [276]. Regulation of other EBNA-2 target genes 
however, such as CD21, CCR7 and FcHR5, was demonstrated to be dependent on RBP-Jκ 
[272, 277]. Although EBNA-2 induces expression of direct target genes (i.e. CD23, RUNX3 
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and c-MYC), indirect targets are likely since RUNX3, c-MYC, HES-1 and BATF are all 
transcription factors upregulated by EBNA-2. 
 
Whole genome microarray analysis has been used to identify all directly and indirectly 
regulated target genes of type 1 EBNA-2 in both BLs and LCLs [111-113, 210, 278]. Type 2 
EBNA-2 regulation of gene expression will be discussed in sections 1.4.4. One study was 
performed using a RBP-Jκ knockout B cell line in order to identify the contribution of RBP-
Jκ to EBNA-2 target gene activation [112]. In another study performed in this laboratory, 
AK31 BL cells were first treated with protein synthesis inhibitors in order to identify direct 
target genes of EBNA-2 only [210]. A proteomic approach was taken in another microarray 
performed with EBV-LCLs and primary B cells [278]. EBNA-2 targets were classified as c-
MYC-dependent or -independent and were mainly implicated in cell growth, metabolism, 
signal transduction, stress responses and protein synthesis and degradation [278]. Many novel 
EBNA-2 target genes with various heterogeneous functions were identified [111-113, 210, 
278] and can be classified as follows: 
 
 transcription factors (TFs) involved in B cell activation and differentiation (e.g. ETS1 
and IRF4) 
 TFs that regulate cell cycle and apoptosis and so are important for survival and 
proliferation of B cells (e.g. MAD1, STAT6, PIK3R1, JunD and GADD45) 
 cytokines, chemokines (CCL3 and CCL4) and chemokine receptors (CXCR7 and 
CCR7) that have a role in lymphocyte trafficking 
 proteins important for cytoskeletal remodelling and cell adhesion 
 Notch signalling pathway members (e.g. HEY1 and DTX1) 
 proteins involved in transcription and RNA processing 
 proteins implicated in endocytosis and recycling 
 
The roles of some direct target genes of EBNA-2, including RUNX3, CXCR7 and PI3K, 
have been investigated in this laboratory [111, 210, 211, 268, 279-281]. RNAi experiments 
showed that all three genes are essential for EBV-LCL survival and proliferation [111, 210, 
279]. A whole genome microarray analysis performed in this laboratory which compared 
direct target genes of type 1 and type 2 EBNA-2 will be reviewed in section 1.4.4. 
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1.3.5.2 RUNX3 
 
RUNX3 is a member of the Runt domain TF family which are generally important in 
hematopoiesis and osteogenesis [268]. The RUNX family of TFs may play a role in the 
development of B cells as both RUNX3 and another family member, RUNX1, are expressed 
at many stages of B cell differentiation [282]. RUNX genes have also been implicated in B 
cell malignancies. For example, acute lymphocytic leukaemia, which is of B cell origin, is 
characterised by a RUNX1 t(12;21) translocation resulting in its deregulated expression 
[280]. In EBV-infected LCLs, RUNX3 cross-regulation of RUNX1 is important to control 
cell proliferation. When EBV infects naive B lymphocytes, EBNA-2 induces RUNX3 
expression which subsequently downregulates RUNX1 [279]. For optimal EBV-mediated B 
cell proliferation, RUNX1 levels must be reduced since its overexpression is consistent with 
inhibition of EBV-LCL proliferation [281]. Therefore, for normal proliferation of EBV-
infected B cells, there is a requirement for RUNX3 and a removal of RUNX1. 
 
1.3.5.3 c-MYC 
 
c-MYC is a proto-oncogene that is a prominent EBNA-2 target [266]. Under normal 
conditions, c-MYC regulates cell growth, proliferation, differentiation and apoptosis. 
However, upon mutation into its activated, oncogenic form where its expression is 
deregulated, c-MYC triggers the pathogenesis of several malignancies [283, 284]. In 
EREB2.5 cells, EBNA-2 induces moderate levels of c-MYC protein, but if c-MYC is 
overexpressed, the EBV-transformed cells are driven to proliferate independently of EBNA-2 
and LMP-1 [285]. As a result, EBV-immortalised cells do not proliferate normally and their 
morphology and phenotype begins to resemble those of BL cells. In contrast to EBV-LCLs, 
EBV-infected cells driven by c-MYC in the absence of EBNA-2 and LMP-1, lose expression 
of adhesion and activation molecules typical of EBV-LCLs, grow as single cells in 
suspension, are poorly immunogenic and are sensitive to apoptosis [285]. A hallmark of BL 
is the deregulation of c-MYC expression due to chromosomal translocations, the most 
common of which is t(8;14) (reviewed in section 1.2.5). This juxtaposes the c-MYC gene 
locus from chromosome 8 with the promoter of the Ig  heavy chain gene on chromosome 14 
[86, 165]. Since EBNA-2 activation causes growth arrest of latency I BL cells and EBNA-2 
is a transcriptional suppressor of the Ig  gene, expression of EBNA-2 in BL cells causes 
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repression of the c-MYC t(8;14) translocation and cell cycle arrest [276]. However, it is not 
known whether c-MYC is a direct EBNA-2 target gene since microarray studies using protein 
synthesis inhibitors have been performed in a BL background where the expression of c-
MYC is deregulated by the translocation [112]. 
 
1.3.5.4 CXCR7 
 
CXCR7 resembles a G-protein-coupled receptor (GPCR) with seven trans-membrane 
domains [286]. The cxcr7 gene is highly conserved among mammals [287] and although it 
was considered an orphan receptor for many years, CXCR7-binding to the inflammatory and 
homing cytokines SDF-1 (CXCL12) and I-TAC (CXCL11) with high affinity has now been 
demonstrated [288]. Importantly, CXCR4 and CXCR3 are also receptors for CXCL12 and 
CXCL11 respectively [288, 289]. However, CXCR7 has not been shown to be G-protein-
coupled or to induce typical chemokine responses, such as receptor-mediated calcium 
mobilisation and chemotaxis, and CXCR7 is thus believed to be an atypical chemokine 
receptor [288-290]. The only typical chemokine receptor function demonstrated by CXCR7 
in several cell types thus far is ligand-induced internalisation [289, 291, 292]. Since CXCR7 
expression on the surface of mature B cells inversely correlates with CXCR4 activity, a role 
for CXCR7 has been proposed in modulating CXCR4 and CXCR3 signalling [293]. In 
addition, CXCR7 was found to be essential for CXCR4 to mediate CXCL12-induced integrin 
activation and adhesion of T lymphocytes to endothelial cells [290]. One mechanism by 
which CXCR7 might control CXCR4 and CXCR3 functions is by acting as a scavenger 
receptor to sequester and internalise CXCL12 and CXCL11 tagging them for degradation 
[294]. A zebra fish model was used to show the ability of CXCR7 to guide cell migration in 
the development of the posterior lateral line by sequestering ligands and forming local 
gradients of CXCL12 [295]. Moreover, CXCR7 can bind to CXCL12 ligand with 10-fold 
greater affinity than CXCR4 [291]. Another mechanism which may describe the role of 
CXCR7 in CXCR4 functions is the ability of the two receptors to heterodimerise and enhance 
CXCL12-induced signalling [296, 297]. Recently, however, the inability of CXCR7 to 
activate G-proteins has been challenged. CXCR7 was shown to trigger -arrestin intracellular 
signalling in a ligand-dependent manner [291, 298]. Therefore, the ability of CXCR7 to act 
independently of CXCR4 and CXCR3 and contribute to CXCL12- and CXCL11-induced 
responses remains possible. 
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The physiological functions of CXCR7 remain unclear. Expression patterns of CXCR7 are 
more restricted than CXCR4 and although it is highly expressed on transformed cells and 
during embryonic development, it is poorly expressed on normal somatic cells [287, 288]. 
CXCR7 mRNA was reported to be broadly expressed in normal human leukocytes although 
the protein was only expressed at the plasma membranes of monocytes, basophils and mature 
B cells [293]. Another study however revealed CXCR7 to be downregulated in activated cells 
compared to resting PBMCs, and CXCR7 to be detected only on the surface of monocytes 
[299]. Other studies also reported inconsistent CXCR7 detection; one study detected CXCR7 
surface expression on T lymphocytes [289], whereas another showed no CXCR7 mRNA or 
protein expression in any peripheral blood leukocytes (T, B and NK cells, neutrophils or 
macrophages [300]. A role for CXCR7 in embryogenesis and cardiac development was 
proposed based on the observation that CXCR7 knockout mice die perinatally with severe 
heart defects [297, 301]. These mice showed no abnormal bone or brain phenotypes despite 
high expression of CXCR7 in osteocytes and brain cells of healthy mice [297, 301]. 
Surprisingly, CXCR7-deficient mice displayed normal hematopoiesis, in contrast to CXCR4- 
and CXCL12-deficient mice which both showed severely impaired B cell lymphopoiesis and 
myelopoiesis [297, 302, 303]. In another report however, CXCR7 expression was found to be 
tightly regulated during B cell development and differentiation, suggesting a role for CXCR7 
in B lymphopoiesis. In fact, CXCR7 has been proposed as a marker for memory B cells, the 
precursors of antibody-secreting cells, since its expression at the plasma membrane correlated 
with their ability to differentiate into antibody-producing plasma cells [293]. 
 
The role of CXCR7 in tumourigenesis is much clearer. CXCR7 has been found to be highly 
expressed at the protein level in many transformed cell lines and in tumour biopsies including 
cancers of the prostate, brain, breast and lung [288, 304-308]. The association of CXCR7 
with tumourigenesis was first described in fibroblasts of nude mice that increased in 
proliferation and tumour development upon ectopic expression of CXCR7 [309]. CXCR7 
was also shown to confer a strong growth and survival advantage to prostate cancer cells in 
vitro by activating the Akt signalling pathway [304]. In addition, a recent study in colorectal 
cancer showed that silencing of the CXCR7 gene caused repression of growth and invasion, 
and induction of cell apoptosis through ERK and -arrestin pathways [310]. The finding that 
the human tumour suppressor HIC1 is involved in the regulation of CXCR7 gene 
transcription further implicated CXCR7 in tumourigenesis [311]. 
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Recently, CXCR7 has been reported as a target gene for a number of different oncogenic 
viruses. In KSHV-infected hDMVECs, CXCR7 mRNA is strongly induced and is essential 
for efficient transformation and focus-formation [309, 312, 313]. Interestingly, when the 
major latent KSHV protein K13 is ectopically expressed in human vascular endothelial cells, 
CXCR7 is upregulated through strong induction of the NF-κB pathway [314]. The 
transcriptional activator Tax of human T cell leukaemia virus type 1 (HTLV-1) also 
upregulates CXCR7 via the NF-κB pathway, resulting in survival and growth of HTLV-1-
infected T cells [299]. Similarly, this laboratory has demonstrated CXCR7 induction by EBV 
EBNA-2 and the essential requirement of CXCR7 for survival and proliferation of EBV-
infected LCLs [111, 210, 211]. A number of CXCR7 transcripts have been reported in B cells 
[210], although the specific EBNA-2-induced CXCR7 mRNA is still unclear as is the 
mechanism of EBNA-2 regulation. 
 
1.3.5.5 LMP-1 
 
Latent membrane protein 1 (LMP-1) is a 63 kDa phosphoprotein consisting of a short N-
terminal cytoplasmic tail, six transmembrane domains and a long C-terminal cytosolic region 
[315]. LMP-1-induced signal transduction that drives B cell proliferation requires the C-
terminal region and the transmembrane domains. The C-terminal region contains two 
functional sub-domains, namely the membrane-proximal C-terminal-activating region 1 
(CTAR1) and the distal CTAR2 [316]. These two domains have similar functions: CTAR1 is 
absolutely essential for EBV-mediated immortalisation by recruiting TNF receptor-associated 
factor (TRAF) family proteins and triggers NF-κB activation [316-319]. CTAR2 is critical 
for long-term EBV-transformed B cell growth and binds to TNF receptor-associated death 
domain (TRADD) leading to activation of NF-κB and signal transduction via the 
JNK/MAPK pathway, resulting in expression of AP-1 transcription factors [316, 320-323]. 
NF-κB and AP-1 prevent B lymphocyte apoptosis and upregulate many LMP-1-inducible 
genes [324, 325]. CTARs 1 and 2 also activate c-JUN and ATF2 transcription factors through 
p38 MAPK signalling, leading to induction of IL-6 and IL-8 cytokines [324]. 
 
LMP-1 mimics a constitutively-active CD40 receptor, a member of the tumour necrosis 
factor receptor (TNF-R) superfamily, which is essential for antigen-activated B cell survival 
[326]. LMP-1 is also functionally similar to oncoproteins of two other gammaherpesviruses. 
These are K1 protein and Saimiri transformation protein (Stp) of KSHV and HVS 
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respectively and, although they do not show a high degree of sequence identity, all interact 
with host factors to activate cell signalling and drive lymphocyte transformation [33]. For 
example, LMP-1 and Stp C bind to TRAFs, presumably involved in a signalling cascade, 
leading to NF-κB activation. Moreover, LMP-1, K1 and Stp can all self-oligomerise and this 
aggregation of membrane proteins is important for their signalling activity [327]. 
 
LMP-1 was the first EBV latent protein identified as an oncoprotein due to it inducing a 
transformed phenotype and tumour formation when ectopically expressed in nude mice. 
LMP-1 was also found to induce lymphomagenesis when expressed in the B cell 
compartment of transgenic mice [328, 329]. Expression of LMP-1 has been observed in the 
tumour cells of many EBV-associated cancers including immunoblastic lymphomas, HL and 
NPC [9]. Remarkably, when LMP-1 is expressed at high levels in EBV-negative BL cells, it 
is cytostatic and inhibits cell growth [330]. In contrast, when it is expressed at normal levels, 
LMP-1 alters gene expression and induces phenotypic changes similar to EBV infection such 
as upregulation of cell adhesion molecules (ICAM, LFA1 and LFA3) and B cell activation 
markers (CD23 and CD40) [324]. Additionally, LMP-1 induces anti-apoptotic gene 
expression (BCL-2, A20, Bfl-1, Mcl-1 and cIAPs) protecting cells from apoptosis [315, 324, 
325]. When transiently expressed in primary resting B cells, LMP-1 also induces DNA 
synthesis and upregulates cytokines including IL-6, -8 and -10 [324]. LMP-1 is thought to 
play an additional role in angiogenesis and metastasis in EBV-associated cancers as it has 
been observed to upregulate matrix metalloproteinases [315]. 
 
LMP-1 is expressed during default and growth programmes of latency, otherwise known as 
latency II and latency III infection respectively. LMP-1 transcription is controlled and 
initiated from two promoters, a proximal (ED-L1p) (Figure 1.6) and a distal (TR-L1p) 
promoter [331, 332]. LMP-1 expression is EBNA-2-independent in latency II, but in latency 
III it is critically dependent on EBNA-2 (Figure 1.6A) which is the most potent transactivator 
of LMP-1 [108, 333]. EBNA-2 regulation of LMP-1 expression in LCLs occurs through the 
proximal ED-L1 promoter and requires many cofactors including RBP-Jκ, PU.1, AP-2, 
p300/CBP, SWI/SNF, ATF/CREB and the DP103/SMN complex (Figure 1.6B) (see section 
1.3.4.1) [240, 241, 244, 252, 254, 255, 263]. 
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Figure 1.6. The EBV LMP-1 promoter. The LMP-1 promoter is shown in the standard genome orientation. 
(A) A model of EBNA-2 interactions with EBNA-2 response element (E2RE)-binding factors and basal 
transcription factors (TFs) at the LMP-1 promoter. Sequence-specific DNA-binding proteins, including RBP-Jκ 
(Jκ) and PU.1, direct EBNA-2 to E2REs. The EBNA-2 transactivation domain (TAD) interacts with a basal TF 
complex including TFIIB, TAF40 and TFIIH to stimulate transcription. (B) Sequence of type 1 B95-8 EBV 
LMP-1 promoter. The TATA box is indicated at the -35 position from the transcription start site (TSS). Binding 
sites for TFs are indicated and closely resemble consensus motifs. PU.1 and IRF binding sites overlap, forming 
an ETS-IRF composite element (EICE). EBF: early B cell factor; oct: octamer; IRF: interferon regulatory factor; 
Jκ: recombination signal-binding protein J kappa (RBP-Jκ); AML1: acute myeloid leukemia 1 (RUNX1). 
 
 
 
68 
 
1.4 EBV types  
 
1.4.1 EBV type classification and sequence variation 
 
Genetic analysis of EBV strains enables their classification as type 1 and type 2 (also known 
as type A and type B). EBV type classification is based on the EBNA-2 gene sequence as this 
is the most divergent locus in the EBV genome showing only 70% identity at the nucleotide 
level and 56% identity in the protein sequence [334]. This is in contrast to most EBV genes 
which differ by less than 5% at the amino acid level between different isolates [334]. 
However, there is linked variation in the latent genes EBNA-3A, -3B, -3C and EBNA-LP 
[335-338] but the degree of sequence difference is much less. There is also additional 
polymorphic variation found in EBNA-1 [339, 340], BZLF1 and LMP-1 [341] but this is not 
linked to type 1 and type 2 variation. Indeed, despite the classification of LMP-1 variants into 
7 main groups [342], there is little evidence to suggest a specific disease association. The 
EBER genes have also been reported as showing additional divergence but this is not as 
consistent [343, 344]. Sequencing of a prototype type 2 EBV strain, AG876, has enabled a 
comparison of the type 1 and type 2 EBV genomes [22]. This revealed that the two EBV 
types are co-linear and very similar, with the exception of the known divergent alleles. 
Recent sequencing analysis of a further 71 EBV isolates worldwide involving this laboratory 
has shown that variation in EBNA-2 and EBNA-3 alleles accounts for most of the type-
specific characteristics of the unique regions of EBV (unpublished data, PJ Farrell and P 
Kellam). 
 
 
1.4.2 Prevalence worldwide and disease associations 
 
Type 1 EBV strains are ubiquitous and are the main EBV type prevalent all over the world. 
Although type 2 strains are rare in European, American and Chinese populations (3-10%), 
type 2 EBV is frequently found in sub-Saharan Africa, where it can be as abundant as type 1 
EBV [345-348]. Type 2 EBV is also less rare in geographical regions that are endemic for BL 
and malaria; type 2 EBV was detected in 24% and 21% of healthy carriers in Kenya and New 
Guinea respectively [345]. At present, the biological significance of the two types of EBV is 
not understood. 
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No EBV type-specific disease associations have been demonstrated despite a clear difference 
in B cell transformation phenotype in vitro and in B cell tumour growth in the SCID mouse 
model. A number of studies were performed to investigate the frequencies at which type 1 
and type 2 EBV are found in EBV-associated tumours however they simply reflected the 
geographical distribution of EBV strains in the normal population [344, 349, 350]. For 
example, type 1 and type 2 EBV were found to be associated with endemic BL in Central 
Africa where they are both prevalent [345, 346], whereas most sporadic EBV-positive BL 
cases in the developed world contained type 1 EBV [346, 351]. Furthermore, EBV-positive 
cases of HL arising in immunocompetent patients in Europe most frequently carried a type 1 
EBV strain [352, 353]. However, this work was based on virus rescue from spontaneous in 
vitro transformed peripheral blood mononuclear cells (PBMCs) of healthy carriers which 
favours type 1 EBV isolation. PBMCs were subsequently used for direct PCR analysis which 
revealed that a population of healthy Americans carried type 1 EBV and 41% had a type 2 
strain [354]. In addition, studies performed on Western communities for EBV types present 
in immunosuppressed individuals (HIV patients and cardiac transplant recipients) showed a 
high prevalence of type 2 EBV (20-30%) [355, 356]. This increased type 2 EBV frequency 
was also observed in human immunodeficiency virus-associated non-Hodgkin lymphomas 
[357-360]. Therefore, for the Western population, type 2 EBV prevalence in HIV patients 
was significantly higher than in the general immunocompetent population (30% compared to 
3-10%). EBV viral load has since been shown to be higher in immuncompromised 
individuals [361] such that type 2 EBV is more easily detectable using this method and thus 
providing an explanation for the results of these studies. Indeed, in immunocompetent 
individuals in which viral load is lower, the type 2 subdominant strain of EBV could remain 
undetected. This would suggest that type 2 EBV has a wider geographical distribution than 
originally anticipated [345-348]. Many of these HIV patient studies involved male 
homosexuals as a specific immunocompromised patient group and this would indicate that a 
high incidence of type 2 EBV in the developed world is specific to immunocompromised 
patients. In fact, when type 2 EBV incidence was compared in two HIV-positive 
immunocompromised groups, homosexual males and haemophilia patients, it was found that 
haemophilia patients had a similar type 2 EBV prevalence to that of the normal population 
from the same geographical area (approximately 10%). Therefore, the findings suggest that, 
while rare in the Caucasian population, type 2 EBV has become endemic in the homosexual 
community [362]. However, the true prevalence of type 2 EBV strains in the Western world 
remains unclear. 
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It is still possible that natural variation in EBV may contribute to differences in disease 
incidence that varies dramatically in different parts of the world. For example, NPC is one of 
the most common tumours exhibited in Southeast Asia. It was recently proposed that 
differences in the properties of the EBV strain isolated from a Chinese NPC might contribute 
to its role in this malignancy [44]. The isolated M81 EBV strain was quite different from 
extensively-characterised Western strains in that it displayed spontaneous replication in B 
cells in vitro and in vivo at unusually high levels and had a reversed tropism favouring 
infection of epithelial cells. These properties were partly ascribed to polymorphisms in viral 
proteins (including BZLF1), shared with other similar viruses isolated from NPC and 
consistent with NPC phenotype [44]. Therefore, specific differences in M81-type EBV 
viruses might contribute to their tight association with NPC. The hypothesis that variation in 
EBV sequence might be linked to human disease was further supported by another study 
which showed that EBNA-3B-deficient EBV promoted B cell lymphomagenesis and induced 
formation of diffuse large B cell lymphoma (DLBCL) tumours specifically in a humanised 
mouse model [139]. This suggested a role for EBNA-3B in tumour suppression. The EBNA-
3B genes from several B cell lymphomas were also sequenced and a number of mutations 
implicated in lymphomas were revealed [139]. 
 
 
1.4.3 Biological differences of type 1 and type 2 EBV in vitro 
 
The difference in growth transformation and B cell immortalisation in vitro remains the 
clearest example of the functional variation of EBV. Type 1 strains have a much greater 
transforming ability compared to type 2 strains and this was first demonstrated by Rickinson 
and colleagues [363]. Type 1 EBV-transformed LCLs were shown to grow more quickly than 
type 2 transformants and to a higher saturation cell density [363]. The molecular determinant 
for this difference in transformation efficiency in vitro was demonstrated to be the EBNA-2 
locus [132]. Indeed, when a type 2 P3HR1 EBV strain was engineered to express a type 1 
EBNA-2 sequence, the virus gained the B cell immortalisation efficiency of a type 1 EBV 
strain [132]. In contrast, EBNA-3 gene type sequence does not affect immortalisation ability 
of viral strains, as replacement of the type 2 EBNA-3A, -3B or -3C loci in the P3HR1 
genome with the corresponding type 1 sequences produced no difference in B lymphocyte 
growth transformation [336, 364]. The transforming ability of type 1 and type 2 EBV in vitro 
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also correlated with tumour formation frequency when SCID mice were inoculated 
intraperitoneally with type 1 and type 2 EBV-LCLs, again determined by the EBNA-2 locus 
[365, 366]. When a type 2 P3HR1 strain carrying type 1 EBNA-2 was used to generate EBV-
LCLs, tumour appearance in the SCID mice model occurred at the same rate as with type 1 
EBV-transformed LCLs [366]. Type 1 and type 2 EBV strains have also been reported to 
differ in their ability to spontaneously enter the lytic cycle and replicate in the context of LCL 
and B cell lines. Despite similar growth rates, type 2 EBV-infected cell lines appear to 
support spontaneous viral replication with a higher frequency compared to type 1 EBV [367]. 
 
Therefore, EBNA-2 provides the most apparent example of EBV functional variation and 
strain classification as type 1 or type 2 is made on the basis of the EBNA-2 sequence. The 
EBNA-2 locus is also the most divergent in the EBV genome with the primary amino acid 
sequence of type 1 and type 2 EBNA-2 showing only 56% identity [334]. This degree of 
divergence is strikingly high when compared to the rest of the EBV genome which shows an 
extremely low degree of variation [335-337]. This biological difference in EBV types has 
been known for many years, yet the molecular mechanism underlying this phenotype is 
poorly understood. Despite extensive reports on type 1 EBNA-2 function, little is known 
about type 2 EBV physiology in vitro (reviewed in section 1.3). 
 
 
1.4.4 Differential gene regulation by type 1 and type 2 EBNA-2 
 
Several studies have used whole genome microarray analysis to identify the targets of type 1 
EBNA-2 (see section 1.3.5.1) [111-113, 278] but little was known about the ability of type 2 
EBNA-2 to regulate gene expression. Recently, however, our laboratory compared the host 
genes induced by type 1 EBNA-2 to those induced by the type 2 protein [210]. 
Approximately 300 cell genes are induced directly by type 1 EBNA-2 [111], but only about 
10 of these were found to be regulated differentially and, of these, all 10 were more strongly 
induced by the type 1 protein (Figure 1.7) [210]. Differentially regulated genes included 
CXCR7, ADAMDEC1, IL-1 and MARCKS and, among these, CXCR7 was the most highly 
expressed, the most differentially regulated and was demonstrated to be essential for the 
proliferation of EBV-infected LCLs [210]. The results indicated that differential gene 
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regulation by type 1 and type 2 EBNA-2 might be the basis for the much weaker B cell 
transformation activity of type 2 EBV strains compared to type 1 EBV. 
 
 
 
 
 
Figure 1.7. Microarray analysis of type 1 and type 2 EBNA-2 target genes reveals only a small number of 
differentially regulated genes. Bar chart summary of microarray expression profiling comparing genes 
regulated by type 1 (black) and type 2 (white) ER-EBNA-2. Taken from [210]. 
 
 
The mechanism of differential gene regulation by type 1 and type 2 EBNA-2 is still unclear. 
Why should type 1 EBNA-2 induce only a specific subset of cell genes more efficiently than 
type 2 EBNA-2? 
 
The ability of type 1 EBV to promote LCL outgrowth more efficiently than type 2 EBV was 
next investigated in our laboratory. Chimeras of type 1 and type 2 EBNA-2 genes were made 
and their ability to maintain growth of an LCL conditionally-dependent on transfected 
EBNA-2 was tested. The results showed that sequences from the C-terminal region of type 1 
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EBNA-2 were sufficient to confer maintenance of LCL growth when swapped into the type 2 
protein [211]. This region of type 1 EBNA-2 contains the arginine-glycine (RG) repeat motif, 
conserved region 7 (CR7) and the transactivation domain (TAD). Expression of both cellular 
CXCR7 and viral LMP-1 induced by type 1, type 2 and the C-terminal chimeric EBNA-2 
correlated with their growth phenotype [211]. In fact, the higher level and more rapid 
induction of CXCR7 and LMP-1 has been demonstrated in EREB2.5 LCLs, AK31, Daudi 
and P3HR1 BL cell lines [210, 211] and in the early stages of infection of primary B 
lymphocytes with BAC-derived EBV expressing type 1 or type 2 EBNA-2 [210]. 
 
LMP-1 is required for establishment of B cell transformation in vitro [133] and continuous 
proliferation of EBV-infected LCLs [75]. EBNA-2 regulation of LMP-1 is complex and 
involves many host cell proteins including RBP-Jκ, PU.1, AP-2, p300/CBP, SWI/SNF, 
ATF/CREB and the DP103/SMN complex (see section 1.3.4.1 and 1.3.5.5) [240, 241, 244, 
252, 254, 255, 263]. Unlike other EBNA-2 target promoters however, the interaction of 
EBNA-2 and RBP-Jκ plays only a minor role in EBNA-2-induced activation of the LMP-1 
promoter [106]. Instead, PU.1 [240, 244], ATF/CREB [254] and EBF1 [368] have been 
demonstrated to be the main cofactors involved in EBNA-2-mediated induction of the LMP-1 
promoter. Therefore, since LMP-1 regulation by type 1 and type 2 EBNA-2 is differential, 
perhaps promoter activation of differentially regulated genes resembles EBNA-2-activation 
of the LMP-1 promoter. 
 
Early studies of EBNA-2 function focussed on viral and artificial promoters where the 
EBNA-2 binding sites are close to the transcription start site (TSS) of any given gene. 
However, recent chromatin immunoprecipitation-sequencing (ChIP-seq) studies in human B 
cell lines have revealed all type 1 EBNA-2 binding sites across the genome. These studies 
have shown that EBNA-2 binding sites are predominantly located far away from TSSs of 
cellular gene targets, at distances up to 100 kb up- or downstream [368, 369]. Therefore, 
EBNA-2-binding at distal as well as proximal promoter elements may be a mechanism 
involved in the differential regulation of type 1 and type 2 EBNA-2 target genes. 
 
Taken together, results from previous studies suggest that the greater immortalisation 
efficiency of type 1 EBV strains is controlled by the enhanced induction of a small subset of 
genes by type 1 EBNA-2. In this study, the molecular mechanism of differential regulation of 
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type 1 and type 2 EBNA-2 target genes was investigated, with particular focus on cellular 
CXCR7 and viral LMP-1. 
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1.5 Aims of the thesis 
 
The aim of this study is to investigate how type 1 EBV strains are more effective at 
immortalising B lymphocytes in vitro compared to type 2 EBV and to identify the molecular 
mechanisms that underlie the superior in vitro transformation ability of type 1 EBV. The 
specific objectives were to: 
 
1. Map and identify the amino acids of type 1 EBNA-2 which confer higher B cell 
immortalisation efficiency compared to type 2 EBNA-2: 
 
 what is the contribution of the transactivation domain (TAD) and conserved 
region (CR) 7 to the EBNA-2-regulated growth of EREB2.5 cells? 
 which amino acids of the EBNA-2 protein are responsible for the superior 
ability of type 1 EBNA-2 to sustain growth of EREB2.5 cells, compared to the 
type 2 protein? 
 what are the EBNA-2-mediated mechanisms of transcriptional activation 
responsible and which host and viral genes are involved? 
 
2. Investigate type 1 and type 2 EBNA-2 regulation of host and viral gene expression, 
focussing on genes important for B cell survival and proliferation: 
 
 which transcript of CXCR7 is regulated by EBNA-2? 
 with what affinity do type 1 and type 2 ER-EBNA-2 bind to promoter 
elements of genes that are differentially regulated by EBNA-2 types? Are the 
affinities equal or different? 
 do the chromatin-binding abilities of wildtype EBNA-2 proteins differ at 
promoter elements of genes relevant to B cell proliferation? 
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2 Materials and Methods 
 
2.1 Solutions and chemicals 
 
All chemicals were supplied by BDH (UK) unless otherwise stated. 
 
2.1.1 Solutions for cell culture protocols 
 
 1X PBS: 137 mM NaCl, 2.7 mM KCl, 19 mM Na2HPO4, 1.7 mM KH2PO4, pH 7.0. 
 0.8 % (w/v) ammonium chloride: 8 g of ammonium chloride (Sigma, UK) was 
dissolved in 1 litre of Cell Culture grade H2O (Sigma) and autoclaved. 
 Cell freezing solution (10% (v/v) DMSO): 5 ml DMSO was diluted in 45 ml fetal 
bovine serum (FBS) (Biosera, UK) and stored at 4°C. 
 Cell resuspension buffer: 10 mM Tris-Cl pH 7.5, 10 mM NaCl, 5 mM MgCl2. 
 1 M sucrose: 342.3 g of sucrose was dissolved in 1 l dH2O and filter-sterilised by 
passing through a 0.22 μm filter (Millipore, Germany). 
 S1 buffer: 0.25 M sucrose, 10 mM MgCl2 and filter-sterilised. 
 Sedimentation buffer: 0.8 M sucrose, 10 mM Tris-Cl pH 7.5, 10 mM NaCl, 5 mM 
MgCl2. The solution was then sterilised by autoclaving. 
 Nuclear resuspension buffer: 0.25 M sucrose, 15 mM Tris-Cl pH 7.5, 60 mM KCl, 
15 mM NaCl, 3 mM MgCl2, 0.05 mM CaCl2, 0.5 mM DTT. The solution was 
sterilised by autoclaving. 
 
2.1.2 Solutions for DNA protocols 
 
 3 M sodium acetate pH 5.2: 408.1 g of sodium acetate (3H2O) was dissolved in 
900 ml dH2O. The pH was adjusted with acetic acid to 5.2, the solution made up to 1 l 
and then autoclaved. 
 1X TBS: 140 mM NaCl, 10 mM Tris-Cl pH 7.5. 
 NET buffer: 100 mM NaCl, 1 mM EDTA pH 7.5, 10 mM Tris-Cl pH 7.5. 
 5 M NaCl: 292.2 g NaCl was dissolved in 1 l dH2O and autoclaved. 
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 1 M Tris-Cl, various pH values between 6.8 and 8.8: 121.1 g of Tris Base was 
dissolved in 900 ml dH2O and the pH adjusted as required with 1 M HCl. The final 
volume was made to 1 l and the solution autoclaved and stored at room temperature. 
 0.5 M EDTA pH 8.0: 186.1 g of EDTA was dissolved in 900 ml of dH2O, the pH was 
adjusted with 0.5 M NaOH and the final volume made to 1 l. The solution was then 
autoclaved and stored at room temperature. 
 Luria Bertani (LB) medium: 10 g tryptone, 5 g yeast extract and 10 g NaCl were 
dissolved in 900 ml dH2O. The pH was adjusted to 7.0 with 0.5 M NaOH, the volume 
adjusted to 1 l and the solution autoclaved and stored at room temperature. 
 Luria Bertani (LB) agar plates: 15 g of bacto-agar was dissolved in 1 l LB medium 
and autoclaved before pouring plates. 
 For antibiotic selection, ampicillin was used at 100 µg/ml and kanamycin at 50 µg/ml 
concentration. 
 SOC media: 20 g tryptone, 5 g yeast extract, 2 ml 5 M NaCl, 2.5 ml 1 M KCl, 10 ml 
1 M MgCl2, 10 ml 1 M MgSO4 and 20 ml 1 M glucose were dissolved in 900 ml 
dH2O, made to a final volume of 1 l and sterilised by autoclaving. 
 Superbroth: 12 g tryptone, 24 g yeast extract and 4 ml glycerol were dissolved in a 
final volume of 950 ml dH2O and autoclaved. 50 ml sterile potassium phosphate 
buffer (KPB) was then added. 
 KPB: 46 g KH2PO4 and 243 g K2HPO4 dissolved in 1 l dH2O.  
 Agarose gels: 0.8-1.5 g agarose (Invitrogen, UK), dependent on the size of the DNA 
fragment of interest, was dissolved in 100 ml 1X TBE by microwaving. 5 μl 
10 mg/ml ethidium bromide (Sigma) was added and gel poured. 
 6X agarose gel loading buffer: 10% (w/v) sucrose, 60 mM EDTA, 10 mM Tris-Cl pH 
7.6, 0.03% (w/v) bromophenol blue, 0.03% (w/v) xylene cyanol FF, 60% (v/v) 
glycerol in dH2O.  
 10X TBE: 108 g Tris Base, 55 g boric acid (Sigma) and 40 mM EDTA pH 8.0 were 
added to 900 ml of dH2O. The volume was adjusted to 1 l and autoclaved. 10X TBE 
was diluted to 1X in dH2O before use.  
 Buffer QG (Qiagen): 5.5 M guanidine thiocyanate (GuSCN), 20 mM Tris-Cl pH 6.6. 
 Buffer PE (Qiagen): 10 mM Tris-Cl pH 7.5, 80% (v/v) ethanol. 
 Buffer EB (Qiagen): 10 mM Tris-Cl, pH 8.5. 
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 T4 DNA ligase reaction buffer (NEB, UK): 50 mM Tris-Cl pH 7.5, 10 mM MgCl2, 
1 mM ATP, 10 mM DTT. 
 TA cloning reaction buffer (Invitrogen): 50 mM Tris-Cl pH 7.6, 10 mM MgCl2, 
1 mM ATP, 1 mM DTT, 25% (w/v) polyethylene glycol (PEG)-8000. 
 Buffer P1 (Qiagen): 50 mM Tris-Cl pH 8.0, 10 mM EDTA, 100 μg/ml RNaseA. 
 Buffer P2 (Qiagen): 200 mM NaOH, 1% (w/v) SDS. 
 Buffer P3 (Qiagen): 3 M potassium acetate pH 5.5. 
 Buffer N3 (Qiagen): 4.2 M Gu-HCl, 0.9 M potassium acetate pH 4.8. 
 Buffer PB (Qiagen): 5 M Gu-HCl, 30% (v/v) isopropanol. 
 Buffer QBT (Qiagen): 750 mM NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol, 
0.15% (v/v) Triton X-100). 
 Buffer QC (Qiagen): 1.0 M NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol. 
 Buffer QN (Qiagen): 1.6 M NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol. 
 TE buffer: 10 mM Tris-Cl pH 7.6 or 8.0, 1 mM EDTA pH 8.0 in dH2O; autoclaved 
and stored at room temperature. 
 10X Pfu DNA polymerase buffer: 200 mM Tris-Cl pH 8.8, 100 mM KCl, 100 mM 
(NH4)2SO4, 20 mM MgSO4, 1% (v/v) Triton X-100, 1 mg/ml BSA. 
 10X Pfu Turbo DNA polymerase buffer for site-directed mutagenesis (SDM): 
200 mM Tris-Cl pH 8.8, 100 mM KCl, 100 mM (NH4)2SO4, 20 mM MgSO4, 1% 
(v/v) Triton X-100, 1 mg/ml BSA. 
 
2.1.3 Solutions for RNA protocols 
 
 Cell resuspension buffer A: 10 mM Tris-Cl pH 7.5, 0.15 M NaCl, 1 mM MgCl2, 0.1% 
(v/v)  Triton X-100. 
 10X RQ1 RNase-free DNase buffer (Promega, USA): 400 mM Tris-Cl pH 8.0, 
100 mM MgSO4, 10 mM CaCl2. 
 2X ProtoScript reverse transcriptase reaction buffer (NEB): 100 mM Tris-Cl pH 8.3, 
150 mM KCl, 6 mM MgCl2, 20 mM DTT. 
 10X RACE-PCR buffer (Invitrogen): 200 mM Tris-Cl pH 8.4, 500 mM KCl. 
 5X RACE tailing buffer (Invitrogen): 50 mM Tris-Cl pH 8.4, 125 mM KCl, 7.5 mM 
MgCl2. 
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 RACE column-DNA binding solution: 6 M sodium iodide. 
 
2.1.4 Solutions for protein protocols 
 
 RIPA lysis buffer: 0.15 M NaCl, 1% (v/v) NP-40, 0.5% (v/v) deoxycholic acid, 0.1% 
(w/v) SDS, 50 mM Tris-Cl pH 8.0, 1 mM phenol methyl sulfonyl fluoride (PMSF) 
(Fluka Analytical, Switzerland). 50 ml RIPA lysis buffer was supplemented with one 
tablet of complete protease inhibitor (Roche, USA). 
 10% (w/v) SDS: 100 g sodium dodecyl sulphate (SDS) salt was dissolved in 1 l dH2O 
by stirring at 50°C. The solution was filtered and stored at room temperature. 
 2X SDS sample buffer: 120 mM Tris-Cl pH 6.8, 4% (w/v) SDS, 2% (v/v) -
mercaptoethanol, 0.01% (w/v) bromophenol blue, 20% glycerol. 
 Laemmli buffer (Bio-Rad, UK): 100 mM Tris-Cl pH 6.8, 4% (w/v) SDS, 200 mM 
DTT, 0.02% (w/v) bromophenol blue, 20% (v/v) glycerol. 
 SDS-PAGE gels: Resolving gel: 7.5-15% (v/v) acrylamide/bis-acrylamide (29:1) 
(Bio-Rad), dependent on the size of the protein of interest, 375 mM Tris-Cl pH 8.8, 
0.1% (w/v) SDS). Stacking gel: 5% (v/v) acrylamide/bis-acrylamide (29:1), 125 mM 
Tris-Cl pH 6.8, 0.1% (w/v) SDS. 
 Western blot 10X SDS running buffer: 250 mM Tris, 1.92 M glycine, 1% (w/v) SDS. 
10X SDS buffer was stored at room temperature and diluted to 1X in dH2O prior to 
use. 
 Coomassie Blue staining solution: 40% (v/v) methanol, 10% (v/v) acetic acid, 1 g/l 
Coomassie Brilliant Blue, R-250 (Thermo Scientific, USA), stored at room 
temperature. 
 Coomassie Blue destaining solution: 40% (v/v) methanol, 10% (v/v) acetic acid, 
stored at room temperature. 
 Western blot transfer buffer (1X): 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS, 
24% (v/v) ethanol, cooled to 4°C before use. 
 Western blot blocking solution for enhanced chemiluminescence (ECL) protocol: 5% 
(w/v) skim milk powder (Fluka Analytical) in Western blot washing buffer (PBS-T) 
and stored at 4˚C. 
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 Western blot wash buffer, PBS-T: 0.1% (v/v) Tween-20 (Sigma) in PBS, stored at 
room temperature. 
 Western blot stripping buffer: 2% (w/v) SDS, 62.5 mM Tris-Cl pH 6.8 in dH2O, 
stored at room temperature. 100 mM β-mercaptoethanol (company) was added prior 
to use. 
 Blocking buffer for immunofluorescence (IF): 1% (w/v) BSA (Sigma) in PBS, stored 
at 4°C. 
 2 M glycine: 75.07 g of sucrose was dissolved in a total volume of 500 ml dH2O and 
filter sterilised. 
 Cell lysis buffer for chromatin immunoprecipitation (ChIP): 5 mM PIPES pH 8.0, 
85 mM KCl, 0.5% (v/v) NP-40. The solution was autoclaved and chilled to 4°C 
before use. 
 SDS lysis buffer for ChIP: 50 mM Tris-Cl pH 8.0, 10 mM EDTA, 1% (w/v) SDS. 
The solution was then autoclaved and chilled to 4°C before use. 
 Blocking buffer for ChIP: 0.5% (w/v) BSA in dH2O and stored at -20°C. 
 IP dilution buffer: 16.7 mM Tris-Cl pH 8.0, 167 mM NaCl, 1.2 mM EDTA, 0.01% 
(w/v) SDS, 1.1% (v/v) Triton X-100. The solution was autoclaved, stored at room 
temperature and chilled to 4°C before use. 
 Low salt wash buffer for ChIP: 150 mM NaCl, 20 mM Tris-Cl pH 8.0, 2 mM EDTA, 
0.1% (w/v) SDS, 1% (v/v) Triton X-100. The solution was autoclaved, stored at room 
temperature and chilled to 4°C before use. 
 High salt wash buffer for ChIP: 500 mM NaCl, 20 mM Tris-Cl pH 8.0, 2 mM EDTA, 
0.1% (w/v) SDS, 1% (v/v) Triton X-100. The solution was autoclaved, stored at room 
temperature and chilled to 4°C before use. 
 2 M LiCl wash buffer for ChIP: 84.78 g of lithium chloride was dissolved in 1 l dH2O 
and then autoclaved. The solution was stored at room temperature and chilled to 4°C 
before use. 
 Elution buffer for ChIP: 10 mM Tris-Cl pH 8.0, 1 mM EDTA, 1% (w/v) SDS. The 
solution was autoclaved and stored at room temperature. 
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2.2 Cell culture protocols 
 
2.2.1 Cell lines and cell maintenance 
 
The cell lines and corresponding culture media used in this study are listed in table 2.1. All 
cells were maintained at 37°C in a humidified incubator with 10% CO2. 
 
2.2.1.1 Suspension cell lines 
 
B cells were grown in suspension in RPMI-1640 (Gibco, UK) medium and supplemented 
with 10% (v/v) heat-inactivated (56°C for 20 min) fetal bovine serum (FBS, Biosera), 2 mM 
L-glutamate (Gibco), 200 U/ml penicillin (Gibco) and 200 U/ml streptomycin (Gibco), unless 
otherwise stated. In LCL-generating experiments, cells were supplemented with 20% (v/v) 
FBS with the appropriate antibiotic selection. EREB2.5 cells were also grown in the presence 
of 1 µM estradiol (in 100% ethanol) (Sigma). For Daudi cells that conditionally expressed 
EBNA-2 proteins, cadmium chloride (CdCl2) was added. B cells were fed 2-3 times a week 
by 1:3 or 1:5 dilution in an equal volume of pre-warmed fresh medium. 
 
2.2.1.2 Adherent cell lines 
 
293 is a transformed human embryonic kidney (HEK) cell line that is in fact likely to be of 
neuronal origin [370]. HeLa cells are derived from a human epithelial carcinoma [371]. 
These adherent cell lines were cultured as monolayers in Dulbecco’s Modified Eagle medium 
(DMEM; Gibco), also supplemented with 10% (v/v) FBS, 2 mM L-glutamate, 200 U/ml 
penicillin and 200 U/ml streptomycin (Gibco). When confluent, adherent cells were split by 
washing in warm 1X phosphate-buffered saline (PBS) before detaching cells with 0.05% 
trypsin-EDTA (Gibco) for 5 min at room temperature. Detached cells were washed in 
complete culture medium and then seeded at 1:10 or 1:20 dilution in fresh pre-warmed 
medium for further cultivation in fresh cell culture flasks. 
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Cell line Characteristics 
Medium and 
selection 
Reference 
EREB2.5 LCL with type 2 P3HR1 EBV genome 
and a conditional type 1 ER-EBNA-2 
(p554-4) 
RPMI, 10% 
(v/v) FBS, p/s, 
glu, 1 µM β-
estradiol 
[134, 372] 
EREB2.5:OriP-
p294-EBNA-2 
LCL with type 2 P3HR1 EBV 
genome, a conditional inactive type 1 
ER-EBNA-2 and OriP-p294 EBNA-2 
RPMI, 20% 
(v/v) FBS, p/s, 
glu 
[211], this 
study 
B95-8 BL infected with type 1 B95-8 EBV RPMI, 10% 
(v/v) FBS, p/s, 
glu 
[373] 
MutuIII BL, EBV positive, latency III RPMI, 10% 
(v/v) FBS, p/s, 
glu 
[374] 
Daudi BL, EBV positive, ΔEBNA-2, ΔY1Y2 
EBNA-LP, type 1/type 2 chimeric 
genome 
RPMI, 10% 
(v/v) FBS, p/s, 
glu 
[375, 376]  
Daudi:ER-EBNA-2 
T1 
BL, EBV positive with a conditional 
ER-EBNA-2 T1 (p554-4) 
RPMI, 10% 
(v/v) FBS, p/s, 
glu, G418 
[210] 
Daudi:ER-EBNA-2 
T2 
BL, EBV positive with a conditional 
ER-EBNA-2 T2 (pERT2) 
RPMI, 10% 
(v/v) FBS, p/s, 
glu, G418 
[210] 
Daudi:pHEBoMT-
EBNA-2 T1 
BL, EBV positive with MT-controlled 
type 1 EBNA-2 expression 
RPMI, 10% 
(v/v) FBS, p/s, 
glu, hygro 
This study 
Daudi:pHEBoMT-
EBNA-2 T2 
BL, EBV positive with MT-controlled 
type 2 EBNA-2 expression 
RPMI, 10% 
(v/v) FBS, p/s, 
glu, hygro 
This study 
Daudi:pHEBoMT-
EBNA-2 T2 S442D 
BL, EBV positive with MT-controlled 
type 2 S442D EBNA-2 expression 
RPMI, 10% 
(v/v) FBS, p/s, 
glu, hygro 
This study 
HEK 293 Human embryonic kidney, EBV 
negative 
DMEM, 10% 
(v/v) FBS, p/s, 
glu 
[370] 
HeLa Human epithelial carcinoma, EBV 
negative 
DMEM, 10% 
(v/v) FBS, p/s, 
glu 
[371] 
 
Table 2.1. Cell lines used in this study. LCL: lymphoblastoid cell line; BL: Burkitt’s lymphoma cell line, 
RPMI: Roswell Park Memorial Institute 1640 (Gibco); DMEM: Dulbecco’s Modified Eagle Medium (Gibco); 
FBS: fetal bovine serum (Biosera); p/s: 200 U/ml penicillin and 200 U/ml streptomycin (Gibco); glu: 2 mM L-
glutamate; G418: 400 μg/ml gentamycin (Calbiochem, UK); hygro: 300 μg/ml hygromycin (Roche); T1: type 1; 
T2: type 2; MT: metallothionein promoter. 
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2.2.2 Viable cell counts 
 
Cells were stained with trypan blue solution (Sigma) at a 1:2 dilution. Cells were visualised 
under a CK2 light microscope (Olympus, Japan) and the number of live cells were 
determined by counting those that excluded trypan blue on an Improved Neubauer 
haemocytometer slide (Superior Marienfeld, Germany). 
 
2.2.3 Cell freezing 
 
5 x 10
6
 adherent cells were trypsinised, washed and resuspended in complete medium and 
then centrifuged at 335 x g for 5 min at 4°C to collect the cells. Suspension cells were 
centrifuged directly using the same conditions. Cell pellets were resuspended in 1 ml of cold 
10% (v/v) DMSO in FBS solution and transferred into a cryovial (Greiner Bio-One, USA). 
The cells were then frozen slowly in a Nalgene Cryo 1 C freezing container (Thermo 
Scientific) overnight at -80°C. The cryovials were subsequently transferred into liquid 
nitrogen for long term storage. 
 
2.2.4 Cell thawing 
 
Cells were thawed rapidly at room temperature and 10 ml complete medium without selective 
antibiotics were added to dilute cells and DMSO. DMSO was removed by centrifugation of 
the cells at 335 x g for 5 min at 4°C. The cell pellet was then resuspended in 10-30 ml of 
fresh medium without selective antibiotics, transferred to a tissue culture flask and incubated 
at 37°C. Where appropriate, the required antibiotic selection was applied after 24-48 h. 
 
2.2.5 Cell harvesting 
 
The required numbers of cells, dependent on downstream experiments, were centrifuged at 
335 x g for 5 min at 4°C. They were then washed once or twice in ice-cold PBS. The 
supernatant was removed by aspiration and RNA/protein extracted as described (see sections 
2.3.4.1 and 2.4.1). Alternatively, the cell pellet was snap-frozen on dry ice and stored at         
-80°C. 
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2.2.6 Cell transfection 
 
2.2.6.1 Lipofectamine 2000 transfection 
 
Lipofectamine 2000 transfections of cells were performed with sterile DNA according to the 
manufacturer’s instructions (Invitrogen). One day before transfection, 5x105 cells were 
seeded in 2 ml supplemented DMEM without antibiotics in individual wells of a 6-well plate 
to be approximately 80% confluent at the time of transfection. For immunofluorescence 
experiments, HeLa cells were grown on coverslips (VWR, UK). The following day, 4 µg 
plasmid DNA was diluted in 250 μl OptiMEM I Reduced Serum Medium (Gibco) for each 
transfection. 10 μl lipofectamine 2000 (Invitrogen) was then diluted with 250 µl OptiMEM I 
Reduced Serum Medium per transfection and incubated at room temperature for 5 min. 
Diluted DNA and lipofectamine 2000 were combined and incubated for a further 20 min at 
room temperature. Approximately 500 µl complexes were added to each well containing cells 
and medium. Cells were incubated for 24 h at 37°C and 10% CO2 prior to testing for 
transgene expression. 
 
2.2.6.2 Amaxa nucleofection of EREB2.5 cells 
 
EREB2.5 cells were diluted 1:2 on two consecutive days prior to nucleofection. Aliquots of 
6x10
6
 cells were washed twice with pre-warmed PBS by centrifuging at 335 x g for 5 min at 
4°C. Cells were resuspended in 100 µl nucleofector solution T (Lonza, Germany) pre-
warmed to room temperature. This was then mixed with 5 μg plasmid DNA, transferred to an 
Amaxa cuvette (Lonza) and nucleofected using the A-23 program. Immediately after 
transfection, 500 μl pre-warmed RPMI medium (supplemented as usual but with 20% FBS 
and no estradiol) was added to the transfected cells. The whole mixture was finally 
transferred to a single well of a 12-well plate already containing 1.5 ml supplemented media 
and incubated overnight at 37°C and 10% CO2. The following day, each transfection (cells in 
one well) was diluted to a final volume of 10 ml with fresh supplemented medium and 
aliquoted out equally into 5 wells of a 24-well plate. Cell growth was then monitored daily 
and medium refreshed every two or three days. At day 5 post-transfection, cells from 3 wells 
were taken for protein extraction and Western blot analysis. On days 7, 14, 21 and 28, viable 
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cell counts were taken (see section 2.2.2). Viable cells were identified under the microscope 
and expanded further. 
 
2.2.6.3 Transfection of B cells using the Neon system 
 
Cells were diluted 1:2 in fresh culture medium one day before transfection. For transfection, 
aliquots of 2x10
6
 cells were harvested by centrifuging at 335 x g for 5 min at 4°C and washed 
twice with pre-warmed PBS. Cell pellets were resuspended in 100 µl Neon resuspension 
buffer/solution R (Invitrogen). Cell suspensions were then mixed with 3 g sterile plasmid 
DNA in Eppendorf tubes and the plasmid-cell suspension transferred to a Neon 100 µl 
electroporation pipette tip (Invitrogen). 3 ml Neon electrolytic buffer/solution E2 was added 
to the electroporation tube in the electroporation unit and the electroporation pipette tip was 
then transferred to the electroporation tube. B cells were electroporated using Neon 
transfection protocol 9 with transfection conditions were set at 1400 V pulse voltage, 30 ms 
pulse width and 1 pulse number. Cells were immediately transferred to 3 ml pre-warmed 
media (containing RPMI, 10% FCS and p/s but no antibiotic selection) in a 6-well plate, 
gently resuspended and incubated at 37°C for 24 hours. For generation of stable cell lines, 
antibiotic selection was then started by adding 300 µg/ml hygromycin in a final volume of 
12 ml. 2 ml aliquots were placed in 6 wells of a 24-well plate and media with selection was 
refreshed every 3 days. Approximately 3-4 weeks after transfection and clear cell line 
outgrowth, cells were transferred to tissue culture flasks and expanded. 
 
2.2.7 Estrogen starvation and induction of EREB2.5 cells 
 
EREB2.5 cells were routinely maintained in RPMI media supplemented with 10% FBS, 
2 mM L-glutamate, 200 U/ml penicillin, 200 U/ml streptomycin and 1 µM estradiol. For 
estrogen starvation and induction of EREB2.5 cells, cells were washed three times in 
unsupplemented RPMI and resuspended at 5x10
5
 cells/ml in supplemented RPMI media 
lacking estradiol. After 4 days, cells were re-counted, centrifuged and resuspended at 
5x10
5
 cells/ml in supplemented RPMI media without estradiol. On the fifth day, estrogen-
starved cells were either harvested or treated with 1 μM estradiol for a further 4 h in the 37°C 
incubator. Cells were then harvested by washing twice in PBS before RNA and protein 
extraction (see sections 2.3.4.1 and 2.4.1). 
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2.2.8 Purifying nuclei 
 
Cells were fractionated and nuclei purified using the sucrose density gradient centrifugation 
method. 5x10
6
 cells were washed twice with cold PBS by centrifuging at 335 x g for 5 min at 
4°C. Cells were resuspended in 130 µl cell resuspension buffer and placed on ice for 30 min. 
Cell membranes were lysed by rotation with 70 µl 5% NP-40 for 5 min at 4°C. Cytosolic and 
nuclei fractions were separated by centrifugation at 250 x g for 5 min at 4°C. Nuclei were 
resuspended in 100 µl S1 buffer, layered onto 200 µl sedimentation buffer and purified by 
centrifugation at 700 x g for 5 min at 4°C. Nuclei were then resuspended in 50 µl nuclear 
resuspension buffer and snap-frozen on dry ice before being kept in the -80°C freezer for 
long term storage. 
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2.3 Nucleic acid protocols 
 
2.3.1 Phenol/chloroform purification, ethanol precipitation and sterilisation 
of nucleic acids 
 
To purify nucleic acids from other reactions, the DNA or RNA solution was diluted to 
100 l. An equal volume of phenol:chloroform:isoamylalcohol (25:24:1) (Sigma) was added 
and vortexed to mix thoroughly. Samples were centrifuged at 16000 x g for 5 min and the 
aqueous phase transferred to a fresh Eppendorf tube. 0.1 x volume of 3 M sodium acetate 
pH 5.2 and 2.5 x volumes of 100% ethanol were subsequently added and samples mixed by 
inversion. Nucleic acids were precipitated by incubation at -20°C for 30 min and then 
pelleted by centrifugation at 18000 x g for 10 min at 4°C. Nucleic acid pellets were then 
washed with 70% (v/v) ethanol, air-dried for approximately 5 min at room temperature under 
sterile conditions in a laminar flow chamber and finally resuspended in sterile, filtered TE 
buffer or DEPC-treated milliQ water (Ambion, USA). 
 
2.3.2 Nucleic acid quantification 
 
Concentration and purity of nucleic acids was determined by measuring the absorption of the 
full spectrum of light (220-750 nm) using a Nanodrop 1000 spectrophotometer (Fisher 
BioReagants, UK). The concentration was calculated from the absorption of light of 
wavelength 260 nm, assuming an absorbance of 1.0 at this wavelength corresponds to 
50 μg/μl for double-stranded DNA and 40 μg/μl for RNA. The purity was calculated from the 
A260/A280 ratio as proteins absorb light at 280 nm. Pure DNA has a A260/A280 ratio of 1.8 in 
sterile water and pure RNA has a ratio of approximately 2.0 in 10 mM Tris-Cl pH 7.6. 
 
2.3.3 DNA protocols and plasmid vectors 
 
2.3.3.1 Genomic DNA extraction 
 
2.5x10
6
 EREB2.5 cells were harvested by centrifugation at 335 x g for 5 min at 4°C. Cells 
were washed twice in TBS (140 mM NaCl, 10 mM Tris-HCl pH 7.5) and resuspended in 
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0.5 ml NET (0.1 M NaCl, 10 mM EDTA, 10 mM Tris-Cl pH 7.5). SDS was added to a final 
concentration of 1% before overnight incubation at room temperature with 0.3 mg/ml 
proteinase K. The lysate was extracted twice with phenol/chloroform (Sigma) and once with 
chloroform (VWR). The DNA was then ethanol precipitated (see section 2.3.1), washed with 
70% (v/v) ethanol and the DNA pellet resuspended in sterile TE. 
 
2.3.3.2 Preparation of chemically competent bacteria 
 
A single colony of E. coli XL1 Blue cells from a Luria-Bertani (LB) agar plate was picked 
and inoculated in 2 ml LB broth under sterile conditions. The culture was incubated overnight 
at 37°C with shaking. The culture was then diluted 1:100 in fresh LB broth and incubated at 
37°C with shaking until the sample reached an absorbance value of 0.3-0.5 at 600 nm. 
Bacterial cells were subsequently pelleted by centrifugation at 3750 rpm for 15 min at 4°C in 
an Allegra 6R centrifuge (Beckman Coulter, USA), resuspended in half the original volume 
of ice-cold 50 mM CaCl2 and incubated for 10 min on ice. Bacterial cells were again pelleted 
by centrifugation at 3750 rpm for 15 min at 4°C and the bacterial pellet was resuspended in 
1/10 the original volume of ice-cold 50 mM CaCl2, 15% glycerol. 100 l aliquots of cells 
were snap-frozen on dry ice and stored for future use at -80°C. 
 
2.3.3.3 Transformation of competent bacteria 
 
Transformations of site-directed mutagenesis products were performed in supercompetent E. 
coli XL1 Blue or XL10-Gold ultracompetent cells (Agilent Technologies, USA) (see section 
2.3.3.13) whereas transformations with ligated DNA were performed in OneShot Top10 
competent (Invitrogen). Once thawed on ice, 50 μl cells were gently mixed with 1-5 µl DNA 
and incubated on ice for 30 min. The mixture was then heat-shocked at 42°C for 40 s and 
immediately returned to ice for 2 min. 500 μl pre-warmed LB broth was added to each 
transformation reaction and incubated at 37°C with shaking for 1 h. Bacteria were then plated 
onto LB-agar with appropriate antibiotic selection and incubated overnight at 37°C. 
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2.3.3.4 Restriction enzyme digestions 
 
Digestions were performed using restriction enzymes sourced from New England Biolabs 
(NEB) and Promega. The amount of DNA required for subsequent steps was calculated and 
then digested with a 10X excess of restriction enzyme. When double digestions were carried 
out, the volume of enzyme in the reaction did not exceed 10% of the total volume. Digestions 
were performed for 1-2 h or overnight at the recommended temperature and analysed on an 
agarose gel of appropriate concentration (see section 2.3.3.6). 
 
2.3.3.5 Removal of 5ʹ phosphate groups from DNA fragments 
 
To minimise self-ligation and re-circularisation of a linearised vector, the 5ʹ phosphate group 
was removed before ligation. Approximately 1.5 μl (10 U/μl) calf intestinal phosphatase 
(CIP) (NEB) was added to restriction enzyme digestions and incubated at 37°C for 45 min. 
 
2.3.3.6 Agarose gel electrophoresis 
 
Depending on the size of DNA to be separated, 0.8-1.5% (w/v) agarose (Invitrogen) was 
dissolved in 1x TBE by heating and poured into a gel-casting tray after the addition of 
0.5 µg/µl ethidium bromide (Sigma) for UV visualisation. 6X gel loading buffer was added to 
the appropriate volume of DNA samples before loading. A DNA ladder (NEB), 1 kb or 
100 bp, was also used as a standard to determine the length of the DNA fragments. 
Electrophoresis was then performed in 1X TBE buffer at 80-120 V. After sufficient 
separation, DNA was visualised using a transilluminator UV light source and GeneSnap 
software (Syngene, India). 
 
2.3.3.7 Gel extraction 
 
DNA fragments were resolved on an agarose gel and the band of interest was excised using a 
scalpel under UV illumination. To extract the DNA from the gel slice, a QIAquick Gel 
Extraction kit (Qiagen, UK) was used according to the manufacturer’s instructions. The gel 
slice was dissolved in three volumes of buffer QG for 10 min at 50°C. The mixture was then 
loaded onto a QIAquick spin column and microfuged at 17900 x g for 1 min to bind the 
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DNA. The column was washed with 750 μl buffer PE and DNA eluted with a small volume 
of buffer EB (10 mM Tris-Cl, pH 8.5). The purity and concentration of the DNA band of 
interest was analysed on an agarose gel and using a Nanodrop 1000 spectrophotometer 
(Fisher BioReagants) (see sections 2.3.3.6 and 2.3.2). 
 
2.3.3.8 DNA ligation 
 
Ligations were performed with T4 DNA ligase (NEB) and an insert:vector ratio of 3:1. The 
amount of insert was calculated using the following formula: 
 
ng of insert = 3 x (ng of vector x size of insert (kb) / size of vector (kb)) 
 
Ligations were carried out in a final volume of 10 μl with 1 μl T4 DNA ligase (400 U/μl) and 
incubated at room temperature for 1 h. A control reaction was also performed with the vector 
alone. 
 
2.3.3.9 TA cloning 
 
PCR products were cloned into the pCR2.1 plasmid vector using the TA cloning kit 
according to the manufacturer’s instructions (Invitrogen). Briefly, the PCR product desired 
was amplified by PCR with GoTaq polymerase (see section 2.3.3.12.1). Amplification with 
this enzyme adds a single deoxyadenosine (A) to the 3 ends of PCR products which is non 
template-dependent. The PCR product is then efficiently inserted into a linearised vector 
(pCR2.1-TOPO) with single 3 deoxythymidine (T) residue overhangs by ligation. Ligation 
reactions were performed with a insert:vector molar ratio of 3:1. The amount of PCR product 
required to ligate 50 ng pCR2.1-TOPO vector was calculated with the following formula: 
 
ng PCR product = (bp PCR product) x 50 ng pCR2.1-TOPO / 3900 bp pCR2.1-TOPO 
 
Ligation reactions were performed in a final volume of 10 l, with 1 l T4 DNA ligase 
(400 U/l) and incubated overnight at 16°C. A ligation reaction with vector only and no 
insert was also set up as a negative control (see section 2.3.3.8). 2-5 l of the ligation reaction 
was used to transform competent E. coli XL1 Blue cells (see section 2.3.3.3) and grown on 
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selective LB-agar plates containing 100 g/ml ampicillin. Positive transformants were 
screened by analytical restriction enzyme digestion (see section 2.3.3.4) and/or sequenced. 
 
2.3.3.10 Plasmid DNA extraction from bacterial cultures 
 
2.3.3.10.1 Small scale plasmid DNA extraction 
 
Small scale preparations of plasmid DNA were performed using the QIAprep Spin Miniprep 
Kit (Qiagen). Individual colonies were picked from a selective LB agar plate and incubated 
overnight at 37°C with vigorous shaking in 1-5 ml LB (containing antibiotic). 1.5 ml of 
overnight culture was centrifuged (>6000 x g, 3 min, room temperature). Cell pellets were 
resuspended in 250 μl buffer P1 (50 mM Tris-Cl, pH 8.0, 10 mM EDTA, 100 µg/mL RNase 
A) and lysed following the addition of 250 μl buffer P2 (200 mM NaOH, 1% (w/v) SDS). 
350 μl buffer N3 was added for neutralisation and DNA precipitation. The samples were 
centrifuged for 10 min at room temperature (17900 x g) and the supernatant applied to a 
QIAprep spin column. The column was centrifuged as before, washed with 500 μl buffer PB 
(5 M Gu-HCl, 30% (v/v) isopropanol) and 750 μl buffer PE and then DNA eluted in 50 µl 
buffer EB. 
 
2.3.3.10.2 Large scale plasmid DNA extraction 
 
Large scale preparations of plasmid DNA were performed using the EndoFree Plasmid Maxi 
Kit (Qiagen). Briefly, 250 ml LB (containing antibiotic) was inoculated with 250 µl overnight 
culture. Bacterial cells were harvested by centrifugation for 15 min at 4°C, 3300 x g. The 
bacterial pellet was resuspended in 10 ml buffer P1 (50 mM Tris-Cl, pH 8.0, 10 mM EDTA, 
100 µg/mL RNase A). Cells were lysed for 5 min at room temperature following addition and 
thorough mixing of 10 ml buffer P2 (200 mM NaOH, 1% (w/v) SDS). 10 ml ice-cold buffer 
P3 (3.0 M potassium acetate, pH 5.5) was then added for DNA precipitation. The lysate was 
poured into QIA filter cartridges and incubated for 10 min at room temperature. 2.5 ml buffer 
ER was added to filtered lysates and incubated on ice for 30 min. QIAGEN-tip 500s were 
then equilibrated with 10 ml buffer QBT (750 mM NaCl, 50 mM MOPS, pH 7.0, 15% (v/v) 
isopropanol, 0.15% (v/v) Triton X-100) before applying the filtered lysates. The tips were 
washed twice with 30 ml buffer QC (1.0 M NaCl, 50 mM MOPS, pH 7.0, 15% (v/v) 
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isopropanol) and DNA was eluted with 15 ml buffer QN (1.6 M NaCl, 50 mM MOPS, pH 7.0 
15% (v/v) isopropanol). 10.5 ml isopropanol were added to the DNA, mixed and centrifuged 
at 3300 x g, 4°C for 1 h. The DNA pellet was washed once with 5 ml 70% (v/v) ethanol 
before another centrifugation step as before. The DNA pellet was air-dried and dissolved in 
sterile TE (10 mM Tris-Cl, 1 mM EDTA, pH 8.0). 
 
2.3.3.11 Caesium chloride purification of DNA 
 
To further purify the large scale preparations of plasmid DNA, caesium chloride (CsCl) 
gradient centrifugation was performed. For this, 11.25 g CsCl (Sigma) and 0.36 ml 
(10 mg/ml) ethidium bromide (Sigma) were added to each DNA sample in 8.6 ml 5X TE. 
The solutions were mixed thoroughly until CsCl was completely dissolved and the refractive 
index (RI) was adjusted, if necessary, to 1.394. The solutions were then transferred to Quick-
Seal centrifuge 16x76 mm tubes (Beckman, USA), heat-sealed and centrifuged at 42000 rpm 
for at least 40 h at 20°C using a Sorvall Ultracentrifuge Discovery 100SE and 70 Ti rotor 
(Hitachi, Japan). This formed a compact band of covalently-closed circular DNA in the 
middle of the CsCl gradient which was collected with a syringe following piercing of the 
centrifuge tube. The DNA was then extracted five times with CsCl-saturated isopropanol and 
dialysed twice against TE overnight. The DNA was then ethanol precipitated (see section 
2.3.1) and the DNA pellet resuspended in sterile TE buffer. 
 
2.3.3.12 Amplification of DNA 
 
DNA was amplified by the polymerase chain reaction (PCR) with either the Taq or Pfu 
polymerase enzymes (Promega). PCR was performed on the Gene Amp System 9700 
(Applied Biosystems, UK). 5-20 l of the PCR reactions were analysed by agarose gel 
electrophoresis (see section 2.3.3.6). 
 
2.3.3.12.1 Polymerase chain reaction (PCR) with Taq polymerase 
 
The following 50 µl reaction mixture and cycling conditions were used for amplification of 
DNA with GoTaq DNA polymerase (Promega): 
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Component Amount/Volume (µl) 
DNA template 5 ng plasmid, 2 μg genomic DNA, 2 μl cDNA 
5X PCR Green GoTaq Flexi buffer 10 
25 mM MgCl2 4 (2.0 mM) 
10 mM dNTP mix 1 (0.2 mM) 
10 μM forward primer 1 (0.2 μM) 
10 μM reverse primer 1 (0.2 μM) 
GoTaq DNA polymerase (5 U/µl) 0.25 (1.25 U) 
Sterile water to a final volume of 50 μl 
 
 
Segment Temperature (°C) Time Cycles 
Activation 95 2 min 1 
Denaturation 95 0.5 – 1 min  
25-40 Annealing 55 0.5 – 1 min 
Extension 72 1 min/kb 
Final extension 72 7 min 1 
 
 
Typical cycling parameters for Taq PCR are shown but were adjusted accordingly for the 
purpose of the experiment. For colony PCR, single bacterial colonies were transferred 
directly into 50 μl GoTaq DNA polymerase reaction mixture.  
 
2.3.3.12.2 Polymerase chain reaction (PCR) with Pfu polymerase 
 
The following 50 µl reaction mixture and cycling conditions were typically used for 
amplification of DNA with Pfu DNA polymerase (Promega): 
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Component Amount/Volume (µl) 
DNA template 5 ng plasmid, 2 μg genomic DNA 
10X Pfu DNA polymerase buffer 5 
10 mM dNTP mix 1 (0.2 mM) 
10 μM forward primer 1 (0.2 μM) 
10 μM reverse primer 1 (0.2 μM) 
Pfu DNA polymerase (3 U/µl) 0.5 (1.5 U) 
Sterile water to a final volume of 50 μl 
 
 
Segment Temperature (°C) Time Cycles 
Activation 95 2 min 1 
Denaturation 95 0.5 – 1 min  
30-40 Annealing 55 0.5 – 1 min 
Extension 72 2 min/kb 
Final extension 72 5 min 1 
 
 
The annealing temperature used in the PCR reactions was the melting temperature of the 
primers minus 4 or 5˚C. The melting temperature (Tm) was calculated using the following 
formula: 
 
Tm = 81.5 + 0.41(% GC) – 675/primer length (bp) 
 
 
2.3.3.13 Site-directed mutagenesis (SDM) 
 
The QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies) was used to 
introduce specific mutations in small plasmids. For larger plasmids, the QuikChange II XL 
Site-Directed Mutagenesis kit was used (Agilent Technologies). Complementary primer pairs 
containing the required mutations for desired amino acid changes were designed according to 
the manufacturer’s instructions. Primers were approximately 40-45 bases long and had a 
melting temperature (Tm) of ≤74.9°C. The Tm was calculated using the following formula: 
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Tm = 81.5 + 0.41(% GC) – 675/ primer length (bp) - % mismatch 
 
The PCR was performed on the Gene Amp System 9700 (Applied Biosystems). For small 
plasmids, the reaction was set up using the QuikChange II Site-Directed Mutagenesis kit 
(Agilent Technologies) as follows: 
 
Component Amount/Volume (µl) 
50 ng/μl DNA template 1 (50 ng) 
10 mM dNTP mix 1 (0.2 mM) 
10X reaction buffer  5 
100 ng/μl forward primer 1.25 (125 ng) 
100 ng/μl reverse primer 1.25 (125 ng) 
Pfu Turbo DNA polymerase (2.5 U/μl) 1 (2.5 U) 
Sterile water to a final volume of 50 μl 
 
 
For larger plasmids, the reaction was set up using the QuikChange II XL Site-Directed 
Mutagenesis kit (Agilent Technologies) as follows: 
 
Component Amount/Volume (µl) 
50 ng/μl DNA template 1 (50 ng) 
10 mM dNTP mix 1 (0.2 mM) 
10X reaction buffer  5 
100 ng/μl forward primer 1.25 (125 ng) 
100 ng/μl reverse primer 1.25 (125 ng) 
QuikSolution 3 
PfuUltra HF DNA polymerase (2.5 U/μl) 1 (2.5 U) 
Sterile water to a final volume of 50 μl 
 
 
The PCR amplification was performed according to the following thermal cycling conditions: 
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Segment Temperature (°C) Time Cycles 
Activation 95 2 min 1 
Denaturation 95 1 min  
18 Annealing 65 1 min 
Extension 72 2 min/kb 
Final extension 72 5 min 1 
 
 
After the cycling reaction, the PCR tubes were cooled on ice. Methylated, parental DNA was 
digested by treating with 1 μl (10 U/µl) DpnI restriction enzyme (Agilent Technologies) for 
at least 1 h at 37°C. For smaller plasmids, 1 µl DpnI-digested DNA was then transformed 
into 50 μl supercompetent E. coli XL1 Blue cells (Agilent Technologies). For larger 
plasmids, 2 μl XL10-Gold -mercaptoethanol mix (Agilent Technologies) was added to 45 μl 
XL10-Gold ultracompetent cells (Agilent Technologies) and incubated for 10 min on ice with 
gentle swirling every 2 min. 2 μl of larger DpnI-digested DNA were added to the bacteria and 
transformed. Transformations were performed on ice for 30 min followed by a heat shock at 
42°C for 40 s and a recovery on ice for 2 min. 0.5 ml SOC broth was added to each 
transformation mix and incubated for 1 h at 37°C with shaking at approximately 225 rpm. 
Bacteria were then plated on selective LB-agar plates and incubated at 37°C overnight. 
Colonies were screened by restriction enzyme digest analysis of plasmid DNA (see sections 
2.3.3.4 and 2.3.3.6) and sequenced for desired mutations. 
 
2.3.3.14 Quantification of DNA 
 
DNA was amplified and quantified by quantitative PCR (qPCR) using GoTaq qPCR Master 
Mix (Promega). qPCR experiments were performed on an ABI 7900HT Fast Real-Time PCR 
machine (Applied Biosystems). At the end of each run, dissociation curves were analysed to 
ensure absence of non-specific products. Results were analysed using SDS2.3 software 
(Applied Biosystems). The reaction components, cycling conditions and quantification 
method differed based on the type of DNA amplified. 
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2.3.3.14.1 Quantitative PCR (qPCR) for cDNA 
 
Quantification of cDNA and therefore mRNA levels was performed using the delta-delta Ct 
(Ct) method. mRNA levels for each gene amplified were normalised with the 
housekeeping gene GAPDH, used as a loading control, for each sample. Reactions were 
carried out in a total volume of 20 μl and the components and cycling conditions were as 
follows: 
 
Component Amount/Volume (µl) 
cDNA template 2 
2X reaction buffer 10 
10 μM forward primer 1 (0.2 μM) 
10 μM reverse primer 1 (0.2 μM) 
Sterile water to a final volume of 20 μl 
 
 
Segment Temperature (°C) Time Cycles 
Activation 95 10 min 1 
Denaturation 95 15 s  
40 Annealing 60 1 min 
 
Melt curve 
95 15 s  
1 60 1 min 
95 15 s 
 
 
2.3.3.14.2 Quantitative PCR (qPCR) of DNA samples from ChIP experiments 
 
To quantify DNA samples from ChIP experiments, the standard curve method was used. 
ChIP input samples were taken and DNA prepared in the same way as ChIP DNA samples as 
described (see section 2.4.7). A 1:4 serial dilution (2.0, 0.5, 0.125, 0.0313, 0.0078, 0.0019%) 
for ChIP input samples was performed. qPCR was then carried out and a standard curve 
produced. The DNA in ChIP samples was then quantified by comparing the Ct value against 
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the standard curve. Reactions were carried out in a total volume of 15 μl and the components 
and cycling conditions were as follows: 
 
 
Component Amount/Volume (µl) 
DNA sample 3 
2X reaction buffer 7.5 
1.5 μM forward primer 1.5 μl 
1.5 μM reverse primer 1.5 μl 
Sterile water to a final volume of 15 μl 
 
 
Segment Temperature (°C) Time Cycles 
Activation 95 10 min 1 
Denaturation 95 15 s  
40 Annealing 60 1 min 
 
Melt curve 
95 15 s  
1 60 1 min 
95 15 s 
 
 
2.3.3.15 Plasmid vectors 
 
All plasmid vectors used in this study are listed in Table 2.2. Cloning strategies for EBNA-2 
sequences in pBlueScript, OriP-p294 and pHEBoMT vectors are described below in section 
2.3.3.16. 
 
2.3.3.15.1 p554-4 and pERT2 vectors 
 
p554-4 is a 28,428 bp-long OriP plasmid carrying two EBV BamHI W repeats and the 
sequence of a chimeric protein where the type 1 EBNA-2 protein is fused to the hormone-
binding domain of the oestrogen receptor (ER-EBNA-2) [134, 372]. The final methionine of 
the ER domain lies in an EcoRI restriction site which defines the start of the EBNA-2 
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sequence. The end of the 3 UTR of the EBNA-2 sequence is defined by a unique NotI 
restriction site (Figure 2.1). 
 
The pERT2 vector is analogous to p554-4 but carries the type 2 EBNA-2 protein sequence, 
instead of that of type 1, such that type 2 EBNA-2 is expressed as a fusion protein with ER. 
The type 2 EBNA-2 sequence was derived from the AG876 strain (GenBank Accession 
number: NC_009334.1). This vector was previously generated in the laboratory [210] (Figure 
2.1). 
 
 
 
 
 
Figure 2.1. p554-4 and pERT2 vectors.  
 
 
2.3.3.15.2 OriP-p294 plasmid vectors 
 
The OriP-p294 MCS vector used in this study was derived from the CMVpEBNA-1 plasmid 
[377] and was available in the laboratory. The vector includes: OriP, which allows the 
plasmid to replicate separately in EBV-transformed cells, the CMV promoter, the ampicillin-
resistance gene, the hph gene (an E. coli-derived gene that encodes hygromycin B 
phosphotransferase and confers resistance to hygromycin B) and a multiple cloning site 
(MCS), which includes BamHI, NotI and HindIII sites. In the OriP-p294 MCS vector used in 
this study, the EBNA-1 gene in the original CMVpEBNA-1 plasmid was replaced by the 
MCS cloned in as a HindIII-BamHI fragment (Figure 2.2). 
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OriP-p294 plasmids expressing wildtype type 1 or type 2 EBNA-2 (OriP-p294:E2T1 and 
OriP-p294:E2T2 respectively) were already available in the laboratory [211]. OriP-
p294:E2T1 was generated by cloning the BglII-NotI fragment of another plasmid (p554), 
which contained a single BamHI W repeat and the type 1 EBNA-2 coding sequence, into the 
OriP-p294 MCS at the BamHI and NotI sites. OriP-p294:E2T2 was cloned by inserting the 
BglII-NotI fragment from a pAG1 vector, consisting of a single BamHI W repeat and the type 
2 EBNA-2 coding sequence, into the BamHI and NotI sites of the OriP-p294 MCS (Figure 
2.2). 
 
To generate OriP-p294 expression plasmids bearing mutated EBNA-2 sequences, the BglII-
NotI fragment from pSuperInt2 vectors (see section 2.3.3.16.1, Figure 2.5) carrying the 
BamHI W repeat and the mutated EBNA-2 ORFs was cloned into the BamHI and NotI sites 
of the OriP-p294 MCS vector (Figure 2.5). In all OriP-p294:EBNA-2 plasmids, the 
expression of the EBNA-2 ORFs was driven by the EBV Wp promoter. 
 
 
 
 
 
Figure 2.2. OriP-p294 plasmids. 
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2.3.3.16 Cloning strategies 
 
2.3.3.16.1 Cloning of OriP-p294 plasmids with mutant EBNA-2 sequences 
 
To generate mutant EBNA-2 sequences, pBluescript (pBS) plasmids were used. These 
plasmids carried type 1 (pBS:E2T1), type 2 (pBS:E2T2), chimera 6 (pBS:E2C6) or chimera 5 
(pBS:E2C5) EBNA-2 coding sequences between EcoRI and NotI sites previously extracted 
from p554 and pAG1 plasmids respectively in this laboratory [210]. These plasmids were 
used in site-directed mutagenesis (SDM) reactions (see section 2.3.3.13) to generate EBNA-2 
sequences with the required mutations (Figure 2.3). To check the success of SDM reactions, 
restriction digest analysis (see section 2.3.3.4) was performed on plasmid DNA of 
transformants using EcoRI and NotI enzymes and then sequenced.              
 
 
 
 
Figure 2.3. Generation of EBNA-2 mutants in the pBlueScript (pBS) background by site-directed 
mutagenesis (SDM). pBS:E2 plasmids were used in SDM reactions to generate EBNA-2 sequences with a 
mutated (*) transactivation domain (TAD). SDM-PCR products were digested with DpnI and transformed into 
XL1 Blue cells (see section 2.3.3.13). Transformants were screened by restriction digest with EcoRI and NotI 
enzymes (generating the 2 kb EcoRI-NotI EBNA-2-spanning fragment and the 3 kb plasmid backbone) and 
sequenced. Black: EBNA-2 sequence; grey: mutated TAD; E2*: mutated EBNA-2. 
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In order to express the mutant or chimeric EBNA-2 sequences in B cells, they were cloned 
into the OriP-p294 MCS expression vector (see section 2.5). It was not possible to clone the 
EBNA-2 sequences, spanning from EcoRI and NotI sites in pBS, directly into this expression 
vector due to it containing several EcoRI restriction sites. Therefore, two intermediate steps 
were required. Firstly, the mutant transactivation domains (TADs) were subcloned as 
EcoRV-NotI DNA fragments from the pBS background into the laboratory-derived 
intermediate vector pSuperInt which carried the required EBNA-2 background (Figure 2.4). 
These intermediate vectors consisted of 1 BamHI W repeat and the EcoRI-NotI DNA 
fragment and EBNA-2 coding sequence. Successful ligations resulted in the generation of 
pSuperInt2 intermediate plasmids that contained the required mutant EBNA-2 sequences 
linked to the EBV W promoter (Wp). pSuperInt2 plasmids were checked by restriction digest 
analysis (see section 2.3.3.4) performed on plasmid DNA of transformants using EcoRV and 
NotI enzymes and then sequenced. 
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Figure 2.4. Subcloning the mutated EBNA-2 sequences from the pBlueScript (pBS) background into the 
intermediate plasmid, pSuperInt2. Mutant EBNA-2 sequences (E2*) spanning between EcoRI and NotI sites 
were subcloned from the pBS vectors expressing mutant EBNA-2 (pBS-E2*) into the intermediate pSuperInt:E2 
plasmid, generating the pSuperInt2 mutant EBNA-2 (pSuperInt2:E2*) plasmids. Ligation reaction products 
were used to transform OneShot Top10 cells (see section 2.3.3.3 and 2.3.3.13) and the integrity of the 
pSuperInt2:E2* constructs were screened by EcoRI/NotI diagnostic restriction digest analysis. Positive clones 
typically produced a 2 kb band corresponding to the mutated EBNA-2 ORF (black) and a 7 kb band, 
representing the plasmid backbone including the single EBV BamHI W fragment (red). Grey: mutated TAD. 
 
 
To generate the final expression plasmids, fragments from the pSuperInt2 vector sequences, 
spanning from the BglII and NotI sites which contained the mutant EBNA-2 sequences and 
the EBV BamHI W repeat, were excised and ligated to the OriP-p294 MCS vector digested 
with BamHI and NotI (Figure 2.5). Transcription of the mutant EBNA-2 ORFs in these 
plasmids is driven by the EBV Wp. 
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Figure 2.5. Generation of EBNA-2 mutant sequences in the OriP-p294 expression vector. The mutated 
EBNA-2 (E2*) sequences together with the EBV BamHI W promoter (Wp) were extracted from the 
pSuperInt2:E2* vectors by digestion with BglII and NotI. The BglII-NotI fragment was then cloned into the 
empty vector OriP-p294 MCS, digested with BamHI and NotI, generating the final OriP-p294:E2* expression 
plasmids. In these plasmids, mutated EBNA-2 sequences are expressed from the EBV Wp. The integrity of the 
final expression plasmids was screened by several diagnostic restriction digests. Note: BglII and BamHI have 
compatible ends. Hyg: hygromycin (blue); MCS: multiple cloning site (yellow); grey: mutated TAD. 
 
 
The final OriP-p294 constructs which carried the mutant EBNA-2 sequences were screened 
using several diagnostic restriction digests (see section 2.3.3.4). This included double 
digestion with EcoRI and NotI to check for the presence of the EBNA-2 ORF. Double 
digestions with BglII and NotI and EcoRI in combination with either EcoRV, BstXI, BstBI or 
SacII were often routinely performed. 
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2.3.3.16.2 Cloning of pHEBo plasmids with inducible expression of EBNA-2 sequences 
 
pHEBo plasmids from which EBNA-2 proteins could be inducibly expressed from the 
metallothionein (MT) promoter were generated. Claudio Elgueta successfully cloned 
wildtype type 1 and type 2 EBNA-2 sequences into pHEBo plasmids modified to carry the 
MT promoter (pHEBoMT-EBNA-2). Briefly, the MT promoter was first cloned out of the 
pMEP4 vector with XhoI and HindIII enzymes and linked to the HindIII-BglII type 1 EBNA-
2 fragment from pSG5:EBNA-2. The BamHI site in pHEBo was converted to a second NotI 
site and the MT-EBNA-2 expression cassette was inserted as a NotI fragment generating 
type 1 pHEBoMT-EBNA-2. The same strategy was used to generate type 2 pHEBoMT-
EBNA-2, but type 2 EBNA-2 was cloned out of the pBS:E2T2 plasmid which had initially 
been modified to convert its SacI site to a BglII. The EcoRI-BglII fragment spanning the type 
2 EBNA-2 sequence was then inserted into pSG5-EBNA-2. The type 2 MT-EBNA-2 
expression cassette was assembled as described above and cloned into pHEBo. 
 
Numerous attempts were made to generate a type 2 S442D pHEBoMT-EBNA-2 vector with 
the same strategy as above but were unsuccessful. Finally, SDM was used with the 
QuikChange II XL Site-Directed Mutagenesis kit (Agilent Technologies) as described (see 
section 2.3.3.13). The whole of the EBNA-2 gene was sequenced to ensure no other 
mutations were inserted in the reaction.  
 
 
Plasmid Relevant information Source 
p554-4 2 BamHI W repeats and type 1 ER-EBNA-2 fusion Laboratory 
pERT2 2 BamHI W repeats and type 2 ER-EBNA-2 fusion Laboratory 
pBS-E2T1 pBS derivative (der.), type 1 EBNA-2, amp Laboratory 
pBS-E2T2 pBS der., type 2 EBNA-2, amp Laboratory 
pBS-E2C6 pBS der., chimera 6 EBNA-2, amp Laboratory 
pBS-E2C5 pBS der., chimera 5 EBNA-2, amp Laboratory 
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pBS-E2C6* pBS der., chimera 6 EBNA-2 TAD mutants, amp This study 
pBS-E2C5 S442D pBS der., chimera 5 S442D EBNA-2, amp This study 
pBS-E2T1 D442S pBS der., type 1 D442S EBNA-2, amp This study 
pBS-E2T2 S442D pBS der., type 2 S442D EBNA-2, amp This study 
pSuperInt-E2T1 1 BamHI W repeat, type 1 EBNA-2, amp Laboratory 
pSuperInt2-E2C6* 1 BamHI W repeat, chimera 6 EBNA-2 TAD 
mutants, amp 
This study 
pSuperInt2-E2C5 S442D 1 BamHI W repeat, chimera 5 S442D EBNA-2, amp This study 
pSuperInt2-E2T1 D442S 1 BamHI W repeat, type 1 D442S EBNA-2, amp This study 
pSuperInt2-E2T2 S442D 1 BamHI W repeat, type 2 S442D EBNA-2, amp This study 
OriP-p294 MCS OriP, CMVp, MCS, hyg Laboratory 
OriP-p294 E2T1 type 1 EBNA-2, OriP, CMVp, hyg Laboratory 
OriP-p294 E2T2 type 2 EBNA-2, OriP, CMVp, hyg Laboratory 
OriP-p294 E2C5 chimera 5 EBNA-2, OriP, CMVp, hyg Laboratory 
OriP-p294 E2C6 chimera 6 EBNA-2, OriP, CMVp, hyg Laboratory 
OriP-p294 E2C7 chimera 7 EBNA-2, OriP, CMVp, hyg Laboratory 
OriP-p294 E2C6* chimera 6 EBNA-2 TAD mutants, OriP, CMVp, 
hyg 
This study 
OriP-p294 E2C5 S442D chimera 5 S442D EBNA-2, OriP, CMVp, hyg This study 
OriP-p294 E2T1 D442S type 1 D442S EBNA-2, OriP, CMVp, hyg This study 
OriP-p294 E2T2 S442D type 2 S442D EBNA-2, OriP, CMVp, hyg This study 
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pCR2.1-TOPO TA vector for subcloning PCR products, amp Invitrogen 
pSG5:E2T1 type 1 EBNA-2, Agilent, amp Laboratory 
pSG5:E2T2 type 2 EBNA-2, Agilent, amp Laboratory 
pSG5:E2T2 S442D type 2 S442D EBNA-2, Agilent, amp This study 
pBK-CMV-MT:E2 EBNA-2 expression driven by metallothionein (MT) 
promoter cassette, amp 
Laboratory 
pMEP4-MT MT cassette, Invitrogen, amp Laboratory 
pHEBo (BamHINotI) OriP, BamHI site modified to NotI, hyg This study 
pHEBoMT-E2T1 type 1 EBNA-2 expression driven by MT, OriP, hyg This study 
pHEBoMT-E2T2 type 2 EBNA-2 expression driven by MT, OriP, hyg This study 
pHEBoMT-E2T2 S442D type 2 S442D EBNA-2 expression driven by MT, 
OriP, hyg 
This study 
 
  
Table 2.2. Plasmids used in this study. ER: oestrogen receptor; T: type; C: chimera; *: mutants; amp: 
ampicillin resistance (100 μg/ml); hyg: hygromycin resistance (150-300 μg/ml); MT: metallothionein promoter. 
 
 
2.3.4 RNA protocols 
 
2.3.4.1 RNA extraction 
 
2.3.4.1.1 Cytoplasmic RNA extraction using TRIzol 
 
Pellets from approximately 10
8
 cells were resuspended in 10 ml buffer A (0.15 M NaCl, 
10 mM Tris-Cl pH 7.5, 1 mM MgCl2, 0.1% Triton X-100), briefly vortexed and incubated on 
ice for 2 min. Nuclei were spun out using a centrifuge at 700 x g, 4°C for 5 min. The 
supernatant (cytosolic fraction) was mixed with 25 ml TRIzol reagent (Invitrogen) and 
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incubated at room temperature for 5 min. 0.2 ml isopropanol (per 1 ml TRIzol) was added 
and the mixture shaken vigorously for 15 s.  Samples were incubated at room temperature for 
a further 2-3 min before being centrifuged at 3750 rpm for 1 h at 4°C in an Allegra 6R 
centrifuge (Beckman Coulter). 0.5 ml isopropanol (per 1 ml TRIzol) was added to the upper, 
RNA-containing phase and incubated at room temperature for 10 min. A cytoplasmic RNA 
pellet was produced by centrifugation at 3750 rpm for 1 h at 4°C and then washed once with 
75% (v/v) ethanol. Pellets were air-dried and re-dissolved in DEPC-treated water (Ambion) 
by incubating at 55°C for 10 min. 
 
2.3.4.1.2 Total RNA extraction using RNeasy kit 
 
The RNeasy Mini Kit (Qiagen) was also used to extract cytoplasmic RNA according to the 
manufacturer’s instructions. Briefly, cells were harvested and washed once in ice-cold PBS 
before centrifugation at 335 x g for 5 min at 4°C. For time-course experiments, cells were 
often resuspended in 500 l RNAprotect buffer (Qiagen) before extraction with all samples. 
Cell suspensions were mixed with 600 l RLT buffer (Qiagen) supplemented with -
mercaptoethanol (10 l per 1 ml RLT buffer). Lysates were homogenised by being passed 
through a blunt 20 G needle (0.9 mm) at least 5 times. 1 volume of 70% (v/v) ethanol was 
then added to the homogenised lysate and mixed well by inverting the tubes 10 times. 
Samples were transferred to RNeasy spin columns and RNA bound by centrigufation. All 
centrifugations from this point in the protocol were performed in a microcentrifuge at 
13000 rpm at 4°C for 30 s. The column was then washed with 700 l RW1 buffer (Qiagen). 
A further two washes were performed with 500 l RPE buffer (Qiagen) for 30 s and 2 min 
respectively. Finally, RNA was eluted with approximately 30 l RNase-free water. 
 
2.3.4.2 DNase treatment of RNA 
 
RNA concentration and purity was first assessed using a Nanodrop 1000 spectrophotometer 
as described previously (see section 2.3.2). Before reverse transcription (RT), 5 µg RNA was 
treated with RQ1 RNase-free DNase (Promega). 1 U DNase per g RNA was incubated for 
35 min at 37°C in a total volume of 10 μl. If necessary, RNA was purified from the reactions 
by phenol/chloroform purification and ethanol precipitation (see section 2.3.1). 
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2.3.4.3 Reverse transcription 
 
Complementary DNA (cDNA) was prepared from RNA using the Protoscript First Strand 
cDNA Synthesis Kit (NEB). 1 µg DNase-treated RNA was mixed with 2 µl dT23VN (50 M) 
(V=A, C or G; N=any base) and 4 l dNTP mix (2.5 mM each) and incubated at 70°C for 
5 min in a total reaction volume of 8 µl. Samples were then transferred to ice before addition 
of 10 µl 2X RT buffer (100 mM Tris-Cl pH 8.3, 150 mM KCl, 6 mM MgCl2, 20 mM DTT) 
and 2 µl M-MULV reverse transcriptase (25 U/l). Samples were incubated at 42°C for 1 h 
for reverse transcription and subsequently at 80°C for 5 min to inactivate the enzyme. cDNA 
was diluted to a final volume of 50 l with DEPC-treated water. 
 
2.3.4.4 5 Rapid amplification of cDNA ends (5 RACE) 
 
5 RACE was performed using the 5 RACE System for Rapid Amplification of cDNA Ends 
according to the manufacturer’s instructions (Invitrogen). RNA was first extracted from cells 
as previously described (see section 2.3.4.1.1). 1-5 μg RNA was then used in a first strand 
synthesis reaction. RNA was denatured in a reaction volume of 15.5 μl with 2.5 pmol gene-
specific primer 1 (GSP1) for 10 min at 70°C and then chilled on ice. 2.5 μl 10X PCR buffer, 
2.5 μl 25 mM MgCl2, 1 μl 10 mM dNTP mix and 2.5 μl 0.1 M DTT were then added to the 
sample and incubated at 42°C for 1 min. cDNA was synthesised after addition of 1 μl 
SuperScript II RT enzyme (Invitrogen) and another 42°C incubation for 50 min. Samples 
were then incubated at 70°C for 15 min to terminate the reaction. The original RNA template 
was degraded by the addition of 1 μl RNase mix (Invitrogen) and incubation at 37°C for 
30 min. 120 μl binding solution (6 M sodium iodide) was added to the sample, transferred to 
a SNAP column and centrifuged at 13000 x g for 30 s at room temperature. cDNA was 
washed four times with cold 1X wash buffer and twice with cold 70% (v/v) ethanol. Residual 
ethanol was removed by centrifuging again at 13000 x g for 30 s at room temperature. 
Purified cDNA was then eluted with dH2O preheated to 65°C and an oligo-dC tail added to 
the 3 end. 10 μl SNAP-purified cDNA were incubated at 94°C for 2 min with 6.5 μl DEPC-
treated water, 5 μl 5X tailing buffer (Invitrogen) and 2.5 μl 2 mM dCTP. 1 μl terminal 
deoxynucleotidyl transferase (TdT) was then added to the sample and incubated at 37°C for 
10 min. The TdT enzyme was then inactivated by incubation at 65°C for a further 10 min. A 
110 
 
RACE-PCR reaction was then performed with the following components and cycling 
conditions: 
 
Component Amount/Volume (µl) 
cDNA template 5 
10X reaction buffer 5 
25 mM MgCl2 4 (2.0 mM) 
10 mM dNTP mix 1 (0.2 mM) 
10 μM gene-specific primer 2 (GSP2) 1 (0.2 μM) 
10 μM abridged anchor primer (AAP) 1 (0.2 μM) 
Taq DNA polymerase (5 U/µl) 0.5 (2.5 U) 
Sterile water to a final volume of 50 μl 
 
 
Segment Temperature (°C) Time Cycles 
Activation 94 2 min 1 
Denaturation 94 1 min  
35 Annealing 55 1 min 
Extension 72 1 min/kb 
Final extension 72 7 min 1 
 
 
5-20 μl 5 RACE products were analysed by agarose gel electrophoresis as previously 
described (see section 2.3.3.6). The 5 RACE product was TA-cloned directly into the 
pCR2.1-TOPO vector (see section 2.3.3.9), before being transformed into OneShot Top10 
cells, screened by colony PCR (see sections 2.3.3.3 and 2.3.3.12.1) and sequenced. 
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2.3.5 Primers 
 
Primers were sourced from Invitrogen or Eurofins MWG Operon (Germany). 
 
2.3.5.1 Primers for site-directed mutagenesis of EBNA-2 plasmids 
 
Complementary oligonucleotides used in site-directed mutagenesis (SDM) reactions were 
designed as described previously (see section 2.3.3.13). These oligonucleotides, 
complementary to type 2 EBNA-2 unless otherwise stated, had the following sequences: 
 
Mutation 1: SD431-432HN 
Forward: 5ʹ-CCAATACATGAACCAGAGTCCCATAATAGTGAAGAACCCCCCTTTC-3ʹ 
Reverse: 5ʹ-GAAAGGGGGGTTCTTCACTATTATGGGACTCTGGTTCATGTATTGG-3ʹ 
 
Mutation 2: EEP434-436PEA 
Forward: 5ʹ-CCAGAGTCCTCTGATAGTCCAGAAGCCCCCTTTCTCTTCCCC-3ʹ 
Reverse: 5 ʹ- GGGGAAGAGAAAGGGGGCTTCTGGACTATCAGAGGACTCTGG-3ʹ 
 
Mutation 3: F438I 
Forward: 5ʹ-GATAGTGAAGAACCCCCCATTCTCTTCCCCAGTGATTGG-3ʹ 
Reverse: 5ʹ-CCAATCACTGGGGAAGAGAATGGGGGGTTCTTCACTATC-3ʹ 
 
Mutation 4: S442D 
Forward: 5ʹ-CCCTTTCTCTTCCCCGATGATTGGTATCCTCCAACG-3ʹ 
Reverse: 5ʹ-CGTTGGAGGATACCAATCATCGGGGAAGAGAAAGGG-3ʹ 
 
Mutation 5: G460Y 
Forward: 5ʹ-GCAGAATTAGATGAAAGTTGGGAGTACATTTTTGAAACAACAGAATC 
TC-3ʹ 
Reverse: 5ʹ-GAGATTCTGTTGTTTCAAAAATGTACTCCCAACTTTCATCTAATTCTGC 
-3ʹ 
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Reverse mutation 4: D442S (complementary to type 1 EBNA-2) 
Forward: 5ʹ-GGCTCCCATTCTCTTCCCCAGTGATTGGTATCCTCCATCTATAGACC-3ʹ 
Reverse: 5ʹ-GGTCTATAGATGGAGGATACCAATCACTGGGGAAGAGAATGGGAGCC 
-3ʹ 
 
2.3.5.2 Primers used for sequencing in this study 
 
The following primers were used to sequence DNA regions of interest: 
 
Type 1 and type 2 EBNA-2 C-terminus 
Forward: 5ʹ-CCACCAGCAGCACCAGCACA-3ʹ 
Reverse: 5ʹ-GTTGGTGGAATAGCTAAAC-3ʹ 
 
Type 1 EBNA-2 N-terminus 
Forward 1: 5ʹ-TGACACGGATAGTCTTGG-3ʹ 
Forward 2: 5ʹ-GCTATGCGAATGCTTTGG-3ʹ 
Forward 3: 5ʹ-ACTTCAACCCACACCATC-3ʹ 
Reverse 1: 5ʹ-GAGGACTGGACTTAGTTCAG-3ʹ 
Reverse 2: 5ʹ-CGTGGTTCTGGACTATCTG-3ʹ 
Reverse 3: 5ʹ-GACAGAGGTGACAAAATGG-3ʹ 
Reverse 4: 5ʹ-ACAGTTGTTCCTGGTAGGG-3ʹ 
 
Type 2 EBNA-2 N-terminus 
Forward 1: 5ʹ-GCCTACATACTATCTTGCG-3ʹ 
Forward 2: 5ʹ-TTTGTTACAGAGTCCCGC-3ʹ 
Reverse 1: 5ʹ-CGTGGTTCAGGAAGTTTG-3ʹ 
Reverse 2: 5ʹ-ATGCGGTGGTAGACTTAG-3ʹ 
Reverse 3: 5ʹ-TATCCAGTGGTAAGGGCTC-3ʹ 
 
M13 
Forward (-20): 5ʹ-GTAAAACGACGGCCAGT-3ʹ 
Reverse (-24): 5ʹ-AACAGCTATGACCATG-3ʹ 
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T7 
Universal sequencing primer: 5ʹ-TAATACGACTCACTATAGGG-3ʹ 
Terminator primer: 5ʹ-CTAGTTATTGCTCAGCGGTG-3ʹ 
 
2.3.5.3 Primers used for RT-PCR 
 
CXCR7: exon 1 
Forward: 5ʹ-CCTGTTCTCAATCTGGTCTGGG-3ʹ 
 
CXCR7: exon 2 
Forward: 5ʹ-CCTGAGGAGATACAAACACTTCTC-3ʹ 
 
CXCR7: exon 3 
Forward: 5ʹ-GGCTCTAAGTATTCATATGAGGCC-3ʹ 
 
CXCR7: exon 4 
Forward: 5ʹ-CCAGAATTCTCGCAGGCGCC-3ʹ 
 
CXCR7: exon 5 
Forward: 5ʹ-TGCCTCCTGCACCACCAACT-3ʹ 
 
CXCR7: all exons 
Reverse: 5ʹ-CGCCTGCTTCACCACCTTC-3ʹ 
 
GAPDH 
Forward: 5ʹ-TGCCTCCTGCACCACCAACT-3ʹ 
Reverse: 5ʹ-CGCCTGCTTCACCACCTTC-3ʹ 
 
2.3.5.4 Primers used for qPCR to quantify mRNA transcripts 
 
Primers used in qPCR were designed to generate products of approximately 80-120 bp using 
Primer3 software. 
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LMP-1 
Forward: 5ʹ-CTAGGAAGAAGGCTAGGAAG-3ʹ 
Reverse: 5ʹ-CAGAAGAGACCTTCTCTGTC-3ʹ 
 
CXCR7 
Forward: 5ʹ-GCAGCCAGCAGAGCTCACAGTTG-3ʹ 
Reverse: 5ʹ-TGGGCATGTTGGGACACATCACC-3ʹ 
 
GAPDH 
Forward: 5ʹ-CGCCTGCTTCACCACCTTC-3ʹ 
Reverse: 5ʹ-TGCCTCCTGCACCACCAACT-3ʹ 
 
2.3.5.5 Primers for CXCR7 5 RACE 
 
Gene-specific primers 1 and 2 (GSP1 and 2) are complementary to sequences in the leading 
exon of CXCR7. GSP1 is used to synthesise cDNA and GSP2, together with AAP, to amplify 
DNA of unknown sequence in the 5 RACE PCR reaction. 
 
GSP1: 5ʹ-CAAGATGTAGCACTGCGTGTCATAGCC-3ʹ 
 
GSP2: 5ʹ-AGAGCAGGACGCTTTTGTTGGGC-3ʹ 
 
Abridged anchor primer (AAP): 5ʹ-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-
3ʹ 
 
2.3.5.6 Primers used for ChIP-qPCR  
 
CXCR7: position 1 
Forward: 5ʹ-GCCTAGAGACTGTCTGGCACTT-3ʹ 
Reverse: 5ʹ-GAATAATAACAGTGACTGCCATAGGA-3ʹ 
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CXCR7: position 2 
Forward: 5ʹ-TTCCAATCAGCCAAGATGG-3ʹ 
Reverse: 5ʹ-GGTCATGTCCAGTGATGTGC-3ʹ 
 
CXCR7: position 3 
Forward: 5ʹ-TTGTGGACAGCTGTTCTCTGTT-3ʹ 
Reverse: 5ʹ-CTCCAGGAATACATGCCATGAG-3ʹ 
 
CXCR7: position 4 
Forward: 5ʹ-AGGTATCCTGCATTCCTCCTT-3ʹ 
Reverse: 5ʹ-GAGACAGACATGCCACCTCA-3ʹ 
 
CXCR7: position 5 
Forward: 5ʹ-TGGCCAGGACTTCTCAATG-3ʹ 
Reverse: 5ʹ-TGAATGAACTTCAGATGCATGA-3ʹ 
 
CXCR7: position 6 
Forward: 5ʹ-GTGACCTGGGTTTGACCCTA-3ʹ 
Reverse: 5ʹ-TCTCTGAGTAAGGCCAGGAAA-3ʹ 
 
CXCR7: position 7 
Forward: 5ʹ-TTGTCAAGCCTTGGAACGTA-3ʹ 
Reverse: 5ʹ-TCTTCCGCTTCTCTCCTCTG-3ʹ 
 
CXCR7: position 8 
Forward: 5ʹ-TGTGTGTGTCTGCCTGTGG-3ʹ 
Reverse: 5ʹ-TGGCTGCAGACTTGCATTAT-3ʹ 
 
CXCR7: position 9 
Forward: 5ʹ-CCATCAGTGAATGGTGGTCA-3ʹ 
Reverse: 5ʹ-TGCCGTGTAACATGGAAGG-3ʹ 
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CXCR7: position 10 
Forward: 5ʹ-TTGATACACATGTACATCCTCAGGT-3ʹ 
Reverse: 5ʹ-TGCCTCTCGTATGCTGTTATCC-3ʹ 
 
CXCR7: position 11 
Forward: 5ʹ-CACACGAAGGCTGGAGTAGT-3ʹ 
Reverse: 5ʹ-AGCATGAGAGGAGTGTTGACC-3ʹ 
 
CXCR7: position 12 
Forward: 5ʹ-AGATCGGTAGTTGGATGGGTTT-3ʹ 
Reverse: 5ʹ-CTCATGGTTCTATGTCCTCACCA-3ʹ 
 
CCL3: position 1 
Forward: 5ʹ-GAGGTATGCTGATTGATTGTGAA-3ʹ 
Reverse: 5ʹ-CTACCTTCTCAGCCAGATTATATGC-3ʹ 
 
CCL3: position 2 
Forward: 5ʹ-GCTGGAGAGTTCATGCACAG-3ʹ 
Reverse: 5ʹ-TTCTCCTGTGAGTGTGAAGAGG-3ʹ 
 
ADAMDEC1: position 1 
Forward: 5ʹ-GTAGATATGCACGCGACCAC-3ʹ 
Reverse: 5ʹ-TTGAGGACTCACATCTGGACA-3ʹ 
 
ADAMDEC1: position 2 
Forward: 5ʹ-CCTGACTAAGGCCCATAACG-3ʹ 
Reverse: 5ʹ-AGAGCTCTGGGAACAAGTGG-3ʹ 
 
LMP-1: position 1 
Forward: 5ʹ-AGAGGAGGAGAAGGAGAGCAA-3ʹ 
Reverse: 5ʹ-CGCCCTACATAAGCCTCTCA-3ʹ 
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LMP-1: position 2 
Forward: 5ʹ-TGAGCAGGATGAGGTCTAGGA-3ʹ 
Reverse: 5ʹ-GGAGATGCTCTGGCGACTTG-3ʹ 
 
PPIA 
Forward: 5ʹ-GGGCCGAACGTGGTATAA-3ʹ 
Reverse: 5ʹ-CCATGGCTAATAGTACACGGTTT-3ʹ 
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2.4 Protein protocols 
 
2.4.1 Cellular protein extraction with RIPA lysis buffer 
 
Cell pellets were resuspended in approximately three volumes of RIPA lysis buffer (0.15 M 
NaCl, 1% (v/v) NP-40, 0.5% (v/v) deoxycholic acid, 0.1% (w/v) SDS, 50 mM Tris-Cl 
pH 8.0), 1 mM PMSF (Fluka Biochemika) with 1X complete protease inhibitor cocktail 
(Roche)). The mixture was incubated under rotation at 4°C for 30 min and then centrifuged at 
25000 x g for 15 min at 4°C to pellet cell debris. Cell lysates were transferred to fresh 
eppendorf tubes and a small sample taken for determination of the protein concentration (see 
section 2.4.2) before being stored at -20°C. 
 
2.4.2 Protein quantification 
 
The protein concentration of cell lysates was determined using the Bio-Rad DC protein assay 
(Bio-Rad) to allow for loading of equal amounts of protein in Western blotting. Bovine serum 
albumin (BSA) (NEB) dilutions (0, 0.078, 0.156, 0.312, 0.625, 1.25, 2.5 and 5.0 g/l) were 
prepared and treated in the same way as lysate samples to produce a standard curve. 5 l cell 
lysates were diluted 1:4 with RIPA lysis buffer. Reagant S was diluted 1:50 in reagent A 
(alkaline copper tartrate solution) and 100 l of this solution was added to each lysate 
sample. This was followed by the addition of 800 l reagent B (dilute Folin reagent), a short 
vortex to mix the samples and then a 15 min incubation at room temperature. The protein 
concentration of the samples was subsequently measured by reading the absorbance at 
750 nm using a Heios spectrophotometer (UNICAM, USA) and comparing the value 
against the standard curve. Protein samples were then snap-frozen on dry ice and stored at      
-20°C. 
 
2.4.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
Proteins were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) using the Bio-Rad Mini Protean II system (Bio-Rad). 7.5-15% (v/v) resolving 
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polyacrylamide gels (7.5-15% (v/v) acrylamide/bis-acrylamide (29:1) (Bio-Rad), 375 mM 
Tris-Cl pH 8.8, 0.1% (w/v) SDS) combined with a 5% (v/v) stacking gel (5% (29:1) 
acrylamide/bis-acrylamide, 125 mM Tris-Cl pH 6.8, 0.1% (w/v) SDS) were used to separate 
proteins dependent on the size of the protein of interest. Mini-gels were polymerised with 
10 l NNN’N’-tetramethylethylenediamine (TEMED) (National Diagnostics, USA) and 
50 l 10% (w/v) ammonium persulphate (APS) (Sigma) per 10 ml gel volume. Protein 
samples were incubated with 2X SDS sample buffer (120 mM Tris-HCl pH 6.8, 4% (w/v) 
SDS, 2% (v/v) -mercaptoethanol, 20% (v/v) glycerol, 0.01% (w/v) bromophenol blue) or 
Laemmli buffer (Bio-Rad) at 95°C for 10 min. 10-20 g of each protein sample were then 
loaded on the gel per well along with Full Range Rainbow Molecular Weight Marker 
(Amersham, UK) to use as a standard for protein size determination. Gels were run at 150-
180 V for approximately 1 h in 1X SDS running buffer (25 mM Tris, 192 mM glycine, 
0.1% (w/v) SDS). 
 
2.4.4 Coomassie staining 
 
Proteins on SDS-PAGE gels were stained with Coomassie blue (40% (v/v) methanol, 10% 
(v/v) acetic acid, 1 g/l Coomassie Brilliant Blue R-250 (Thermo Scientific)) for 1-4 h and 
then left in destaining solution (40% (v/v) methanol, 10% (v/v) acetic acid) overnight. 
 
2.4.5 Western blotting 
 
2.4.5.1 Western blotting using enhanced chemiluminescence (ECL) 
 
10-20 µg protein samples were resolved by SDS-PAGE as previously described (see section 
2.4.3). Proteins were blotted on to an Amersham Protran 0.45 μm nitrocellulose blotting 
membrane (GE Healthcare, UK) in cold transfer buffer (25 mM Tris, 192 mM glycine, 
0.1% (w/v) SDS, 24% (v/v) ethanol) at 100 V for 1 h. The membrane was then saturated in 
blocking solution (PBS with 0.1% (v/v) Tween-20 (Sigma) and 5% (w/v) skimmed milk 
powder (Sigma)) for 1 h at room temperature. Membranes were then incubated with the 
appropriate primary antibody diluted in blocking solution at 4°C overnight (Table 2.3). The 
following day, membranes were washed three times for 10 min in PBS-T wash buffer (PBS-
0.1% tween-20) and then incubated for 1 h at room temperature with an appropriate 
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secondary antibody conjugated to horse-radish peroxidise (HRP) (Table 2.3) diluted in 
blocking solution. Membranes were washed a further four times for 10 min. Equal volumes 
of Amersham ECL Western blotting detection reagents (GE Healthcare) were added to the 
membranes and proteins were visualised by detecting the chemiluminescent signal by 
exposure to Super RX X-ray film (Fujifilm, Japan). 
 
2.4.5.2 Western blotting using Odyssey Infrared Imaging System 
 
Protein samples were separated by SDS-PAGE and electrotransferred onto nitrocellulose 
membranes as previously described (see section 2.4.3 and 2.4.5.1). After blocking with 
Odyssey blocking buffer (LI-COR Biosciences, USA) diluted 1:1 with 1X PBS, membranes 
were incubated with primary antibody in Odyssey blocking buffer overnight at 4°C. 
Membranes were then washed with PBS-T three times for 10 min at room temperature and 
incubated with IRDye infrared dye-conjugated secondary antibodies diluted at 1:10000 in 
Odyssey blocking buffer for 1 h at room temperature in the dark. All subsequent steps were 
performed in the dark. The membranes were washed three times for 10 min in PBS-T and for 
a further 10 min with PBS only to remove any residual Tween-20. The membranes were then 
patted dry on filter paper and wrapped in aluminium foil for storage at 4°C. The protein of 
interest was visualised by scanning the appropriate channels in the infrared wavelength range 
using an Odyssey Infrared Imaging System (LI-COR Biosciences). 
 
2.4.5.3 Stripping of Western blot membranes 
 
Western blot membranes were reprobed for a second protein of interest by removing the first 
primary and secondary antibodies from the membrane. Membranes were incubated in 
Western blot stripping solution (2% (w/v) SDS, 62.5 mM Tris-Cl pH 6.8) supplemented with 
-mercaptoethanol at 55°C for 1 h in a tightly-sealed plastic box. The membrane was then 
washed with PBS-T three times for 10 min in a fume cupboard and another three times for 
10 min on a fast rocker to remove all traces of -mercaptoethanol. The membrane was 
subsequently blocked and incubated with different antibodies as before (see section 2.4.5.1). 
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2.4.6 Immunofluorescence (IF) 
 
Cover slips (VWR) were sterilised by baking overnight at 150°C. Cover slips were then 
treated for 5 min at room temperature with poly-L-lysine (Sigma) diluted 1:5 in PBS and 
washed twice for 2 min in PBS in 6-well plates. 5x10
5
 adherent HeLa cells per well were 
added and transfected using the lipofectamine 2000 method (see section 2.2.6.1). 24 h after 
transfection, cells were washed twice in PBS and fixed with 4% (v/v) paraformaldehyde 
(PFA) (Electron Microscopy Sciences, USA) for 45 min at room temperature. Cells were 
then washed three times in PBS before quenching with 50 mM ammonium chloride (Sigma) 
for 10 min. After a further three washes with PBS, cells were permeabilised with 0.25% (v/v) 
Triton-X 100 (Sigma) in PBS for 7 min at room temperature and then PBS-washed four times 
and blocked in 1% (w/v) BSA in PBS for 30 min. Cells were then incubated for 45 min at 
room temperature with mouse monoclonal anti-EBNA-2 PE2 antibody diluted 1:100 in 
blocking buffer. Cover slips were washed three times for 10 min with PBS. TRITC-
conjugated anti-mouse secondary antibody (Sigma) at a 1:5000 dilution in blocking buffer 
was then used to incubate cover slips for a further 45 min at room temperature. Coverslips 
were again washed three times for 10 min in PBS and once in dH2O. Cells were then 
counterstained with 2 g/l DAPI (Thermo Scientific) and mounted in Mowiol (Sigma) to a 
carrier slide. Slides were stored in the dark at 4°C and cells visualised using a Zeiss 510 Meta 
laser confocal microscope (Zeiss, Germany). 
 
2.4.7 Chromatin immunoprecipitation (ChIP) 
 
5x10
5
 cells/ml were prepared and treated as required. Cells were then washed once in warm 
PBS and resuspended in fresh media at a density of 1x10
7
 cells/ml. Formaldehyde (Sigma) 
was added to a 1% (v/v) final concentration to crosslink protein and DNA and incubated for 
15 min at room temperature with rocking. Glycine was added to a final concentration of 
0.125 M to quench the reaction. Cells were then centrifuged at 335 x g for 10 min at 4°C and 
washed once with PBS. Cells were subsequently resuspended in cell lysis buffer (300 μl per 
1x10
7
 cells) and incubated on ice for 10 min. Samples were centrifuged at 8000 rpm for 
5 min at 4°C in a microcentrifuge and nuclei resuspended in SDS lysis buffer (200 μl per 
1x10
7
 cells) on ice. Nuclear lysates were then sonicated to reduce DNA length to 
approximately 200-600 bp. This was done by sonicating 1 ml aliquots of nuclear lysate on icy 
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water with a micro-tip probe for 10x10 s at 30% amplitude using an Ultrasonic XL2020 
Processor (Heat Systems, USA). Alternatively, 300 μl aliquots were sonicated at high speed 
for 15x30 s pulses in icy water using a Bioruptor UCD-200 (Diagenoke, Belgium). Sonicated 
chromatin was stored at -80°C. Protein A sepharose 4B Fast Flow beads (Sigma) were 
washed twice with PBS and IP dilution buffer and then blocked with 0.5% (w/v) BSA for 1 h 
at 4°C with rotation. 105 μl chromatin from approximately 5x106 cells was diluted 10-fold in 
IP dilution buffer and pre-cleared with blocked beads for 1 h at 4°C with rotation. The pre-
clear reaction was centrifuged at 4000 rpm for 5 min at 4°C in a microcentrifuge and an input 
sample was removed and stored at -20°C. Proteins were specifically precipitated by overnight 
rotation at 4°C with approximately 8 μg primary antibodies (Table 2.3). For proteins 
immunoprecipitated with mouse monoclonal antibodies, 10 μg of rabbit anti-mouse 
secondary antibody was added the following day to the immunoprecipitation reactions and 
incubated with rotation for a further 2 h at 4°C. Blocked beads were subsequently added to 
collect immunocomplexes by rotation at 4°C for 3 h. Beads were pelleted by centrifugation at 
4000 rpm for 1 min at 4°C and washed once for 10 min at 4°C with low salt, high salt and 
LiCl wash buffers. Beads were then washed twice with TE buffer and samples taken for 
protein analysis by Western blot (see section 2.4.5) if necessary. To elute DNA from the 
immunocomplexes and reverse cross-links, 150 μl elution buffer was added to beads and 
incubated for 20 min at 65°C. Samples were centrifuged at 4000 rpm for 2 min at room 
temperature and the supernatant transferred to fresh Eppendorf tubes. Input samples were 
then processed alongside ChIP samples and incubated overnight at 65°C. Following 
proteinase K (Thermo Scientific) digestion, DNA was purified using a QIAquick gel 
extraction kit (Qiagen) (see section 2.3.3.7) and eluted in 60 or 110 μl DEPC-treated water. 
1:4 serial dilution of input DNA was performed and qPCR carried out as described previously 
(see section 2.3.3.14.2). 
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2.4.8 Antibodies  
 
Antigen Antibody Source Dilution 
EBNA-2 PE2, mouse monoclonal Hybridoma cell line 
Dr M W West 
1:100 WB 
8 μg per IP 
LMP-1 CS 1-4, mouse monoclonal Dako, Denmark 1:500 WB 
Human β-actin AC-74, mouse monoclonal Sigma 1:2000 WB 
Human histone H1 Sheep polyclonal Abcam, USA 1:500 WB 
Human GAPDH GC5, mouse monoclonal Ambion 1:4000 WB 
Mouse IgG Rabbit polyclonal Dako 1:1000 WB 
10 μg per IP 
Rabbit IgG Goat polyclonal-HRP Dako 1:1000 WB 
Mouse IgG Sheep polyclonal-HRP GE Healthcare 1:10000 WB 
Sheep IgG Rabbit polyclonal-HRP Dako 1:2000 WB 
Mouse IgG Goat polyclonal-TRITC Sigma 1:10000 IF 
Rabbit IgG IRDye 680RD goat 
polyclonal 
LI-COR Biosciences 1:10000 WB 
None (control for 
ChIP assays) 
Mouse monoclonal Santa Cruz, USA 8 μg per IP 
Human p300 C-20, rabbit polyclonal Santa Cruz 8 μg per IP 
Human acetylated 
histone H3 
Rabbit polyclonal Millipore 8 μg per IP 
 
Table 2.3. Antibodies used in this study. WB: Western blot; IP: immunoprecipitation; IF: 
immunofluorescence. 
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3 Mapping of amino acids of type 1 EBNA-2 which confer 
higher B cell immortalisation efficiency compared to type 
2 EBNA-2 
 
The aim of this chapter is to identify the amino acids of EBNA-2 which are important for the 
enhanced ability of type 1 EBNA-2 to promote B cell growth when compared to type 2 
EBNA-2. 
 
3.1 Introduction 
 
Numerous studies performed previously have led to the identification of structures and 
functional domains of EBNA-2. These have mostly been focussed on the type 1 protein. 
Using either primary B cell transformation experiments with recombinant EBV viruses [224, 
230-233, 235] or the EREB2.5 assay [134, 207-209, 211, 333] several domains of the protein 
important for EBNA-2-mediated B cell immortalisation have been identified. The former 
system involves reconstitution of the EBNA-2/EBNA-LP deletion in P3HR1 EBV strains 
using DNA fragments that contain specifically mutated EBNA-2 genes. The resultant 
recombinant EBV viruses are then tested for their primary B cell transformation ability. In 
this system, however, EBNA-2 functions are studied in the context of EBV infection. 
Therefore, other variables such as the expression of other EBV genes, EBV strain sequence 
variation and B cell activation and cell cycle induction may play a role.  
 
However, Kempkes et al. [134] developed the EREB2.5 cell system which enabled the 
investigation of EBNA-2 functions in isolation of other variables involved in virus-B cell 
interactions that usually occur during primary B cell infection. These EREB2.5 cells contain 
an endogenous P3HR1 EBV genome which lacks the EBNA-2 locus and the last two EBNA-
LP exons. EBNA-2 (and a two-repeat EBNA-LP) is supplied by a separate plasmid (p554-4) 
from which it is expressed as an ER-EBNA-2 fusion protein. Hence, EBNA-2 activity and B 
cell survival and proliferation are oestrogen-dependent. When EREB2.5 cells are cultured in 
growth medium supplemented with -estradiol, the oestrogen derivative binds to the ER-
EBNA-2 fusion protein in the cytoplasm. This causes it to translocate to the nucleus where it 
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can active target gene expression. In the absence of oestrogen, the cells undergo growth arrest 
and apoptosis before eventually dying out due to ER-EBNA-2 inactivation [134, 333]. If, 
however, wildtype EBNA-2 is stably expressed in trans, the growth of oestrogen-depleted 
cells can be rescued [111, 207-209, 211]. Therefore, expressing mutant EBNA-2 proteins in 
trans has been used to determine their effect on B cell growth and to identify the domains of 
EBNA-2 that are important for B cell maintenance and proliferation [111, 207-209, 211]. 
Moreover, this laboratory and others have used the EREB2.5 cell line to measure the effects 
of EBNA-2 on gene expression and to monitor the regulation of EBNA-2 targets [111, 268, 
273]. 
 
In this laboratory, the EREB2.5 trans-complementation approach was adapted into an assay 
to functionally distinguish between type 1 and type 2 EBNA-2-induced B cell proliferation 
[210]. After oestrogen removal, B cell proliferation is only rescued when an OriP plasmid 
constitutively expressing type 1 EBNA-2 is transfected into the cells. In this assay, only 
wildtype type 1 EBNA-2 can functionally replace the endogenous ER-EBNA-2 fusion 
protein to provide critical EBNA-2 functions in trans. Therefore, this is a functional assay to 
distinguish between type 1 and type 2 EBNA-2-driven B cell proliferation. 
 
 
3.2 Results 
 
3.2.1 Testing the EREB2.5 growth assay 
 
As a pilot experiment, the effects of the two EBNA-2 alleles were compared in the EREB2.5 
growth assay. Separate EREB2.5 cells were transfected with caesium chloride density 
gradient-purified DNA preparations of OriP-p294 plasmids expressing wild-type type 1 and 
type 2 EBNA-2 sequences using the Amaxa system as described in section 2.2.6.2. The cells 
were also transfected with an empty vector as a control. In all experiments, transfections were 
carried out using culture medium with no oestrogen. Consistent with previous work carried 
out in this laboratory and published by Cancian et al. [211], only the OriP vector expressing 
type 1 EBNA-2 was able to sustain long term cell proliferation and lymphoblastoid cell line 
(LCL) establishment (Figure 3.1). Only cells transfected in this way formed big clusters and 
clumps characteristic of B cell growth 1 month after transfection (Figure 3.1A). Control cells 
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failed to cluster at 1 week post-transfection and only dying cells were visible under the 
microscope. Cells transfected with an OriP vector expressing type 2 EBNA-2 initially formed 
small clusters of cells. However, these soon lost growth and 1 month post-transfection only 
single or dying cells were observed. Therefore, type 2 EBNA-2 was not able to sustain B cell 
growth and establish LCLs. Live cell counts of proliferating cells were carried out by 
counting cells that excluded Trypan blue on a haemocytometer slide every week for 4 weeks 
after transfection (Figure 3.1B). The differences observed in cell phenotype by microscopic 
observation of cells in culture were consistent with the differences in live cell counts. This 
confirmed that only type 1 EBNA-2 was able to sustain B cell growth, thus functionally 
replacing the ER-EBNA-2 in EREB2.5 cells. Western blot analysis was also performed to 
assess EBNA-2 protein expression at 5 days post-transfection (Figure 3.1C). RIPA lysis 
buffer was used to extract the protein from several cell clones. SDS-PAGE was used to 
analyse protein samples and immunoblots were probed with the EBNA-2-specific antibody, 
PE2. Transfected clones expressed the constitutive forms of EBNA-2 but despite more type 2 
EBNA-2 (72 kDa) being expressed, when compared to type 1 (80 kDa), this was still not 
enough to rescue B cell growth. This further illustrated the unique ability of type 1 EBNA-2 
to promote EREB2.5 cell growth and establishment of LCLs. 
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Figure 3.1. Testing the EREB2.5 growth assay. 6x10
6
 EREB2.5 cells were transfected using the Amaxa 
method, with 5 µg OriP-p294 plasmids expressing type 1 EBNA-2 (E2T1), type 2 EBNA-2 (E2T2) or empty 
vector (e.v) as a control. Cells were grown in the absence of -estradiol following transfection. (A) Phase-
contrast micrographs of EREB2.5 cells transfected with type 1 and type 2 EBNA-2 expressing plasmids, or 
empty vector OriP-p294. Non-transfected cells are also shown as a control. Images were taken 4 weeks post-
transfection. Cells only clump and cluster when transfected with a type 1 EBNA-2. (B) Proliferating cells were 
monitored over a period of 4 weeks by counting cells that excluded Trypan blue on a haemocytometer. 
Duplicate wells of cells for each transfection were counted. Error bars represent standard errors from at least 3 
independent experiments. p-value: ***<0.005. (C) A representative Western blot analysis for EBNA-2 
expression 5 days post-transfection of EREB2.5 cells. The PE2 antibody was used which detects type 1 and type 
2 EBNA-2 with equal affinity [210]. It also detects the conjugated ER-EBNA-2 protein [211], although this is 
not shown on this immunoblot. A -actin immunoblot was also performed as a loading control. 
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3.2.2 Confirming the regions and domains of type 1 EBNA-2 which confer 
higher B cell immortalisation efficiency compared to type 2 EBNA-2 
 
Previous work published by this laboratory [211] identified the regions of type 1 EBNA-2 
that complement the deficiency of type 2 EBNA-2 to establish LCLs in the EREB2.5 growth 
assay. Domains of type 1 EBNA-2 were precisely swapped into the corresponding positions 
of the type 2 protein. Several type 1/type 2 EBNA-2 chimeric sequences were generated and 
subsequently tested in the EREB2.5 growth assay for their ability to rescue growth of 
oestrogen-starved EREB2.5 cells [211]. It was initially found that the C-terminal region of 
type 1 EBNA-2 – from the WWPP motif (aa 323-326) to the end of the protein – was 
important for B cell growth [211]. This C-terminal region of EBNA-2 contains the arginine-
glycine (RG) repeat region, conserved region 7 (CR7), the transactivation domain (TAD) or 
conserved region 8 (CR8) and the nuclear localisation signal (NLS/CR9) (Figure 3.2A). The 
C-terminus of type 1 EBNA-2 was further mapped to identify the minimal sequences 
required for higher B cell immortalisation efficiency. Only when type 1 RG, CR7 and NLS 
sequences together were swapped into the homologous positions of the type 2 EBNA-2 
protein was the resultant chimera (chimera 7) able to sustain proliferation (Figure 3.2B) 
[211]. Indeed, EBNA-2 chimera 6 – identical to chimera 7 but for a type 2 TAD – had 
absolutely no growth-promoting effects, indicating that type 1 TAD is required for B cell 
proliferation. 
 
Fresh preparations of OriP plasmids expressing chimeric EBNA-2 sequences were made and 
the experiment repeated (Figure 3.2). It was found that EBNA-2 chimera 7 displays a type 1-
like growth phenotype, rescuing cell growth although not to the same level as type 1 EBNA-2 
(Figure 3.2B and C). At 4 weeks post-transfection, proliferating cells accumulated and were 
restored to almost type 1 levels. EBNA-2 chimera 6 was unable to promote B cell growth 
despite being expressed to a similar level as chimera 7 (Figure 3.2D). Therefore, only 
wildtype type 1 and chimera 7 EBNA-2 are able to establish continuously proliferating LCLs. 
These results demonstrate that the minimum type 1 sequences required to rescue the growth-
promoting ability of type 2 EBNA-2 of oestrogen-starved EREB2.5 cells, are the RG, CR7 
and TAD of the C-terminus. Type 1 function cannot be restored by any other combination of 
type 1 domains in the type 2 background. 
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Figure 3.2. Chimeric EBNA-2 proteins tested in the EREB2.5 growth assay. The carboxy (C)-terminus of 
type 1 EBNA-2 rescues the type 2 EBNA-2 phenotype and restores growth of EREB2.5 cells. The minimum 
sequences required include the RG, CR7 and TAD domains. (A) Cartoon representation of the structure of 
EBNA-2 (see section 1.3.2). Adapted from [211]. (B) Panel of EBNA-2 proteins tested in the EREB2.5 growth 
assay. Black and white indicate type 1 and type 2 sequences respectively. T: type; C: chimera. The growth 
phenotype was scored as “++” for type 1 EBNA-2 and chimera 2 and “+” for chimera 7. In these cases, cell 
growth was maintained over 4 weeks and LCLs were successfully established. A growth phenotype score of “-”, 
as with type 2 EBNA-2, chimera 1 and chimera 6, defines growth arrest after transfection and removal of -
estradiol and cell death. (C) Total live cell counts of transfected EREB2.5 cells expressing the panel of EBNA-2 
proteins. Proliferating cells were monitored over a period of 4 weeks by counting cells that excluded Trypan 
blue on a haemocytometer. Duplicate wells of cells for each transfection were counted. Error bars represent 
standard errors from at least 3 independent experiments. p-values: ns=not significant, *<0.05, **<0.01, 
***<0.005. (D) Western blot analysis of whole cell lysates from transfected EREB2.5 cells. EBNA-2 expression 
was examined 5 days post-transfection with the PE2 antibody which detects all EBNA-2 types. A representative 
immunoblot is shown, together with -actin as a loading control. 
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3.2.3 Determining the amino acids of the type 1 TAD that play a role in the 
higher B cell immortalisation efficiency of type 1 EBNA-2 
 
The initial aim of this study was to fine-map the amino acids of the transactivation domain 
(TAD) of EBNA-2 that are important for lymphocyte transformation. Since there is less 
variation between the amino acid sequence of type 1 and type 2 TADs of EBNA-2 in 
comparison to the RG and CR7 regions (see section 1.3.2, Figure 1.4), it was thought that the 
growth-promoting amino acids of the TAD would be more easily characterised. This domain 
is also important for activating gene expression and it was proposed that this could also be 
vital for B cell immortalisation. Furthermore, the loss of EREB2.5 growth maintenance with 
a type 2 TAD compared to a type 1 TAD (compare chimeras C6 and C7 in Figure 3.2A and 
B) showed that some type 1 amino acids in this region must be required. 
 
3.2.3.1 Generating OriP-p294 plasmids expressing TAD mutants in the chimera 6 
EBNA-2 background for use in the EREB2.5 trans-complementation assay 
 
OriP-p294 plasmid vectors expressing type 1 EBNA-2 (E2T1), type 2 EBNA-2 (E2T2), a 
chimera of E2T2 with the RG and CR7 domains of E2T1 (E2 chimera 6; E2C6) or a chimera 
of E2T2 with the RG, CR7 and TAD domains of E2T1 (E2 chimera 7; E2C7) were available 
in the laboratory. However, they were not suitable for mutagenesis due to their large size and 
abundance of repeated restriction enzyme sites. Therefore, smaller pBlueScript (pBSSK+) 
vectors were first used to mutagenise E2C6 (Figure 3.3) before being subcloned into 
pSuperInt2 vectors (Figure 3.4) and finally into OriP-p294 plasmids (Figure 3.5) for use in 
the EREB2.5 growth assay (Figure 3.6). E2C6 TAD mutants were then tested for their ability 
to sustain proliferation of oestrogen-starved EREB2.5 cells (see section 3.2.3.2). 
 
Briefly, since there are relatively few amino acid differences between the TAD domains of 
type 1 and type 2 EBNA-2, it was feasible to mutate each amino acid that differed 
significantly (in terms of side-chain chemistry) either individually or in groups (Figure 3.3). 
Five primers were designed in order to individually mutate a total of seven significantly 
different amino acids of the type 2 TAD to the corresponding type 1 residue (Figure 3.3A). 
Mutation 1 corresponds to a double mutation from serine and aspartate to histidine and 
asparagine residues. Although these are located just upstream of the TAD, they were also 
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investigated as they were proposed to be involved in possible orientation and steric alignment 
of this domain. Mutation 2 refers to a double mutation at the N-terminal side of the TAD, 
whilst all other mutants are single amino acid changes within the recognised TAD (Figure 
3.3A). SDM reactions were successfully performed using the QuikChange Site-Directed 
Mutagenesis Kit (Agilent Technologies) (Figure 3.3B). PCR products of the SDM reactions 
were then digested with DpnI and the PCR-synthesised DNA transformed into competent E. 
coli XL1 Blue cells (Agilent Technologies). Restriction enzyme digest analysis with EcoRI 
and NotI was performed to analyse the integrity of the mutagenised pBS:E2C6 plasmids, 
confirming the presence of the pBS vector backbone (3 kb) and the mutated EBNA-2 allele 
(2 kb) (Figure 3.3C). Transformants were also screened by sequencing to confirm that 
specific mutations had been successfully introduced. 
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Figure 3.3. Cloning of TAD mutants into pBS vector with chimera 6 EBNA-2 background. Five TAD 
mutants were generated in the pBS:E2C6 vector. (A) Sequence alignment of the TADs (amino acids 426-463 in 
the type 1 EBNA-2 sequence) of type 1 and type 2 EBNA-2. Amino acids of the type 2 TAD that differed 
greatly in side group chemistry were substituted for the residue found at the corresponding position in the type 1 
protein (red). Mutations were performed individually (mutants 3, 4 and 5) or for groups (mutants 1 and 2) of 
amino acids. Amino acids that had similar side chain chemistry (teal) were not mutated. (B) The PCR product 
for each SDM reaction was run on a 1% agarose gel and stained with ethidium bromide. A product was 
generated for all mutations, achieved only after several troubleshooting steps. (C) Restriction digest of 
mutagenised pBS:E2C6 plasmid vectors. Approximately 150 ng DNA was digested with EcoRI and NotI and 
analysed on a 1% agarose gel. All plasmids displayed the characteristic banding pattern of a 3 kb (vector 
backbone) and a 2 kb (EBNA-2 gene) fragment. 
 
 
In order to then generate a plasmid from which mutagenised E2C6 proteins could be 
expressed in the EREB2.5 cell line and used in a growth assay, a two-step cloning procedure 
was utilised as described previously (see section 2.3.3.16.1). Firstly, the mutagenised TAD 
domains were cloned into a pSuperInt2 vector (approximately 9 kb) which is a laboratory 
plasmid bearing the E2C6 sequence and the EBV Wp promoter (Figure 3.4). The C-terminal 
regions of the chimera 6 TAD mutants were transferred into the pSuperInt2 vector by cloning 
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the EcoRV/NotI fragment. Transformants were screened by restriction enzyme digest 
analysis with EcoRV and NotI to analyse the integrity of the mutagenised pSuperInt2:E2C6 
plasmids, confirming the presence of the pSuperInt2 vector backbone+EBNA-2 N-terminal 
region (approximately 8 kb) and the C-terminal region of the EBNA-2 allele containing the 
TAD mutations (approximately 0.9 kb) DNA fragments (Figure 3.4). 
 
 
 
 
 
Figure 3.4. Cloning of mutant TADs from E2C6 sequences into pSuperInt2. A representative EcoRV/NotI 
restriction digest indicating the TAD mutants have successfully been cloned into pSuperInt2:E2C6. Following 
cloning, approximately 200 ng DNA was digested and separated on a 1% agarose gel to screen for the EBNA-2 
C-terminal and TAD-specific EcoRV/NotI fragment (approximately 0.9 kb). A plasmid containing the wildtype 
(WT) E2C6 sequence was used as a positive control. 
 
 
To generate the final expression plasmid, a further sub-cloning step was required as described 
above (see section 2.3.3.16.1). The BglII/NotI fragment which contains the mutagenised 
E2C6 sequences and the EBV Wp was cloned into the MCS of the OriP-p294 vector cut with 
BamHI and NotI (Figure 3.5). Transformants were screened by EcoRV/NotI digestion to 
confirm the presence of the C-terminal region of the EBNA-2 allele containing the TAD 
mutations (approximately 0.9 kb) (Figure 3.5A). In order to then test the expression of these 
E2C6 TAD mutants from the p294 plasmids, HEK 293 cells were transfected for 24 h using 
lipofectamine (see section 2.2.6.1). Cells were harvested after 24 h, lysed and analysed by 
Western blotting (Figure 3.5B). This revealed that mutated EBNA-2 sequences were indeed 
expressed correctly and at approximately equivalent levels. 
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Figure 3.5. Western blot analysis of HEK 293 cells transfected with correctly cloned OriP-p294 plasmids 
expressing T1, T2, C6, C7 or TAD mutants of C6 EBNA-2. (A) A representative EcoRV/NotI restriction 
digest indicating that the E2C6 TAD mutants were successfully cloned into OriP-p294. Inserts were digested 
with BglII and NotI, and the vector with BamHI and NotI (BamHI and BglII have compatible ends). 
Approximately 200 ng DNA was digested with EcoRV and NotI restriction enzymes to screen for the TAD-
specific fragment (approximately 0.9 kb). An empty vector (e.v) and a plasmid containing the wildtype E2C6 
sequence (WT) were used as negative and positive controls, respectively. (B) Western blot analysis of HEK 293 
cells transfected with OriP-p294 plasmids expressing various EBNA-2 alleles. Cells were harvested 24 h post-
transfection and protein extracts obtained by RIPA lysis. Proteins were analysed by Western blot using the PE2 
(α-EBNA-2) antibody. The molecular weights of type 1 (T1) and type 2 (T2) EBNA-2 are approximately 80 and 
72 kDa respectively. Cells were also transfected with p294:MCS empty vector (e.v) as a control. 
Immunoblotting for β-actin was performed as a loading control. 
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3.2.3.2 Aspartate-442 is the single amino acid of the type 1 TAD that contributes to 
type-specific effects of EBNA-2 
 
OriP-p294:E2C6 TAD mutants were then purified using caesium chloride gradient 
centrifugation as described (see section 2.3.3.11). Subsequently, the purified vectors were 
used in the EREB2.5 growth assay (Figure 3.6). The ability of the mutant chimeras to 
maintain cell growth in the absence of -estradiol was measured every week for 4 weeks 
(Figure 3.6B). As expected, cells that were transfected with an OriP plasmid expressing 
E2T2, E2C6 and empty vector failed to grow. Transfections with mutants 1, 2, 3 and 5 of 
E2C6 produced a similar negative result. However, transfection of EREB2.5 cells with the 
mutant 4 variant of E2C6 led to cell proliferation. The results showed that this mutation, an 
amino acid substitution of a serine residue for the corresponding aspartate at position 442 of 
type 1 EBNA-2 (S442D), rescued the growth maintenance ability of chimera C6 to become 
equivalent to that of C7 (“+”; Figure 3.6A and B). The EBNA-2 proteins were all expressed 
with the expected size on a Western blot (Figure 3.6C). This shows that aspartate-442 (D442) 
is the single “active” amino acid of the type 1 TAD that contributes to type-specific EBNA-2 
function in this assay and is essential for B cell growth (Figure 3.6A). 
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Figure 3.6. S442D in the EBNA-2 chimera 6 background rescues growth of EREB2.5 cells. Previous 
mapping revealed the ability of EBNA-2 proteins to rescue proliferation of oestrogen-starved EREB2.5 cells and 
the investigation was extended to focus on the TAD. Five different EBNA-2 chimera 6 (E2C6) mutants were 
tested in the EREB2.5 growth assay (see section 3.2.3.1, Figure 3.3). (A) Cartoon representation of the structure 
of EBNA-2 as described previously. Type 1 sequences are shown in black and type 2 sequences in white. (B) 
Total live cell counts for EREB2.5 cells expressing different EBNA-2 proteins. -estradiol was removed from 
the culture medium and cell proliferation was monitored at 1, 2, 3 and 4 weeks post transfection by counting 
cells that excluded Trypan blue on a haemocytometer. An average of data from at least 4 independent 
experiments is shown. Transfections were performed in duplicate and every well of cells was counted. Error 
bars indicate standard deviations. p-values: ns=not significant, *<0.05, **<0.01, ***<0.005. The growth 
phenotype was scored as “+” (C7 and C6 S442D), when cell proliferation was maintained after transfection, -
estradiol removal and LCL establishment, or as “-” (C6), when proliferation ceased after transfection, in (A). Of 
the mutants tested, only mutant 4 (S442D in the C6 background) was able to rescue B cell growth and to a level 
similar to C7. D442 is the single amino acid of the type 1 TAD that contributes to the growth phenotype. (C) 
Western blot analysis of protein extracts from EREB2.5 cells transfected with various EBNA-2 proteins. Cells 
were harvested 5 days after transfection and proteins extracted by RIPA lysis. EBNA-2 was detected using the 
PE2 antibody and α--actin was used as a loading control. 
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3.2.4 Determining the contribution of EBNA-2 CR7 to the B cell growth 
phenotype 
 
The aim of this study was to map the single amino acids of type 1 EBNA-2 responsible for 
the higher B cell immortalisation efficiency and so the contribution of conserved region 7 
(CR7) to this phenotype was also investigated. Another EBNA-2 chimera available in the 
laboratory, E2C5, contains the type 1 RG domain in the type 2 EBNA-2 background. Like 
C6, it was unable to promote cell proliferation in this assay [211] which suggests that CR7 
has no role in B cell growth. Indeed, there is no evidence in the literature to support a role for 
CR7 in B cell immortalisation. Therefore, the S442D mutation was introduced into the 
chimera 5 background and tested in the EREB2.5 growth assay and its ability to maintain cell 
growth in the absence of -estradiol was measured (see section 3.2.4.2).  
 
3.2.4.1 Generating an OriP-p294 plasmid expressing an EBNA-2 protein with a type 1 
RG domain and aspartate-442 in the type 2 background 
 
Site-directed mutagenesis was initially performed to insert the S442D mutation into a pBS 
vector carrying E2C5 (Figure 3.7A) using the QuikChange Site-Directed Mutagenesis Kit 
(Agilent Technologies). The PCR product was then DpnI-digested and transformed into 
competent E. coli XL1 Blue cells (Agilent Technologies). Transformants were screened by 
sequencing to confirm that the S442D mutation had been successfully introduced. EcoRI/NotI 
restriction enzyme digest analysis was also performed to ensure integrity of the mutated 
pBS:E2C5 plasmid which confirmed the presence of the pBS vector backbone (3 kb) and the 
mutated EBNA-2 allele (2 kb) (Figure 3.7B). 
 
 
 
 
Figure 3.7. Cloning the S442D mutation into the pBS vector and chimera 5 EBNA-2 background. (A) The 
PCR product of the SDM reaction was run on a 1% agarose gel and stained with ethidium bromide. (B) 
Restriction digest of mutagenised pBS:E2C5 plasmid vector. Approximately 150 ng DNA was digested with 
EcoRI and NotI enzymes and run on a 1% agarose gel. The characteristic vector backbone (3 kb) and EBNA-2 
(2 kb) DNA fragments were present. 
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To generate the expression vector, the S442D mutation was first cloned into the pSuperInt2 
vector carrying E2C5. Initial attempts at cloning the BstXI/NotI fragment which spans the C-
terminal region of EBNA-2 including the RG domain proved unsuccessful. The whole of the 
EBNA-2 locus from the pBS:E2C5 S442D plasmid was then sequenced and found to contain 
only the S442D mutation. The EBNA-2 locus was therefore cloned as an EcoRI/NotI 
fragment into the pSuperInt2 vector and the integrity of the ligated product was screened by 
BstXI/NotI digestion (Figure 3.8). 
 
 
 
 
Figure 3.8. Cloning E2C5 S442D into pSuperInt2. A representative BstXI/NotI restriction digest indicating 
the E2C5 S442D allele was successfully cloned into pSuperInt2. Approximately 100 ng DNA (of pSuperInt2:  
E2C6 S442D vector) was digested to screen for the EBNA-2 C-terminal and RG-specific BstXI/NotI fragment 
(approximately 1.2 kb) with a 1 kb marker (M). 
 
 
To generate the final expression plasmid, a further sub-cloning step was required as described 
(see section 2.3.3.16.1). The BglII/NotI fragment from the pSuperInt2 vector containing the 
E2C5 S442D allele was then cloned into the OriP-p294 plasmid cut with BamHI and NotI 
enzymes. Transformants were screened by EcoRV/NotI digestion to ensure correct ligation 
(Figure 3.9A). Western blot analysis of HEK 293 cells transfected with OriP-p294:E2C5 
S442D revealed that the mutated E2C5 protein was expressed correctly (Figure 3.9B). 
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Figure 3.9. Western blot analysis of HEK 293 cells transfected with correctly cloned OriP-p294 
expressing chimera 5 S442D EBNA-2. (A) A representative EcoRV/NotI restriction digest indicating that the 
E2C5 S442D mutation was successfully cloned into OriP-p294. Approximately 200 ng DNA was digested and 
an empty vector (e.v) was used as a negative control. (B) Western blot analysis of HEK 293 cells transfected 
with an empty vector (e.v) or an OriP-p294 plasmid expressing chimera 5 S442D EBNA-2 (C5 S442D). Cells 
were harvested 24 h post-transfection and protein extracts prepared by RIPA lysis. Proteins were analysed by 
Western blot using PE2 (the EBNA-2 antibody) and a β-actin antibody which acted as a loading control. 
 
 
3.2.4.2 Aspartate-442 complements the deficiency of chimera 5 EBNA-2 in the EREB2.5 
growth assay 
 
OriP-p294:E2C5 S442D was then purified using caesium chloride gradient centrifugation as 
described (see section 2.3.3.11) and subsequently used in the EREB2.5 growth assay (Figure 
3.10). The ability of chimera 5 S442D EBNA-2 to maintain cell growth in the absence of -
estradiol, and therefore the requirement for a type-specific CR7, was measured. It was found 
that transfection of EREB2.5 cells with C5 S442D EBNA-2 led to cell proliferation and 
establishment of LCLs (Figure 3.10B). The results showed that, irrespective of sequence 
type, CR7 has no role in B cell growth maintenance (compare C6 S442D and C5 S442D in 
Figure 3.10A). As before, EBNA-2 protein expression was checked on a Western blot (Figure 
3.10C). 
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Figure 3.10. EBNA-2 CR7 does not contribute to cell proliferation in the EREB2.5 growth assay. C5 
S442D EBNA-2 was found to promote B cell growth. (A) Cartoon representation of the structure of EBNA-2 as 
described previously. Type 1 and type 2 sequences are shown in black and white respectively. (B) Total live cell 
counts for EREB2.5 cells expressing different EBNA-2 proteins. Cell proliferation was monitored over 4 weeks 
by counting cells with a haemocytometer. Transfections were performed in duplicate and an average of data 
from at least 4 experiments is shown. Error bars indicate standard deviations. p-values: ns=not significant, 
**<0.01, ***<0.005. (C) Western blot analysis of protein extracts from EREB2.5 cells transfected with various 
EBNA-2 proteins. Cells were harvested 5 days after transfection and proteins extracted by RIPA lysis. EBNA-2 
was detected using the PE2 antibody and α--actin was used as a loading control. 
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3.2.5 Investigating the effect of single point mutations on the ability of 
wildtype type 1 and type 2 EBNA-2 to rescue growth of cells in the 
EREB2.5 assay 
 
Although C7, C6 S442D and C5 S442D all had similar activity in the EREB2.5 growth assay, 
they were quantitatively not as effective as type 1 EBNA-2 or the chimera C2. The 
contribution of aspartate-442 to this phenotype was investigated further by making this single 
amino acid change (S442D) in type 2 EBNA-2 with no other changes. The reciprocal amino 
acid change, D442S, was also made in type 1 EBNA-2 and these EBNA-2 point mutants 
were tested in the EREB2.5 growth assay (see section 3.2.5.2). 
 
3.2.5.1 Generating type 1 and type 2 EBNA-2 point mutants to test the requirement of 
aspartate-442 to sustain B cell growth in the EREB2.5 assay 
 
As before, SDM reactions were performed with pBS vectors in order to insert S442D and 
D442S point mutations into type 2 and type 1 EBNA-2 respectively (Figure 3.11A). PCR 
products were digested with DpnI and then transformed into competent E. coli XL1 Blue 
cells (Agilent Technologies). Transformants were screened by sequencing to confirm that the 
S442D and D442S mutations had been successfully introduced into type 2 and type 1 EBNA-
2 sequences respectively. The integrity of the mutated EBNA-2 alleles were checked by 
EcoRI/NotI restriction enzyme digest analysis, confirming the presence of the pBS vector 
backbone (3 kb) and the mutant EBNA-2 (2 kb) (Figure 3.11B). 
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Figure 3.11. Cloning the point mutations into pBS vectors expressing type 1 or type 2 EBNA-2. (A) The 
PCR products of the SDM reactions were run on a 1% agarose gel and stained with ethidium bromide. (B) 
Restriction digest of mutagenised pBS:E2T2 (T2 S442D) and pBS:E2T1 (T1 D442S) plasmid vectors. 
Approximately 150 ng DNA was digested with EcoRI and NotI enzymes and analysed on a 1% agarose gel. 
2 kb and 3 kb fragments were present corresponding to the characteristic EBNA-2 allele and vector backbone 
respectively. 
 
 
In order to generate the OriP-p294 expression vectors, the point mutants were first cloned 
into the pSuperInt2 vector carrying E2C5. Initial attempts at cloning the C-termini of the 
EBNA-2 alleles using BstXI and NotI enzymes sourced from NEB proved unsuccessful. 
BstXI and NotI restriction enzymes were subsequently ordered from Promega and used to 
clone the mutated type 1 and type 2 EBNA-2 C-termini into pSuperInt2 vectors. BstXI/NotI 
digestion was then used to check the integrity of ligated and column-purified products 
following antibiotic selection (Figure 3.12). 
 
 
 
 
 
 
Figure 3.12. Cloning type 1 D442S and type 2 S442D point mutants into pSuperInt2 vectors. A 
representative BstXI/NotI restriction digest indicating that T1 D442S and T2 S442D alleles were successfully 
cloned into pSuperInt2. Approximately 100 ng DNA was digested to screen for the presence of a 1.2 kb DNA 
fragments that spanned the EBNA-2 C-terminus including the RG domain. M: 1 kb marker. 
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The final OriP-p294 expression plasmids were then generated as described (see section 
2.3.3.16.1). The pSuperInt2 vectors carrying the EBNA-2 alleles with single point mutations 
were cut with BglII and NotI restriction enzymes and cloned into BamHI/NotI-digested OriP-
p294. Transformants were screened by EcoRV/NotI digestion to ensure DNA fragments had 
ligated correctly (Figure 3.13A). HEK 293 cells were also transfected with OriP-p294:E2T1 
D442S and T2 S442D vectors and cell lysates used in Western blotting to show that both 
EBNA-2 proteins were expressed correctly (Figure 3.13B). 
 
 
 
 
Figure 3.13. Correct cloning and expression of type 1 D442S and type 2 S442D EBNA-2 from OriP-p294 
vectors. (A) A representative EcoRV/NotI restriction digest indicating that the E2T1 D442S and E2T2 S442D 
mutants were successfully cloned into OriP-p294 plasmids. Approximately 200 ng DNA was digested and an 
empty vector (e.v) was used as a negative control in the analysis. (B) Western blot analysis of HEK 293 cells 
transfected with OriP-p294 plasmids expressing empty vector (e.v), type 1 D442S (T1 D442S) or type 2 S442D 
(T2 S442D) EBNA-2. After 24 h transfection, cells were harvested and lysates prepared following RIPA lysis. 
EBNA-2 expression was analysed using the PE2 antibody. The molecular weight of type 1 and type 2-like 
EBNA-2 proteins are approximately 80 and 72 kDa respectively. β-actin acted as a loading control. 
 
 
3.2.5.2 Aspartate-442 is necessary and sufficient to sustain B cell growth in the EREB2.5 
trans-complementation growth assay 
 
OriP-p294:E2T1 D442S and T2 S442D were subsequently purified using caesium chloride 
gradient centrifugation as described (see section 2.3.3.11) and used in the EREB2.5 growth 
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assay (Figure 3.14). The contribution of aspartate-442 to the growth phenotype was therefore 
investigated further by making these single point mutations in EBNA-2 proteins (Figure 
3.14A). With this minimal disruption of the whole protein structure, the S442D point 
mutation was able to convert type 2 EBNA-2 to be equally as effective as type 1 EBNA-2 at 
restoring EREB2.5 cell growth (Figure 3.14B). The reciprocal point mutation of D442S 
abolished the growth-promoting activity of type 1 EBNA-2 in the EREB2.5 assay (Figure 
3.14B). Again, these EBNA-2 proteins were all expressed correctly and with the expected 
size on a Western blot at 5 days post-transfection (Figure 3.14C). The results show that the 
aspartate residue at position 442 is essential for type 1 EBNA-2 function in the cell growth 
assay. Furthermore, this S442D point change is sufficient to convert type 2 EBNA-2 to be as 
effective as, if not slightly more so than, type 1 EBNA-2 in this assay. Amazingly, 
substituting this single amino acid (D442) from type 1 EBNA-2 abolishes its growth-
promoting function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
148 
 
 
 
 
 
 
 
 
 
 
 
149 
 
Figure 3.14. S442D in type 2 EBNA-2 is sufficient to sustain LCL proliferation in the EREB2.5 assay.  
Aspartate-442 is absolutely essential for type 1 EBNA-2 function in this assay. (A) Type 2 S442D and the 
reciprocal type 1 D442S EBNA-2 were made. Type 1 sequences are shown in black and type 2 sequences in 
white. (A and B) OriP-p294 plasmids expressing wild-type type 1 (T1), type 2 (T2), type 1 D442S (T1 D442S), 
type 2 S442D (T2 S442D) and empty vector (e.v) were transfected into 6x10
6
 EREB2.5 cells and cell 
proliferation monitored as previously described every week for 4 weeks. The growth phenotype was scored as 
“++” (T1 and T2 S442D) and “+” (C5 S442D) when cells grew after -estradiol removal from the culture 
medium and LCLs were established, or as “-” (T2 and T1 D442S) when proliferation ceased. Transfections were 
done in duplicate and each well of cells was counted. The average of data from at least 4 independent 
experiments is shown with error bars which indicate standard error. p-values: ns=not significant, *<0.05, 
**<0.01, ***<0.005. (C) Western blot analysis of protein extracts 5 days after transfection of EREB2.5 cells 
with e.v, T1, T1 D442S, T2, T2 S442D and C5 S442D EBNA-2.  Immunoblotting was performed with the PE2 
antibody to check EBNA-2 expression and for -actin as a loading control. Adapted from [378]. 
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3.2.6 Expression levels and subcellular localisation of type 1, type 2, 
chimeric and mutant EBNA-2 proteins 
 
Western blot analysis and immunofluorescence experiments were performed to ensure that 
lack of oestrogen-starved EREB2.5 cell growth was not due to the lack of expression and/or 
inappropriate localisation of chimeric and mutant EBNA-2 proteins. The PE2 antibody was 
used in Western blot analysis for EBNA-2 expression in whole cell extracts from transfected 
EREB2.5 cells. This revealed that all chimeras and mutants of EBNA-2 were expressed at 
levels comparable to wildtype type 1 and type 2 EBNA-2. All EBNA-2 proteins also 
displayed the expected size – around 80 or 72 kDa for EBNA-2 proteins with a type 1 or type 
2 backbone respectively (C panels in Figures 3.6, 3.10 and 3.14). 
 
In order to determine EBNA-2 protein subcellular localisation, HeLa cells were transiently 
transfected with individual OriP-p294 plasmids expressing the various EBNA-2 sequences 
(Figure 3.15). Cells were analysed by immunofluorescence 24 hours post-transfection. The 
results indicate that all chimeric and mutant EBNA-2 proteins were localised to the cell 
nucleus but excluded from the nucleoli (Figure 3.15A), similar to the pattern observed with 
wildtype type 1 and type 2 EBNA-2 (Figure 3.15B) consistent with previous reports [211, 
227]. Variable staining patterns of discrete nuclear speckles or more diffuse staining were 
observed in different transfections but these did not correlate with a specific EBNA-2 protein. 
Similar staining variability has previously been reported [118, 379] and it is thought that this 
is due to variations in transfection efficiencies. Therefore, differences in EREB2.5 phenotype 
are due to bona fide properties of EBNA-2 proteins they were transfected with. 
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Figure 3.15. Nuclear localisation of chimeric, mutant, and wildtype type 1 and type 2 EBNA-2 proteins in 
HeLa cells. HeLa cells were transiently transfected with OriP-p294 plasmids expressing (A) C7, C6 TAD 
mutants, C5 S442D and the point mutants T2 S442D and T1 D442S or (B) wildtype T1 and T2 EBNA-2. 24 
hours post-transfection, cells were fixed, permeabilised and probed with PE2, followed by TRITC-conjugated 
anti-mouse secondary antibody. Confocal microscopy was used to visualise cells and determine subcellular 
EBNA-2 localisation. Cells were also: transfected with empty vector (e.v), non-transfected (n-t) or transfected 
with E2T1-expressing plasmid but stained only with secondary antibody (T1 + 2°Ab) as controls. 
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3.2.7 EREB2.5 cells rescued by type 1-like EBNA-2 proteins establish LCLs 
 
Consistent with previous work published by this laboratory [211], the OriP vector expressing 
type 1 EBNA-2 was able to sustain long-term proliferation of EREB2.5 cells (Figure 3.1). 
Other EBNA-2 proteins reported in this study to show the same phenotype were C7 [211], C6 
S442D, C5 S442D and the point mutant T2 S442D (Figures 3.6, 3.10 and 3.14). The growth 
of cells transfected with these type 1-like EBNA-2 proteins was monitored over at least 1 
month. These cells were observed to continuously proliferate in big clumps characteristic of 
B cell growth and LCL establishment, when visualised under the microscope 1 month after 
transfection (Figure 3.16A). T2, T1 D442S and other C6 TAD mutants did not support B cell 
proliferation resulting in no LCL outgrowth (data not shown).  
 
Cells transfected with OriP plasmids expressing other EBNA-2 proteins with a similar 
phenotype to that of the type 1 protein were maintained in culture media lacking -estradiol. 
Western blot analysis was performed 2 months post-transfection to assess the expression of 
the constitutive EBNA-2 protein (Figure 3.16B). All LCLs expressed the constitutive form of 
EBNA-2 (72-80 kDa) they had been transfected with. The cells also maintained a very low 
level of the ER-EBNA-2 fusion protein (120 kDa) consistent with a previous report [211]. 
This ER-EBNA-2 however was non-functional without oestrogen in the culture medium. 
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Figure 3.16. LCLs are established when EREB2.5 cells are transfected with EBNA-2 proteins that have a 
type 1-like phenotype. Proliferating transfected EREB2.5 cells are maintained in culture lacking oestrogen for 
(A) 1 month and (B) 2 months. (A) Phase-contrast micrographs of EREB2.5 cells transfected with OriP-p294 
vectors expressing different EBNA-2 proteins. Type 1 (T1), C6 S442D, C5 S442D and T2 S442D all formed 
clumps of continuously proliferating B cells, or LCLs. Non-transfected cells growing in culture containing -
estradiol are also shown as a control. (B) A representative Western blot showing EBNA-2 expression by 
transfected EREB2.5 cells 2 months post-transfection. Cell lysates from 5 days post-transfection were loaded for 
type 2 (T2) and empty vector (e.v) which do not generate LCLs. The PE2 antibody was used to detect EBNA-2 
proteins and the immunoblot was overexposed to reveal the low levels of non-functional ER-EBNA-2. -actin 
was monitored as a loading control. 
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3.2.8 The growth phenotype induced by type 1, C5 S442D and T2 S442D 
EBNA-2 proteins in EREB2.5 cells correlates with the expression of LMP-1 
and CXCR7 
 
The major EBV oncogene LMP-1 and cellular CXCR7 are differentially regulated by type 1 
and type 2 EBNA-2 [210, 211]. CXCR7 is also absolutely essential for the proliferation of 
EBV-LCLs such as the EREB2.5 cell line [210]. Expression of LMP-1 was assessed in the 
EREB2.5 growth assay at the protein (Figure 3.17A) and mRNA (Figure 3.17B) levels. 
Western blot analysis revealed that the amount of LMP-1 protein at 3 and 5 days post-
transfection of oestrogen-starved cells with T1, C5 S442D and T2 S442D EBNA-2 is 
maintained to a similar level as detected in non-transfected cells growing in culture medium 
containing -estradiol (Figure 3.17A). In cells expressing T2 or T1 D442S EBNA-2, or 
transfected with empty vector, LMP-1 expression is lost (Figure 3.17A). 
 
qRT-PCR analysis was also performed on RNA samples harvested 3, 5 and 7 days after 
transfection in a similar experiment (Figure 3.17B). When wildtype type 1 EBNA-2 was 
expressed, the level of LMP-1 transcripts rapidly increased relative to non-transfected 
EREB2.5 cells growing in oestrogen-conditioned media. By day 7, LMP-1 mRNA had 
increased approximately 12-fold (Figure 3.17B). In cells transfected with type 2 EBNA-2, 
LMP-1 transcripts decreased by 5 days post-transfection (fold increase <1) relative to the 
non-transfected cells (Figure 3.17B). It was not possible to assess the level of LMP-1 mRNA 
at 7 days after transfection with type 2 EBNA-2 as many cells had already died and, in this 
specific experiment, only approximately 25% of cells were still viable. When type 2 S442D 
EBNA-2 was expressed in EREB2.5 cells, the level of LMP-1 mRNA increased compared to 
control cells, and to a similar level as type 1 EBNA-2 (reaching approximately an 11-fold 
increase at day 7; Figure 3.17B). The number of LMP-1 transcripts also increased upon C5 
S442D EBNA-2 expression but to a lesser degree than with type 1 and type 2 S442D EBNA-
2 proteins, consistent with slower growth of EREB2.5 cells with this chimeric mutant form 
Figures 3.17B and 3.10).  
 
The effect of these transfections on the level of CXCR7 mRNA was also determined (Figure 
3.17C). CXCR7 transcripts gradually increased in cells expressing type 1 EBNA-2, up to a 
maximum 14-fold increase in comparison to non-transfected EREB2.5 cells at day 7 (Figure 
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3.17C). In cells expressing type 2 S442D EBNA-2, the level of CXCR7 mRNA peaked 
earlier at day 5 and was then maintained until day 7 (approximately 12-fold increase relative 
to control cells; Figure 3.17C). As before, transfection with C5 S442D also caused a gradual 
increase in CXCR7 mRNA levels but with a lower peak of upregulation (6-fold at day 7) 
compared to type 1 and type 2 S442D EBNA-2 (Figure 3.17C). Cells transfected with the 
type 2 EBNA-2-expressing vector showed normal levels of CXCR7 mRNA at day 3 (fold 
increase of 1 relative to non-transfected cells) but after this time-point the cells died as they 
began to lose CXCR7 expression (Figure 3.17C). 
 
These results indicate that the expression levels of LMP-1 (mRNA and protein) and CXCR7 
(mRNA) correlate with the growth phenotypes of the various EBNA-2 proteins found in the 
EREB2.5 trans-complementation system and growth assay. Cells that expressed type 2 
EBNA-2 failed to induce LMP-1 and CXCR7 expression, followed rapidly by growth arrest 
and cell death. Type 1, C5 S442D and type 2 S442D EBNA-2 induced LMP-1 and CXCR7 
expression levels as well as promoting growth of EREB2.5 cells. Indeed, cells that were 
rescued by C5 S442D displayed a slower growth rate (scored as “+”; Figure 3.10A) and a 
smaller induction of LMP-1 and CXCR7 (Figure 3.17). Therefore, the C-terminal region of 
C5 S442D and type 2 S442D EBNA-2 can induce LMP-1 and CXCR7 expression and confer 
the type 1 growth phenotype. Remarkably, this single point mutation in the type 2 protein, 
S442D, is sufficient to confer approximately type 1 levels of EREB2.5 cell growth and 
expression of LMP-1 and CXCR7. 
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Figure 3.17. LMP-1 and CXCR7 expression levels correlate with the growth phenotype of EREB2.5 cells 
expressing type 1, type 2, C5 S442D and T2 S442D EBNA-2. EREB2.5 cells were transfected with OriP-p294 
plasmids expressing type 1 (T1), type 1 D442S (T1 D442S), type 2 (T2), type 2 S442D (T2 S442D) or chimera 
5 S442D (C5 S442D), or with an empty vector (e.v) and then grown in culture medium lacking -estradiol. 
Cells were lysed (A) in RIPA lysis buffer to extract proteins or (B and C) in Trizol to extract total RNA. (A) 
Protein samples were collected at 3 and 5 days post-transfection and resolved on a 7.5% SDS-PAGE gel. 
Western blot analysis was performed with antibodies specific to EBNA-2 (PE2) and LMP-1 (CS 1-4). -actin 
was used as a loading control. All EBNA-2 proteins expressed in this cell system are detected by the PE2 
antibody. The conditional ER-EBNA-2 and constitutive type 1 and type 2-like EBNA-2 proteins have molecular 
weights of approximately 120, 80 and 72 kDa respectively. (B and C) cDNA was retro-transcribed from total 
RNA samples prepared 3, 5 and 7 days post-transfection. qPCR analysis was performed to quantify (B) LMP-1 
and (C) CXCR7 transcript levels. RNA could not be extracted from cells transfected with type 2 EBNA-2 on 
day 7 as most cells had died. The histograms show the ratio of (B) LMP-1/GAPDH mRNA or (C) 
CXCR7/GAPDH mRNA for each transfection and relative to non-transfected EREB2.5 cells grown in media 
supplemented with -estradiol. All experiments were performed in triplicate. Data shown are the averages taken 
from at least 3 independent experiments and error bars indicate standard error. 
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3.2.9 D442 is a novel amino acid and does not occur in other type 2 EBV 
strains 
 
In experiments performed previously to map the amino acids of type 1 EBNA-2 that are 
important for B cell growth (sections 3.2.2 to 3.2.5), EBNA-2 sequences from the B95-8 and 
AG876 EBV strains were used. These are prototype type 1 and type 2 EBV strains, 
respectively. To determine whether functional differences between EBNA-2 types, mapped to 
the C-terminus, were indeed typical of EBV type sequence, the C-terminal sequence of the 
EBNA-2 gene from additional EBV strains had to be analysed. Previous EBV strain analysis 
carried out in the laboratory was based on laboratory LCL, Burkitt’s lymphoma (BL) and 
nasopharyngeal carcinoma (NPC) cell lines and BL patient biopsies obtained from Malawi, 
Africa (kind gift from Prof Beverly Griffin, Imperial College London). Genomic DNA 
samples were prepared and PCR amplification performed with type-specific EBNA-2 
oligonucleotides. Of the laboratory EBV strains, 8 were found to be type 1 and 6 were type 2 
[211]. 13 African BL patient samples were analysed with 4 type 1 and 4 type 2 EBV strains 
(unpublished data, L Cancian and PJ Farrell). The frequency of EBV strain type observed 
was similar to those reported previously on the African continent [345] despite the small 
sample size. 
 
The C-terminal region of the EBNA-2 ORF from all laboratory and African BL samples was 
also sequenced to check for mutations between EBV strains. PCR reactions were previously 
performed with specific primers that annealed to identical sequences in type 1 and type 2 
EBNA-2 (B95-8 strain, Genbank accession number NC_007605.1, coordinates 37104-37859) 
in order to amplify the EBNA-2 region that corresponded to the C-terminus (unpublished 
data, L Cancian and PJ Farrell). Sequencing of the PCR products was then carried out using 
the same primers. 
 
I performed sequence alignments of the EBNA-2 C-terminal regions of the laboratory and 
African BL strain samples in MacVector and compared them to the type 1 and type 2 EBV 
prototypes, B95-8 and AG876 (Table 3.1 and 3.2). The region examined was the C-terminus, 
as defined by the BstXI site at codons 323-326 of type 1 EBNA-2 (see section 1.3.2, Figure 
1.4) to the end of the ORF of EBNA-2. In this C-terminal region of EBNA-2, there was a 
very high sequence identity of at least 98.6% in type 1 EBV isolates obtained from laboratory 
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cell lines and BL patients when compared to the type 1 prototype, B95-8 (Tables 3.1 and 3.2). 
Only some nucleotide variations were detected, most of which were silent. Nucleotide 
variations that did result in an amino acid change almost exclusively occurred outside 
functional domains of the EBNA-2 C-terminus. However, two type 1 laboratory strains were 
found to have a single amino acid change each within a functional domain. These strains 
were Mak 1 and MABA where alanine-452 had been mutated to threonine (A452T) in the 
TAD and proline-478 to serine (P478S) in the NLS, respectively (Table 3.1). Interestingly, 
EBNA-2 C-terminal sequence alignments of type 2 EBV isolates, both laboratory and BL 
patient-derived, with the type 2 prototype, AG876, showed even greater sequence identity 
than type 1 (≥99.6%, Tables 3.1 and 3.2). Only two laboratory strains displayed nucleotide 
changes. Alueck contained one silent variation and Wewak showed one silent and one non-
silent mutation although this was not in a functional domain (Table 3.1). Type 2 EBV isolates 
from African BL patients were found to be absolutely identical to the prototype strain (Table 
3.2). Similarly, the EBV isolates of patients infected with type 1 strains were found to contain 
a single silent nucleotide variation compared to the B95-8 prototype strain (Table 3.2). 
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Table 3.1. Sequence analysis of EBNA-2 C-terminal regions obtained from type 1 and type 2 EBV isolates 
of laboratory LCL, BL and NPC cell lines. Adapted from [211]. *B95-8 Genbank accession number: 
NC_007605.1; 
#
AG876 Genbank accession number: NC_009334.1; TAD: transactivation domain; NLS: nuclear 
localisation signal. 
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Table 3.2. Sequence analysis of EBNA-2 C-terminal regions obtained from type 1 and type 2 EBV isolates 
of BL patients from Malawi, Africa. *B95-8 Genbank accession number: NC_007605.1; 
#
AG876 Genbank 
accession number: NC_009334.1; TAD: transactivation domain; NLS: nuclear localisation signal. 
 
 
The results indicate that functional differences observed between type 1 and type 2 EBNA-2, 
mapped to the C-terminal region, are typical of EBV type sequence. Interestingly, only a 
single point mutation in the EBNA-2 TAD was found in one EBV isolate, Mak 1. This 
indicates the novel nature of EBNA-2 TAD mutations in EBV strains. Furthermore, the 
observation that W454T (W458 of B95-8 type 1) EBNA-2 was a transcriptionally null mutant 
[230] and unable to bind p300 [255] further revealed the importance of the TAD. Therefore, 
the finding that a single point mutation in the type 2 EBNA-2 TAD (S442D) complements 
the deficiency of type 2 EBNA-2 to rescue B cell proliferation in the EREB2.5 growth assay 
is hugely novel. It would be of great interest to investigate the effect of the S442D mutation 
on the phenotype of a type 2 EBV virus. 
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3.3 Discussion 
 
The most striking biological and phenotypic difference between type 1 and type 2 EBV 
strains is that type 1 EBV immortalises B lymphoctyes in vitro much more efficiently. The 
key determinant of this difference is the EBNA-2 gene and EBV viral types are therefore 
classified based on this [132, 363]. A mechanism involving lower and delayed induction of 
viral (LMP-1) and host (CXCR7) genes essential for continuous proliferation of EBV-LCLs 
and mediated by the C-terminal region of EBNA-2 was previously reported [211]. The 
experiments and results presented in this chapter provide the first functional identification of 
the amino acid of the EBNA-2 protein that is the key determinant of the enhanced ability of 
type 1 EBNA-2 to sustain and promote B cell growth, compared to the type 2 protein. For 
this, the EREB2.5 trans-complementation assay, previously used to map the domains of type 
1 EBNA-2 required for B cell transformation and to distinguish between type 1 and type 2 
EBNA-2-driven B cell proliferation [134, 207-211], was again used to initially determine the 
amino acids of the TAD that are important for this phenotype. From the chimera 6 EBNA-2 
TAD mutants tested in the ERE2.5 growth assay, TAD mutant 4 indicated that aspartate-442 
was the single amino acid of the type 1 TAD that contributed to type-specific EBNA-2 
function (Figure 3.6). Further EBNA-2 mutational analysis revealed that CR7 did not 
contribute to this type-specific effect (Figure 3.10). Remarkably, when a type 2 EBNA-2 
carrying the S442D mutation was constructed and assayed in the EREB2.5 growth assay, this 
single point mutant protein was sufficient to rescue growth of the B cells (Figure 3.14). 
Importantly, the growth phenotype of EBNA-2 proteins tested in the EREB2.5 growth assay 
correlated with their ability to induce LMP-1 and CXCR7 genes at the mRNA and protein 
levels (Figure 3.17). Type 1 and type 2 S442D maintained high levels of LMP-1 and CXCR7 
expression, thus driving continuous cell proliferation and establishment of LCLs within 4 
weeks. In cells expressing type 2 EBNA-2 however, LMP-1 and CXCR7 expression was not 
maintained at physiological levels required to support B lymphocyte proliferation, resulting 
ultimately in cell death. These results indicate that aspartate-442 of the TAD of type 1 
EBNA-2 confers the ability to sustain sufficient levels of LMP-1 and CXCR7 that are 
absolutely essential for EBV-LCL proliferation. In summary, the results obtained with the 
EREB2.5 growth assay and presented in this chapter further demonstrated that the 
mechanism underlying the superior ability of type 1 EBNA-2 to sustain B cell growth 
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compared to the type 2 protein, is higher induction of LMP-1 and CXCR7 by aspartate-442 of 
the TAD. 
 
This was a remarkable result since a single point mutant of a protein which shows just 56% 
identity [212, 213] was able to alter the phenotype completely. The result was very surprising 
given that most of the EBNA-2 sequence variation occurs in the diversity region of the N-
terminal half of the protein, rather than in the C-terminal region (Figures 1.4 and 1.5). In fact, 
sequence homology in the diversity region is just 30%, 48% in the N-terminal half and 62% 
in the C-terminal region of EBNA-2. That a single amino acid substitution can have such a 
profound phenotypic effect is very interesting, especially due to the diversity of the protein 
itself and shows just how significant the aspartate-442 residue is. Furthermore, previous work 
performed in this laboratory revealed that a chimeric EBNA-2 protein consisting of a type 1 
TAD and NLS in a type 2 sequence was not able to rescue growth of EREB2.5 cells in this 
assay [211]. In the results presented in this chapter, it has been demonstrated that this single 
S442D amino acid change in the TAD converts type 2 EBNA-2 to be as effective as the type 
1 protein in the EREB2.5 growth assay. It is possible that a single amino acid change rather 
than substituting whole domains of the protein results in minimal disruption of the EBNA-2 
protein structure, enabling it to be more compatible in this assay. Furthermore, the reciprocal 
point change of D442S in the type 1 protein abolished the activity of type 1 EBNA-2 in the 
EREB2.5 assay further demonstrating the critical nature of the aspartate-442 residue (Figure 
3.14). 
 
In previous results published by this laboratory, it was suggested that, within the C-terminus 
of type 1 EBNA-2, the RG, CR7 and TAD were the minimum type 1 sequences required to 
complement the inability of type 2 EBNA-2 to rescue growth of oestrogen-starved EREB2.5 
cells. Therefore, it was expected that specific amino acids from these three domains would 
contribute to the EBNA-2 type-specific effects tested for in this assay. However, in the results 
shown in this chapter, it was demonstrated that CR7 has no effect on the ability of EBNA-2 
to rescue growth of oestrogen-depleted EREB2.5 cells. Both the chimera 5 S442D and 
chimera 6 S442D EBNA-2 mutants, which differ only in their CR7 sequence, were able to 
sustain B cell proliferation with a similar “+” phenotype (Figures 3.6 and 3.10). Therefore, 
irrespective of CR7 sequence type, both type 1 and type 2 EBNA-2 were shown to rescue 
EREB2.5 cell growth provided they contained aspartate-442 in the TAD. This was not 
surprising since EBNA-2 CR7 has not been shown to play a role in B cell immortalisation. 
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The EBNA-2 TAD is a strong transcriptional activator and is absolutely essential for EBNA-
2-mediated activation of both viral and host genes, and for B cell transformation, since 
viruses that lack this domain are immortalisation-incompetent [224, 230]. This region of 
EBNA-2 is particularly rich in acidic amino acids (aspartate and glutamate) as well as several 
hydrophobic and aromatic residues [230]. This composition is similar to other human and 
viral TADs, such as those of the human tumour suppressor protein p53 and the herpes 
simplex viral protein 16 (VP16). Unsurprisingly, the EBNA-2 TAD also targets similar 
factors as other TADs from mammalian and viral proteins, including the general transcription 
factor IIB (TFIIB) and TAF40 [257], p300/CBP and PCAF [255], TFIIH [256] and the co-
activator p100 that interacts with TFIIE [380]. The RG sequence is also involved in protein-
protein as well as protein-nucleic acid interactions, and is important for efficient B cell 
transformation [235]. Furthermore, the RG domain downregulates EBNA-2 activation of 
LMP-1, but not of Cp [235]. The results of chimera 5 S442D and type 2 S442D EBNA-2 in 
the EREB2.5 growth assay performed in this study (Figures 3.10 and 3.14) demonstrated that 
the RG domain does not play a sequence-specific effect on the ability of EBNA-2 to promote 
B cell growth. These proteins contain a type 1 and type 2 RG domain respectively, but both 
displayed a growth phenotype. Whilst it is true that type 2 S442SD, which has a type 2 RG, 
was quantitatively better at supporting B cell proliferation, type 2 EBNA-2 proteins that do 
not contain the S442D mutation cannot rescue EREB2.5 cell growth. Therefore, this result 
again demonstrated the critical role of the aspartate-442 residue of the TAD in type-specific 
EBNA-2 effects and induction of LMP-1 and CXCR7 in EREB2.5 cells.  
 
Recent studies on the type 1 RG domain have revealed that it is highly methylated in a 
symmetric or asymmetric fashion on its arginine residues [229]. Symmetrically dimethylated 
arginine residues (sDMA) have previously been shown to enable EBNA-2-binding to the 
survival motor neuron (SMN) protein that plays a role in transcriptional regulation, by co-
activating the RNA polymerase II (RNAPII) transcription complex, and in RNA metabolism. 
Reporter assays have also shown the role of SMN in the activation of the LMP-1 promoter in 
the presence of EBNA-2 [263, 264]. Asymmetric dimethylation of the RG domain was 
apparently shown to promote EBNA-2-targetting of the viral LMP-1, LMP-2A and Cp 
promoters through RBP-Jκ-association [229]. Due to the role of type 1 RG domain 
methylation in LMP-1 regulation, it might have been interesting to investigate the 
methylation status of type 2 EBNA-2 and to determine if any differences in RG methylation 
patterns provided a mechanistic explanation for the failure of type 2 EBNA-2 to induce LMP-
165 
 
1 and CXCR7 and therefore promote B cell proliferation. However, since type 2 S442D 
EBNA-2 carried a type 2 RG domain and showed type 1-like levels of EREB2.5 growth 
rescue, it was clear that RG methylation did not play a significant role in LMP-1 induction in 
this assay. Therefore, methylation patterns of type 1 and type 2 EBNA-2 were not 
investigated in this thesis and the inability of the antibody to detect asymmetric dimethylation 
in Western blot would have made a comparative analysis difficult. 
 
The results presented in this chapter indicated that the critical aspartate-442 amino acid is 
found in the type 1 TAD and this is the key determinant of EREB2.5 cell growth in this 
assay. Interestingly, the amino acid substitution that occurs is the conversion of a serine 
residue in type 2 EBNA-2 to an aspartate found in the type 1 protein. Therefore, a possible 
phosphomimetic mechanism for the S442D change and its effect on B lymphocyte 
proliferation was considered. Phosphorylation of EBNA-2 has previously been shown to be 
important for EBNA-2 function. Studies have revealed that the EBV BGLF4 gene encodes a 
serine/threonine protein kinase (PK) which phosphorylates EBNA-2 at the serine-243 residue 
in a cdc2/cyclin B1-dependent manner and suppresses the ability of EBNA-2 to transactivate 
the LMP-1 promoter. During EBV reactivation from latently-infected B cells, EBNA-2 is 
hyperphosphorylated and this is associated with decreased levels of the LMP-1 protein [381, 
382]. Similarly, although Pim kinases do not directly phosphorylate EBNA-2, Pim-1 and -2 
phosphorylate p100, a component of the EBNA-2-containing protein complex, during EBV 
infection [383, 384], resulting in enhanced EBNA-2-mediated transcriptional activation of 
LMP-1 [383]. In addition, phosphorylation of EBNA-2 at the consensus casein kinase (CK) II 
site close to the TAD and conserved in both EBNA-2 alleles (SS469) is required for 
interaction with the host chromatin remodelling component hSNF5/Ini1 [236, 237]. Here, the 
amino acid sequences of the EBNA-2 TADs were first compared with the PEST domains of 
Notch receptors, to identify possible phosphorylation consensus motifs (Figure 3.18). This 
revealed a high level of sequence similarity and in the 15 amino acid-long sequences 
analysed, seven residues were identical (Figure 3.18).  
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Figure 3.18. Alignment of type 1 and type 2 EBNA-2 TAD sequences with different Notch PEST domains. 
Amino acids in red are conserved in all five sequences (also given by *). Amino acids shown in green are those 
conserved between type 2 EBNA-2 TAD and some or all Notch PEST domains. PEST domains are important 
for protein stability. Amino acids with similar side chain chemistry that are conserved in all five sequence are 
also represented (.). The arrow depicts the position of amino acid 442 in type 1 EBNA-2. 
 
 
A conserved amino acid between PEST domains was the serine-442 residue of the type 2 
EBNA-2 TAD (Figure 3.18). This serine residue was immediately preceded by a conserved 
proline residue in all sequences. However, only in the Notch PEST domains are the serine 
residues followed by proline amino acids. It is this Ser/Pro (SP) motif that constitutes a 
consensus phosphorylation site for proline-directed protein kinases, such as the mitogen-
activated proteins (MAPs) or cyclin-dependent protein kinases (cdks) [385, 386]. Since 
serine-442 of type 2 EBNA-2 does not lie in any known consensus phosphorylation site 
protein sequence [387], this would suggest that a physiological phosphomimetic mechanism 
for the S442D change is unlikely. Therefore, the phosphorylation state of the EBNA-2 TAD 
was not thought to have an effect on the type-specific mechanism of EBNA-2 function and 
was therefore not investigated. 
 
This is the first report which identifies aspartate-442 as critical to type-specific EBNA-2 
function. Sequence analysis and comparisons of the EBNA-2 C-terminal regions obtained 
from type 1 and type 2 EBV isolates of laboratory LCLs, BL and NPC cell lines as well as 
BL patients from Malawi (see section 3.2.9, Tables 3.1 and 3.2) revealed that their functional 
differences were typical of EBV type sequence. All type 2 EBV strains sequenced contained 
a serine residue at position 409 of EBNA-2 (position 442 in the type 1 EBNA-2 sequence). 
Therefore, the S442D change identified is a novel mutation that does not occur in any type 2 
EBV strains. It would be very interesting to investigate the S442D mutation in the context of 
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a type 2 EBV virus and test its effect on B cell infection, immortalisation and LCL 
establishment. A recombinant EBV-BAC virus expressing a type 2 S442D EBNA-2 protein 
was initially thought to have been engineered by Claudio Elgueta in the laboratory. A serial 
dilution of the virus was prepared and used to infect cells in order to measure the 50% tissue 
culture infective dose (TCID50). The TCID50 value for the type 2 S442D virus was similar to 
that of the type 1 virus. Furthermore, purified primary B lymphocytes were infected and 
LCLs established with the recombinant EBV-BAC virus. Unfortunately, sequence analysis of 
the EBNA-2 gene of the established LCLs revealed it to be of type 1 origin. This was 
possibly due to another recombination event at the resolution of cointegrants stage of the 
protocol. Therefore, the effect of the S442D mutation in vivo has yet to be elucidated and 
future work will investigate the B cell immortalisation and LCL establishment properties of a 
recombinant EBV-BAC expressing a type 2 S442D EBNA-2 protein. 
 
From an evolutionary point of view, once a DNA sequence is sufficiently different to prevent 
homologous recombination, variants can persist in a population. This is true for type 1 and 
type 2 EBNA-2 sequences and since it is not necessary for all amino acid differences to be 
selected for in order to maintain a characteristic sequence for EBNA-2 types, EBNA-2 point 
mutations can persist and have been identified. In the EBV isolate sequencing analysis and 
comparisons performed in this study (see section 3.2.9), two type 1 laboratory strains were 
found to have single point mutations within EBNA-2 functional domains. MABA contained a 
P478S amino acid change in the NLS whereas Mak1 had a A452T mutation in the TAD [211] 
but their effects on EBNA-2 function have not been characterised. A previous report 
identified W458 of B95-8 type 1 EBNA-2 (equivalent to W454 of the W91 isolate) as 
another key TAD amino acid residue. When mutated to a threonine residue, W458T, the 
resultant EBNA-2 was found to be transcriptionally inactive [230] and further analysis 
revealed that this was due to an inability to bind the coactivator and histone acetyltransferase 
(HAT) p300 [255]. These experiments provided further evidence for the importance of 
specific residues of the TAD in transactivation, but crucially of the role of the EBNA-2 TAD 
in protein-protein interaction functions also. 
 
Another study revealed the interaction between both EBNA-2 alleles and the host chromatin 
remodelling component hSNF5/Ini1 using a yeast two-hybrid system [255]. It was found that 
the EBNA-2-hSNF5/Ini1 interaction maps to two key sites of the EBNA-2 protein. One site, 
IPP286-288, was within the variable diversity domain and only differed by one amino acid in 
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the type 2 protein and the second site, DQQ311-313, was found in the RBP-Jκ-binding 
domain and was identical in the EBNA-2 alleles (see section 1.3.4, Figure 1.4). As mentioned 
above, this interaction also requires phosphorylation of the consensus CKII site at serine-469 
or serine-470, identical in both EBNA-2 alleles [236, 237]. Deletion or substitution of any of 
these conserved sites prevented the binding of EBNA-2 to hSNF5/Ini1 and diminished the 
growth-promoting potential of EBNA-2 in the trans-complementation assay [236]. Taken 
together, these data suggest that the interaction of EBNA-2 with hSNF5/Ini1, and therefore 
chromatin modification, is important for the growth-transformation phenotype of type 1 
EBNA-2. Since the sequences identified are almost identical in the type 2 protein, and the 
mapping analysis performed in the present study revealed a type 1-like growth phenotype in 
the EREB2.5 system for type 2 S442D EBNA-2, the EBNA-2-hSNF5/Ini1 interaction is 
unlikely to be the key mechanism that accounts for EBNA-2 type differences in 
transcriptional activation and transforming phenotype. However, the results published from 
this study indicate a possible role for the TAD in the folding or conformation of other 
domains. A truncated EBNA-2 lacking amino acids 1-181 and 344-487 failed to activate -
galactosidase in the yeast two-hybrid system but another truncated EBNA-2 protein, which 
retained the amino acids 344-487 including the TAD, was able to rescue the -galactosidase-
activating phenotype [237]. 
 
As described above, other studies have shown that the EBNA-2 TAD targets factors such as 
TFIIB and TAF40 [257], p300/CBP and PCAF [255], TFIIH [256], and the co-activator p100 
that interacts with TFIIE [380]. In another more recent study, the interaction between EBNA-
2 TAD and TFIIH was more fully characterised. Amino acids 448-471 were found to be 
sufficient to mediate the interaction between type 1 EBNA-2 and the Tfb1/p62 (yeast/human) 
subunit of TFIIH by nuclear magnetic resonance (NMR) spectroscopy [388]. Upon binding, 
the intrinsically disordered TAD formed a 9-residue α-helix in complex with the PH domain 
of Tfb1 and the hydrophobic residues W458, I461 and F462 were found to be important for 
this interaction. The same region of EBNA-2 was also identified as the point of binding to the 
KIX domain of p300/CBP [388]. Since it has also been shown that an EBNA-2-responsive 
element may require multiple interacting sites [220, 240, 241], more than one EBNA-2 
molecule may be required to form a competent transcription factor-promoter complex [380]. 
Furthermore, EBNA-2 self-association may be important in this process as a mutation that 
disrupts oligomerisation has previously been shown to result in a transformationally null 
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virus [217]. Therefore, taken together, these studies have shown that the EBNA-2 TAD is 
involved in many protein interactions with other transcription factors and may facilitate 
transcriptional transactivation by acting as a transcription adaptor molecule. 
 
Since acidic amino acids are frequently present in TADs [389], it is perhaps not surprising 
that aspartate-442 should increase TAD activity. This however is not limited to simply the 
transactivation function of the TAD as protein interactions of EBNA-2 have already been 
mapped to this region. Paulo Correia in the laboratory investigated whether TAD mutations 
used in this study might give a higher transactivation function compared to the wildtype type 
2 TAD. The EBNA-2 TADs were fused to the Gal4 DNA-binding domain (DBD) and tested 
for the ability to induce expression of a synthetic promoter containing Gal4 DNA binding 
sites in a transient transfection reporter assay in BJAB cells [378] (Figure 3.19). 
 
 
 
 
Figure 3.19. Aspartate-442 mediates a greater, type 1-like transactivation domain (TAD) function in TAD 
reporter assays. EBNA-2 TADs were expressed as fusion proteins with the GAL4 DBD and could activate 
luciferase reporter gene expression by binding to GAL4 binding sites in the reporter plasmid gene promoter. The 
transactivation domain assay with EBNA-2 TADs was performed in BJAB cells 24 h after transient transfection. 
TAD and luciferase activity is given as relative to the empty vector (GAL4) after normalizing for transfection 
efficiency with a co-transfected Renilla luciferase plasmid. Two independently derived T2 S442D TAD 
plasmids used in this assay are shown. Results are depicted as the mean  standard deviations from at least 3 
independent experiments. Adapted from [378]. 
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This system had been used for the original identification of the TAD of type 1 EBNA-2 
[224]. The activity of the type 1 TAD was found to be about 2-fold higher than that of the 
type 2 TAD (Figure 3.19), contrary to a previous study where type 1 and type 2 EBNA-2 
TADs were found to display similar levels of transcriptional activities in CAT assays [234]. 
S442D increased type 2 TAD transactivation activity to a level similar to that shown by the 
type 1 TAD, whereas the reciprocal D442S mutation in the type 1 TAD reduced its activity to 
a type 2 TAD-like level (Figure 3.19). The other TAD mutations that did not increase LCL 
growth (Figure 3.6) also did not increase TAD activity (Figure 3.19). Aspartate-442 therefore 
confers increased activity to the TAD of type 2 EBNA-2 and was unique among the amino 
acids tested in having this activity. It can be concluded that a slightly stronger activation 
domain function of type 1 EBNA-2 is mediated by aspartate-442. This may be a significant 
factor in the activation of specific genes by EBNA-2 during B cell transformation that results 
in the superior growth transforming properties of type 1 EBNA-2. However, in the 
microarray analysis previously carried out in the laboratory [210] (see section 1.4.4, Figure 
1.7), differentially regulated genes were found to have a 4-5 fold greater upregulation by type 
1 EBNA-2 compared to the type 2 protein. Therefore, this increase in the expression of 
specific differentially regulated genes cannot be explained solely by an only moderate 
increase in transactivation function of the EBNA-2 TAD as mediated by aspartate-442. Other 
TAD functions must also contribute to the overall mechanism of differential regulation of 
EBNA-2 target genes. 
 
It has previously been postulated by this laboratory that EBNA-2 and EBNA-LP cooperation 
may explain the difference in LMP-1/CXCR7 activation and therefore growth phenotype 
observed in type 1 and type 2 EBNA-2 [211]. Indeed, EBNA-LP has been demonstrated to 
enhance EBNA-2-mediated transcriptional activation of viral and host promoters (LMP-1 and 
-2B, Cp and cyclin D2) [114-118]. Although the mechanism of this cooperative function 
remains unclear, a role for histone deacetylase 4 interaction has been proposed [390]. The 
EBNA-2 TAD has been shown to be required for EBNA-LP co-activation with EBNA-2 in 
LMP-1 promoter reporter assays and in vitro binding assays have revealed a direct interaction 
between EBNA-LP and the EBNA-2 TAD, not involving W458 [117]. Since Co-IP and IF 
assays in previous studies have shown that EBNA-2 and EBNA-LP proteins do not 
significantly associate in lymphoblasts [117, 118] it has been suggested that EBNA-LP co-
activation with EBNA-2 occurs only when they transiently and unstably interact. This would 
allow recruitment of transcriptional regulators at EBNA-2-specific promoters by the EBNA-2 
171 
 
TAD [117]. In fact, recent ChIP-seq analysis has shown that EBNA-2 and EBNA-LP 
associate with similar regions of the genome and that EBNA-2 sites are enriched for EBNA-
LP-associated cell TFs [259]. The RG and CR7 elements have also been shown to be 
involved in EBNA-2/EBNA-LP transcriptional cooperation [235]. Moreover, the RG and 
CR7 domains are able to downregulate the transcriptional activity of the EBNA-2 TAD in the 
context of Gal4 DNA-binding fusions, indicating a possible modulating role of these domains 
in EBNA-LP function [225]. Since EBNA-LP is important for enhancing the ability of 
EBNA-2 to activate genes essential for B lymphocyte proliferation such as LMP-1 [115, 
116], this laboratory previously determined the EBNA-LP species expressed in the EREB2.5 
cell system [211]. It may have been possible that the absence of a full-length type 2 EBNA-
LP could account for the null growth phenotype and weaker LMP-1/CXCR7 induction in 
EREB2.5 cells transfected with a type 2 EBNA-2 (only a type 1 full-length EBNA-LP from 
the endogenous p554-4 plasmid and a type 2 Y1Y2-truncated EBNA-LP isoform encoded by 
the resident P3HR1 EBV genome are expressed). However, when these cells were co-
transfected with a full-length type 2 EBNA-LP the inability of type 2 EBNA-2 to rescue 
EREB2.5 cell growth was still not complemented [211]. Therefore, it is clear that the 
EREB2.5 growth assay functionally distinguishes between the ability of type 1 and type 2 
EBNA-2 to sustain B cell proliferation, and this might be enhanced by EBNA-LP cooperation 
but is not affected by the EBNA-LP isoforms present in the cell system. In this study, type 1 
and type 2 S442D EBNA-2 were both shown to rescue growth of oestrogen-depleted 
EREB2.5 cells to a similar level (Figure 3.14). These EBNA-2 proteins had type 1 and type 2 
RG and CR7 domains, respectively. Therefore, it is unlikely that EBNA-LP distinguishes 
between type 1 and type 2 RG and CR7 domains and both types are used similarly in EBNA-
2 cooperation and activation of LMP-1 and CXCR7. EBNA-LP however could be affected by 
the TAD type-sequence. As described above, EBNA-LP directly interacts with the EBNA-2 
TAD and binding is not affected by mutation of the tryptophan-458 residue in the 
transcriptionally-null EBNA-2 W458T mutant [117]. Future work could address the specific 
site of EBNA-2-EBNA-LP interaction and how it is affected by the aspartate-442 residue. 
The results presented in this chapter indicate that aspartate-442 could be important to EBNA-
LP cooperative function and may contribute to the mechanism of differential regulation of 
target genes by type 1 and type 2 EBNA-2. 
 
At the biochemical level, the differences between type 1 and type 2 EBNA-2 transcriptional 
activation may be determined by differences in the cell transcription factors or histone 
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acetyltransferases that are recruited by their TADs, resulting in higher induction of LMP-1 
and CXCR7. The inability of RBP-Jκ to mediate differential effects between type 1 and type 
2 EBNA-2 activation of target genes is unsurprising since a previous study used EMSA 
assays to show that RBP-Jκ-binding is equal in type 1 and type 2 EBNA-2 [219]. This is 
consistent with the observation that chimera 1 EBNA-2, which has a type 1 N-terminus and 
RBP-Jκ-binding domain, has a null growth phenotype in the EREB2.5 cell system [211]. 
Results in this chapter show that EBNA-2 proteins can contain either type 1 or type 2 RBP-
Jκ-binding domains (type 1 and type 2 S442D EBNA-2 respectively) and still cause 
EREB2.5 cell proliferation (Figure 3.14). Therefore, this further confirms that RBP-Jκ-
mediated transactivation of EBNA-2 target genes is unlikely to be the key mechanism that 
accounts for the higher transforming ability of type 1 EBNA-2. Significantly, EBNA-2-
mediated expression of the LMP-1 promoter, which is differentially regulated by EBNA-2 
types, occurs mainly through transcription factors other than RBP-Jκ, such as PU.1 [240, 241, 
244, 252, 254, 255]. Therefore, it would be interesting to determine whether the CXCR7 
promoter is regulated in a similar way in future work and if PU.1 is used as a common co-
activator in all EBNA-2 differentially regulated genes. 
 
Therefore, it is envisaged that the most likely mechanism for the differential regulation of 
LMP-1 and CXCR7 compared to other EBNA-2 target genes would be that their promoters 
require specific transcription factors, such as PU.1, that cooperate with EBNA-2. These 
transcription factors cannot be required for most EBNA-2-responsive genes as most genes are 
equally regulated by EBNA-2 types. Furthermore, general transcription factors of the basal 
RNA polymerase II (RNAPII) transcriptional machinery affect all genes and are therefore 
unlikely to play a role in differential gene-specific effects of EBNA-2. Although it remains 
unclear how the S442D mutation in the TAD could mediate these effects, the differentially 
regulated CXCR7 promoter was studied in greater detail in the next chapter in order to 
elucidate how genes may be differentially expressed by type 1 and type 2 EBNA-2. 
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4 Type 1 and type 2 EBNA-2 regulation of expression of 
viral and host genes important for B cell proliferation 
 
The aim of this chapter is to investigate the regulation of host and viral gene expression by 
type 1 and type 2 EBNA-2. Genes that are differentially regulated by type 1 and type 2 
EBNA-2 and that are known to be important for B cell survival and proliferation were the 
focus of this study. 
 
4.1 Introduction 
 
The ability of type 1 and type 2 EBV strains to transform primary B cells in vitro is their 
most prominent functional difference. The greater B cell transforming ability of type 1 EBV, 
in comparison to type 2 strains, was first demonstrated by Rickinson and colleagues [363]. 
Type 1 EBV-transformed LCLs also grow more quickly and to a higher saturation cell 
density than type 2 transformants [363]. The molecular determinant for this difference in in 
vitro transformation efficiency is the EBNA-2 locus [132]. Indeed, when a type 2 P3HR1 
EBV strain was engineered to express a type 1 EBNA-2 sequence, the virus gained the 
immortalisation efficiency of a type 1 EBV strain [132]. Therefore, EBV viral strain 
classification as type 1 or type 2 is defined by the EBNA-2 sequence. This locus is also the 
most divergent in the EBV genome with the primary amino acid sequence of type 1 and type 
2 EBNA-2 showing only 56% identity. This degree of divergence is strikingly high when 
compared to the rest of the EBV genome which shows an extremely low degree of variation 
[213, 214, 335-337, 391]. This biological difference in EBV types has been known for many 
years, yet the molecular mechanism underlying this phenotype is poorly understood and 
despite extensive reports on type 1 EBNA-2 function, little is known about type 2 EBV 
physiology in vitro (reviewed in section 1.4). 
 
EBNA-2 drives B cell transformation into LCLs following naive B cell EBV infection in 
vitro (reviewed in sections 1.2.4.3 and 1.3.1). It acts as a potent transcription factor, 
activating the expression of viral and host cell genes that cause infected cells to survive and 
proliferate [12, 111-113, 210, 211]. Therefore the transforming mechanism of EBV is reliant 
on EBNA-2 upregulation of viral and host gene expression. One viral gene induced by 
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EBNA-2 is the major EBV oncogene LMP-1. This activates several cell signalling pathways 
in EBV-infected LCLs leading to potent oncogenic effects [107, 333]. LMP-1 is also required 
to initiate primary B cell transformation in vitro [133], and maintenance of continuous EBV-
LCL proliferation [75]. Whole genome expression profiling analysis has revealed that most 
host genes induced by EBNA-2 are involved in B cell activation and differentiation, control 
of cell survival and growth and cell cycle regulation and apoptosis (reviewed in section 
1.3.5.1). Most studies have focussed on the direct targets of type 1 EBNA-2. However, the 
ability of type 1 and type 2 EBNA-2 to regulate the viral gene LMP-1 and the cell gene CD23 
promoters was compared in some early reports [107, 392]. It was found that in some transient 
transfection assays carried out in Daudi Burkitt’s lymphoma and BL30/P3HR1 cell lines, 
LMP-1 induction was higher with type 1 EBNA-2, but equal in others [107]. When CAT 
assays were performed in EBV-negative cell lines, it was found that LMP-1 and CD23 gene 
promoters were both more strongly induced by type 1 EBNA-2 [392]. This supports the 
hypothesis that the molecular mechanism for the greater ability of type 1 EBV to immortalise 
B cells involves the superior transactivation function of type 1 EBNA-2. More recently, this 
laboratory has performed whole genome microarray analysis to compare the induction of 
type 1 and type 2 EBNA-2 target genes [210]. Very few target genes were reported to be 
differentially regulated by EBNA-2 (e.g. CXCR7, MARCKS, ADAMDEC and IL-1), with 
all genes showing a higher induction by the type 1 protein. The most significant gene was 
CXCR7 as this was most strongly expressed and differentially regulated, and was 
demonstrated to be required for EBV-infected LCL proliferation [210]. This laboratory also 
showed that type 1 EBNA-2 induces LMP-1 more rapidly and more strongly than type 2 in 
Burkitt’s lymphoma cell lines engineered to express stable oestrogen-dependent ER-EBNA-2 
fusion proteins [210]. Taken together, these results suggest that the greater immortalisation 
efficiency of type 1 EBV strains is controlled by the enhanced induction of a small subset of 
genes by type 1 EBNA-2. In this study, the molecular mechanism of differential regulation of 
type 1 and type 2 EBNA-2 target genes was investigated, with particular focus on the cell 
gene CXCR7 and the viral oncogene LMP-1. 
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4.2 Results 
 
4.2.1 Identification of the EBNA-2-regulated transcript of CXCR7 
 
4.2.1.1 RT-PCR assays reveal a number of CXCR7 transcripts in B cells 
 
Although cellular CXCR7 is the most differentially regulated target gene of EBNA-2 and 
therefore represents a good candidate to investigate the differences in gene expression 
activation by type 1 and type 2 EBNA-2, its gene promoter is poorly characterised. The 
RefSeq human CXCR7 gene encodes two transcripts (accession number NM020311) 
although additional exons are present in the UCSC consensus (accession number BC036661) 
(Figure 4.1A). Alternative splicing of the 5 end of CXR7 has been demonstrated in a number 
of reports [210, 393]. This laboratory confirmed the induction of CXCR7 by type 1 EBNA-2 
in EREB2.5 cells responsive to oestrogen activation of ER-EBNA-2 by RT-PCR [210]. 
Further RT-PCR analysis revealed a novel splice variant of exon 2 which is directly linked to 
the coding exon as well as two known splice variants in the leader exons of CXCR7 [210]. 
However, in the RT-PCR assay performed, total RNA was used. Furthermore, our laboratory 
had previously constructed a luciferase reporter with a published CXCR7 promoter sequence 
[299] that was not responsive to EBNA-2 (unpublished data, L Cancian and PJ Farrell). 
Therefore, the aim of this study was to establish the true EBNA-2-regulated transcription start 
site (TSS) of CXCR7 in LCLs. This would reveal the bona fide EBNA-2-regulated CXCR7 
promoter and allow for investigation of the mechanism of differential gene regulation by 
type 1 and type 2 EBNA-2. 
 
The EREB2.5 cell line was used to elucidate which CXCR7 mRNA is upregulated by EBNA-
2. In this cell line, EBNA-2 is only active and can subsequently induce target gene expression 
in the presence of oestrogen since it is expressed as a fusion protein with the oestrogen 
receptor (ER), ER-EBNA-2. Therefore, to determine the promoter sequence of CXCR7 that 
is regulated by EBNA-2, EREB2.5 cells were cultured in media containing and lacking -
estradiol. Some cells were also treated for 4 h with -estradiol following oestrogen-starvation 
for 5 days. Cytosolic fractions of cells were treated with TRIzol and hence only cytoplasmic 
RNA was extracted. RNA was then converted to cDNA and analysed by RT-PCR for 
GAPDH mRNA as a control (Figure 4.1B). Primers complementary to putative CXCR7 
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exons were then used in a similar RT-PCR assay using the same cDNA (Figure 4.1C). 
Induction of CXCR7 in EREB2.5 cells grown in media containing -estradiol was confirmed 
by RT-PCR. In the presence of -estradiol and in healthily growing EREB2.5 cells where 
EBNA-2 is active, PCR products were generated with primer combinations for putative exons 
2, 3 and 5 (Figure 4.1C). In the absence of -estradiol and EBNA-2 function, CXCR7 
transcripts were downregulated (exons 2 and 5) or completely lost (exon 3) (Figure 4.1C). 
When cells were previously oestrogen-starved and then treated with -estradiol for 4 h, 
CXCR7 mRNA was re-expressed in response to EBNA-2 function (Figure 4.1C). Primer 
pairs for exons 3 and 5 generated RT-PCR products of similar size (Figure 4.1C). Since the 
forward primer of exon 5 anneals to a sequence upstream of exon 3 (Figure 4.1A), it is 
unlikely that these RT-PCR products were generated from the same CXCR7 mRNA. 
Therefore, it is likely that a number of CXCR7 transcripts were expressed. Alternatively-
spliced forms of CXCR7 were detected with exon 2 primer combinations but as only one 
splice variant seemed to be downregulated in the absence of -estradiol and was then re-
expressed when -estradiol was added back to the culture medium for 4 h, this suggests that 
this may be a CXCR7 species directly regulated by EBNA-2 (Figure 4.1C, upper panel). 
These results were consistent with those previously reported by this laboratory [210]. Taken 
together, the results indicated that further characterisation of the putative CXCR7 exons was 
required. In addition, sequencing analysis at the Singapore Genomics Institute revealed that 
LCLs express many CXCR7 mRNAs. These data, which suggest an array of CXCR7 
transcripts are produced, have recently been made available by the Encyclopaedia of DNA 
Elements (ENCODE) Consortium. Further work was required to confirm the CXCR7 
transcript expressed in response to EBNA-2 function in the EREB2.5 cell line. 
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Figure 4.1. A number of different CXCR7 transcripts are expressed in B cells. (A) Cartoon representation 
of the various expressed sequence tags (ESTs) of CXCR7 cDNA that have been sequenced. Adapted from the 
Human Genome browser. Two main CXCR7 transcripts have been proposed but there are at least 5 putative 
exons. Forward primers used in RT-PCR assays (C) for each putative exon are indicated by the numbered 
arrows. A single reverse primer complementary to the coding exon was used to detect alternatively spliced 
forms. RT-PCR assays for (B) GAPDH and (C) CXCR7. Standard PCR amplification was performed for (B) 30 
and (C) 40 cycles. 10 µl of each PCR product was resolved on a 1.3% agarose gel stained with ethidium 
bromide. B95-8 cells (carrying the type 1 EBV genome) were used as a control cell line. A 100 bp DNA marker 
(M) ladder was used. (B) GAPDH mRNA expression remained constant in all cell treatments. (C) RT-PCR 
analysis of CXCR7 mRNA. CXCR7 was transcribed when EREB2.5 cells were cultured with -estradiol or 
treated with -estradiol for 4 h following oestrogen-starvation (i.e. in response to EBNA-2 activity). 
Alternatively-spliced forms were detected with exon 2 primer combinations. Single products were generated 
with exon 3 and 5 primer combinations. RT-PCR with primers complementary to putative exons 1 and 4 
generated no products.  
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4.2.1.2 Identification of the bona fide CXCR7 target of EBNA-2 by rapid amplification 
of cDNA ends (5 RACE) 
 
To determine the true EBNA-2-regulated transcription start site (TSS) of CXCR7, 5 rapid 
amplification of cDNA ends (5 RACE) was used. EREB2.5 cells were again oestrogen-
starved and then treated, or left untreated, with -estradiol for 4 h. Cytoplasmic RNA was 
extracted and CXCR7 mRNA was in vitro transcribed using a gene-specific primer. A dC-tail 
was added to the 3 end and RT-PCR performed with an abridged anchor primer (AAP) and a 
second nested CXCR7 gene-specific primer. RACE products were analysed by standard 
agarose gel electrophoresis (Figure 4.2A), TA-cloned and then screened by colony PCR. 
Colonies were sequenced and BLASTed against the human genome to find regions of 
sequence homology (Figure 4.2B). Surprisingly, a single RACE product was produced in the 
reaction, indicating that this is the CXCR7 mRNA induced by EBNA-2 (Figure 4.2A). 
Sequencing and a BLAST search of this product (Figure 4.2B) demonstrated that the shorter 
isoform of CXCR7 that has a promoter with a TSS at 237,478,380 on chromosome 2 in the 
human hg19 genome assembly (indicated by a red arrow in Figure 4.2B, upper panel) is the 
TSS induced by EBNA-2. This corresponds to exon 5 (see section 4.2.1.1, Figure 4.1A and 
C) which is spliced with the coding exon (Figure 4.2B). Therefore, it was this CXCR7 
mRNA species that was assayed in all subsequent experiments in this study. 
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Figure 4.2. The shorter isoform of CXCR7 is regulated by EBNA-2. (A) 5 RACE was performed using 
EREB2.5 cells treated (+) or untreated (-) for 4 h with -estradiol (est) in the culture media. 35 cycles were used 
in the PCR reaction of the experiment and water (H2O) was used as a non-template negative control. PCR 
products were resolved on a 1.3% agarose gel stained with ethidium bromide and a 100 bp DNA marker (M) 
ladder was included. The single RACE product was the CXCR7 TSS induced by EBNA-2 and was assayed in 
all subsequent experiments. (B) BLAST search and sequence alignment of TA colonies transformed from 
RACE products. Sequences obtained for RACE products align perfectly with the shorter isoform of CXCR7 
(given by a red arrow) from the Human Genome Database at positions indicated by red horizontal lines in the 
upper panel. Small red vertical lines indicate positions of the CXCR7 RefSeq in the upper panel that correspond 
to the sequence alignments in the lower panel. The most 5 end of the CXCR7 sequence cannot be read due to 
binding of primers and limitations of the RACE technique. Splicing is denoted by symbol ^. 
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4.2.2 Comparing type 1 and type 2 ER-EBNA-2 binding at the CXCR7 
locus by chromatin immunoprecipitation (ChIP) 
 
Having showed that type 1 EBNA-2 regulates expression of a specific CXCR7 mRNA and to 
a higher level than type 2 EBNA-2, the hypothesis that differential regulation of EBNA-2 
target genes was due to a greater binding efficiency of type 1 EBNA-2 at the chromatin level 
was investigated. 
 
4.2.2.1 Type 1 EBNA-2 binding sites across the CXCR7 locus (and the whole genome) 
revealed by chromatin immunoprecipitation-sequencing (ChIP-seq) in the Mutu III BL 
cell line 
 
The sequences required for EBNA-2 activation of the LMP-1 promoter are close to the TSS 
and have been extensively mapped previously [240, 241, 244, 254, 394]. However, EBNA-2 
binding across the cellular genome was unclear until a collaborating laboratory recently used 
chromatin immunoprecipitation-sequencing (ChIP-seq) to reveal all EBNA-2 binding sites in 
the Mutu III BL cell line. This demonstrated that most EBNA-2 binding sites in the human 
genome are located far away from gene TSSs at distances up to 100 kb up- and/or 
downstream. Results were initially shared with us and have since been published [369]. Of 
particular importance to this study, was the EBNA-2 binding sites up- and downstream from 
the confirmed CXCR7 gene TSS (Figure 4.3). EBNA-2 preferentially binds to specific 
sequences along the CXCR7 locus (green peaks), defined as MACS peaks (black boxes) 
(Figure 4.3). These peaks often overlapped with regions of histone H3 lysine 27 acetylation 
(H3K27Ac), indicative of an active chromatin state (Figure 4.3, lower panel) and therefore 
probable EBNA-2-induced CXCR7 expression. EBNA-2 was found to bind to the CXCR7 
TSS it was reported to regulate (see section 4.2.1.2, Figure 4.2) at position 8 (Figure 4.3).  
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Figure 4.3. EBNA-2 binding at the CXCR7 gene locus. ChIP-seq analysis of type 1 EBNA-2 binding sites at 
the CXCR7 gene locus in the Mutu III BL cell line [369]. There are EBNA-2 binding sites 50 kb up- and 
downstream of the CXCR7 TSS. EBNA-2 binding is shown by green peaks and defined as such by a MACS 
algorithm (black boxes). ENCODE data for H3K27 acetylation is also shown. Specific regions along the 
CXCR7 locus are numbered 1-10 and defined as EBNA-2-binding (black) or non-binding (red), and were 
assayed in subsequent ChIP-qPCR experiments.  
 
 
4.2.2.2 Establishing an assay to compare type 1 and type 2 ER-EBNA-2 binding at 
promoters of differentially regulated target genes in Daudi cells 
 
EBV-positive Daudi BL cells were chosen in order to compare binding of type 1 and type 2 
EBNA-2 at sites found to be bound by EBNA-2 in ChIP-seq. These cells were readily 
available in the laboratory and contain a deletion for the EBNA-2 locus. Similar to EREB2.5 
cells, the Daudi cells were previously engineered to express EBNA-2 proteins fused to an 
oestrogen receptor (ER-EBNA-2), but in contrast, type 2 ER-EBNA-2-expressing cells are 
viable and can proliferate. Furthermore, the cells were previously used in this laboratory to 
show that type 1 EBNA-2 induces CXCR7 and LMP-1 mRNA expression more strongly and 
more rapidly than type 2 EBNA-2 [211]. Since EBNA-2 activity can also be controlled, 
Daudi:ER-EBNA-2 cells were ideal to use in a ChIP-qPCR study. 
 
Firstly, Daudi:ER-EBNA-2 cell lines were treated with -estradiol and protein expression 
probed after 12 h (Figure 4.4). Treatment with -estradiol produced an increased amount of 
ER-EBNA-2 proteins and a shift in their electrophoretic mobility (Figure 4.4) due to 
phosphorylation [372]. Only type 1 EBNA-2 was able to induce detectable levels of LMP-1 
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protein (Figure 4.4). Hence, the greater induction of LMP-1 at the protein level by type 1 
EBNA-2 was confirmed. 
 
            
 
Figure 4.4. Stable Daudi cell lines expressing inducible type 1 and type 2 ER-EBNA-2. Daudi cells were 
induced (+) and uninduced (-) with -estradiol (est) for 12 h to activate ER-EBNA-2 proteins. Whole cell 
lysates were prepared and samples analysed by Western blot, probing for EBNA-2 (PE2 antibody), LMP-1 (CS 
1-4 antibody) and -actin as a loading control. 
 
 
ChIP experiments were subsequently performed using Daudi:ER-EBNA-2 type 1/type 2 cells 
treated with -estradiol for 12 h (Figure 4.5). Cells were treated with formaldehyde to cross-
link proteins with DNA and subsequently lysed. Nuclear lysates were prepared and chromatin 
was sheared by sonication to generate DNA fragments of 200-600 bp in length. Sonicated 
samples were then pre-cleared with BSA-blocked beads to remove any non-specific 
interacting partners. Some of these samples were taken as input controls and analysed for 
EBNA-2 content (Figure 4.5, upper panel). Immunoprecipitations with pre-cleared sonicated 
samples were performed overnight using the EBNA-2 (PE2) antibody and a mouse 
monoclonal immunoglobulin (IgG) control antibody as a negative control. 
Immunoprecipitated samples were then treated with a secondary anti-mouse antibody and 
captured with protein A sepharose beads. Immuno-complexes were subsequently washed 
with a number of buffers. Samples were taken from immunoprecipitations with PE2 and IgG 
antibodies at this stage and EBNA-2 analysed by Western blotting (Figure 4.5, middle and 
lower panels).  
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As with the whole cell lysates, a much greater level of type 2 EBNA-2 expression compared 
to the type 1 protein was observed in the input samples (Figure 4.5, upper panel). No EBNA-
2 was found to precipitate with the IgG control antibody (Figure 4.5, middle panel). Western 
blot analysis also demonstrated that much more type 2 EBNA-2 was precipitated by the 
EBNA-2 PE2 monoclonal antibody in ChIP protein samples (Figure 4.5, lower panel). 
 
            
 
Figure 4.5. Immunoprecipitations with samples from Daudi cell lines expressing inducible type 1 and type 
2 ER-EBNA-2. Daudi cells were induced (+) and uninduced (-) with -estradiol (est) to activate ER-EBNA-2 
proteins for 12 h. Sonicated nuclear lysates were prepared and immunoprecipitations (IP) performed with the 
EBNA-2 PE2 antibody and with the mouse monoclonal immunoglobulin (IgG) antibody as a negative control. 
ChIP samples were prepared further and analysed by Western blot for EBNA-2 using the PE2 antibody. 
 
 
The results indicated that type 1 and type 2 ER-EBNA-2 were specifically pulled down by 
the PE2 antibody. The next step was to investigate DNA fragments that were bound by the 
EBNA-2 proteins. After washing of the immuno-complexes, formaldehyde cross-links were 
reversed and proteins degraded by treatment with proteinase K. DNA fragments were 
subsequently column-purified using a QIAquick gel extraction kit. In order ensure specificity 
of the assay, EBNA-2 binding at a number of control genes was initially investigated. If this 
proved successful, the assay would be extended to test for specific EBNA-2 binding at 
promoter elements of CXCR7 (see section 4.2.2.3). 
 
PPIA was used as a negative control in this assay as it is a gene that is not regulated by 
EBNA-2 and no MACS peaks of EBNA-2 binding were reported in ChIP-seq experiments 
[369]. When immunoprecipitated DNA from type 1 and type 2 Daudi:ER-EBNA-2 cells were 
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assayed for PPIA-binding by EBNA-2, no enrichment was present (Figure 4.6). In 
immunoprecipitations with PE2 and IgG antibodies with nuclear lysates prepared from cells 
induced to express type 1 or type 2 ER-EBNA-2 or not, PPIA levels were found to be 
comparable (Figure 4.6). These results, from a single experiment, indicate that a negative 
control had been established for the ChIP-qPCR assay. 
 
 
 
 
Figure 4.6. EBNA-2 does not bind to the PPIA gene in Daudi:ER-EBNA-2 cell lines. Daudi:ER-EBNA-2 
type 1 and type 2 cells were induced (+) and uninduced (-) with -estradiol for 12 h to activate ER-EBNA-2 
proteins. Inputs were taken to allow for quantification of qPCR products by the standard curve method. 
Immunoprecipitations were performed with EBNA-2 (PE2) and mouse monoclonal immunoglobulin (IgG) 
antibodies. qPCR was performed in triplicate using primers for PPIA and histograms represent qPCR values for 
EBNA-2 ChIP (black) and IgG control (white) relative to ChIP input (%). 
 
 
A positive control for the ChIP-qPCR was required. This needed to be a gene which EBNA-2 
ChIP-seq in Mutu III BL cells had shown to have a type 1 EBNA-2 binding site. 
Furthermore, another region that was not bound by EBNA-2 within that same gene had to be 
tested as an internal gene control. This would demonstrate EBNA-2 binding to be specific to 
the regulatory element along the gene locus. Ideally, this gene would also be equally 
regulated by type 1 and type 2 EBNA-2 as the EBNA-2 binding at its promoter elements 
would likely be equal between protein types.  
 
CCL3, a gene previously reported to be equally regulated by type 1 and type 2 EBNA-2 
[210], was chosen. In addition, ChIP-seq experiments in Mutu III BL cells revealed a single 
EBNA-2 binding site, or MACS peak, in the CCL3 locus (Figure 4.7A) [369]. qPCR primers 
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were subsequently designed for this EBNA-2 binding site and another non-binding site 
(marked as CCL3 (2) and CCL3 (1) respectively in Figure 4.7) and tested in the assay using 
the same immunoprecipitated DNA as in Figure 4.6. The experiment was repeated a total of 
three times and qPCR performed in triplicate (Figure 4.7). No difference in ChIP values for 
immunoprecipitations with IgG and PE2 antibodies irrespective of EBNA-2 type and 
expression was reported at the region not bound by EBNA-2 (Figure 4.7B). At CCL3 position 
2 previously shown to bind EBNA-2, however, ChIP values increased when cells induced for 
EBNA-2 expression were immunoprecipitated with the PE2 antibody in comparison to the 
IgG antibody (Figure 4.7C). Binding was therefore defined as an increase in ChIP-qPCR 
value with PE2 immunoprecipitation, relative to IgG. The result demonstrated that EBNA-2 
binding could be tested in this assay and that it occurred at specific sites of a gene locus. In 
addition, ChIP-qPCR values were comparable in cells induced for type 1 and type 2 ER-
EBNA-2 expression in PE2 immunoprecipitations (Figure 4.7C). This indicates that both type 
1 and type 2 ER-EBNA-2 are shown to bind in this assay and do so equally at this specific 
promoter element of CCL3. Therefore, it was possible to compare type 1 and type 2 ER-
EBNA-2 chromatin binding using this ChIP-qPCR assay. 
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Figure 4.7. EBNA-2 proteins bind to a specific promoter element of the CCL3 gene in Daudi:ER-EBNA-2 
cell lines. (A) ChIP-seq analysis of type 1 EBNA-2 binding sites at the CCL3 gene locus in the Mutu III BL cell 
line [369]. EBNA-2 binding sites, defined as such by a MACS algorithm, are depicted as black boxes. ENCODE 
data for H3K27 acetylation is also displayed. Specific regions along the CCL3 locus numbered 1 (red, non-
binding) and 2 (black, EBNA-2-binding) were assayed in subsequent ChIP-qPCR experiments. (B and C) 
Daudi:ER-EBNA-2 type 1 and type 2 cells were induced (+) and uninduced (-) with -estradiol for 12 h to 
activate ER-EBNA-2 proteins. Immunoprecipitations were performed with EBNA-2 (PE2) and mouse 
monoclonal immunoglobulin (IgG) antibodies. qPCR was performed in triplicate using primers for regions of 
CCL3 which showed (B) no binding or (C) binding of EBNA-2 in ChIP-seq experiments [369]. Inputs were also 
assayed to allow for quantification of qPCR products by the standard curve method. qPCR values are 
represented as histograms for EBNA-2 ChIP (black) and IgG control (white) relative to ChIP input (%) with 
errors bars indicating standard deviation from at least 3 independent experiments. p-values: ns=not significant, 
***<0.005. 
 
 
Taken together, these results indicate that a ChIP-qPCR assay with positive and negative 
controls had been established to investigate specific binding of EBNA-2 types at gene 
regulatory elements. Both type 1 and type 2 ER-EBNA-2 were shown to associate with a 
previously known EBNA-2 binding site at a specific region of the CCL3 gene and to not 
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associate with other regions of the genome. Therefore, this assay could be used to compare 
the binding of type 1 and type 2 EBNA-2 at promoter elements of genes including those that 
are differentially regulated by EBNA-2 types. 
 
4.2.2.3 Type 1 ER-EBNA-2 binds at higher levels to CXCR7 gene regulatory elements 
compared to type 2 
 
As the ChIP-qPCR assay for Daudi:ER-EBNA-2 cell lines had been established, it was 
possible to investigate differential binding of type 1 and type EBNA-2 at the many regions of 
CXCR7 that showed EBNA-2-binding in ChIP-seq [369] (see section 4.2.2.1, Figure 4.3). 
Sites that showed no evidence of EBNA-2-binding were also included in the investigation as 
an internal gene control (Figure 4.8). 
 
An initial qPCR assay for CXCR7 was performed using DNA from one β-estradiol induction 
experiment (Figure 4.8). The qPCR primers used were complementary to specific regions 
along the CXCR7 locus (numbered in section 4.2.2.1, Figure 4.3) which included EBNA-2-
binding and non-binding sites (Figure 4.5). 
 
Immunoprecipitations with the IgG antibody resulted in similar levels of each position along 
the CXCR7 locus in both cell lines and treatments (β-estradiol) indicating the background 
level of each (Figure 4.8). Binding was defined as an increase in ChIP-qPCR value with PE2 
immunoprecipitation in cells induced to express type 1 or type 2 ER-EBNA-2, compared to 
the background level with IgG. There were very small differences in EBNA-2 binding at 
positions across the CXCR7 gene (Figure 4.8) that ChIP-seq experiments demonstrated to not 
be bound by EBNA-2 [369] (Figure 4.3). These were namely CXCR7 positions 2, 4, 7 and 9 
and this showed that EBNA-2 binding occurred at specific sites along the CXCR7 gene locus 
in this assay. ChIP-qPCR values however increased in cells induced for type 1 ER-EBNA-2 
in PE2 immunoprecipitations, in contrast to type 2 ER-EBNA-2-expressing cells at CXCR7 
position 1 (Figure 4.8). This indicated only type 1 ER-EBNA-2 binding at this site and was 
consistent with ChIP-seq data (see section 4.2.2.1, Figure 4.3). This result showed that it was 
possible to assess differential binding of EBNA-2 types at the CXCR7 locus also. Further 
qPCR experiments revealed similar EBNA-2 binding profiles at CXCR7 positions 5, 8 and 10 
(Figure 4.8) with type 1 ER-EBNA-2 binding much more abundantly than the type 2 protein 
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in oestrogen-treated cells. There may have been an increase in type 2 ER-EBNA-2 binding at 
CXCR7 position 10 relative to uninduced type 2 Daudi:ER-EBNA-2 cells (Figure 4.8), but 
this was only a moderate change. Interestingly, only type 1 ER-EBNA-2 binds at CXCR7 
position 8 (Figure 4.8) which the 5 RACE study revealed to be the EBNA-2-regulated TSS 
of CXCR7 (see section 4.2.1.2, Figure 4.2). Type 2 ER-EBNA-2 was enhanced at CXCR7 
position 6, however there was a high level of background in the PE2 immunoprecipitation of 
uninduced type 2 cells, and did not reach type 1 ER-EBNA-2 levels of binding (Figure 4.8). 
Both type 1 and type 2 ER-EBNA-2 were also found to bind at CXCR7 position 3, but as the 
ChIP-qPCR value for the type 1 protein was much greater, it can be concluded that type 1 
ER-EBNA-2 bound more abundantly at this CXCR7 promoter element also (Figure 4.8). 
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Figure 4.8. ER-EBNA-2 proteins bind to specific promoter elements of the CXCR7 gene in Daudi:ER-
EBNA-2 cell lines. ER-EBNA-2 proteins were activated by treating Daudi:ER-EBNA-2 type 1 and type 2 cells 
with (+) or without (-) -estradiol for 12 h. Immunoprecipitations were carried out with EBNA-2 (PE2) and 
mouse monoclonal immunoglobulin (IgG) antibodies. qPCR was performed in triplicate using primers for 
regions of CXCR7 (given in brackets) which showed both EBNA-2 binding and non-binding in ChIP-seq 
experiments [369] (Figure 4.3). Inputs were assayed to quantify qPCR products by the standard curve method. 
qPCR values are represented as histograms for PE2 ChIP (black) and IgG control (white) relative to ChIP input 
(%) from one experiment. 
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The results of this ChIP-qPCR assay show that type 1 ER-EBNA-2 binds to specific promoter 
elements of CXCR7 and are consistent with ChIP-seq data in Mutu III BL cells [369]. 
Furthermore, type 1 and type 2 ER-EBNA-2 seem to differentially bind at these regulatory 
elements. However, the differential EBNA-2-binding effects were unclear at some positions 
across the CXCR7 locus. In order to demonstrate the significance of EBNA-2 binding and 
compare type 1 and type 2 ER-EBNA-2 association at CXCR7 promoter elements, ChIP-
qPCR experiments with Daudi:ER-EBNA-2 cell lines were repeated. 
 
For this, DNA from the experiment shown in Figure 4.7 was used as well as 
immunoprecipitated DNA from further experiments in which type 1 and type 2 EBNA-2 
were again expressed and activated in Daudi cell lines treated with -estradiol for 12 h. The 
experiment was repeated at least four times and qPCR performed in triplicate (Figure 4.9). 
Samples were also taken to analyse the expression and immunoprecipitation of ER-EBNA-2 
proteins by Western blot, as type 2 ER-EBNA-2 was previously found to be more abundantly 
expressed and immunoprecipitated by the PE2 antibody compared to the type 1 protein 
(Figure 4.5) despite the PE2 antibody binding to EBNA-2 types equally [210]. The remaining 
samples were treated with proteinase K and DNA bound by EBNA-2 proteins was purified 
with a QIAquick gel extraction column. qPCR experiments were then performed for specific 
regions along the CXCR7 locus to include both EBNA-2-binding and non-binding sites 
(Figure 4.9). The amount of EBNA-2 immunoprecipitated in all experiments was first 
quantified by LI-COR and used to normalise qPCR raw data (Figure 4.5). 
 
ChIP-qPCR data for immunoprecipitations with PE2 and IgG antibodies and in induced and 
uninduced cells were compared. ChIP-qPCR with the IgG control antibody revealed the 
background level of each genomic region (Figure 4.9). EBNA-2-binding was defined as an 
increase in ChIP input value at any given region, in cells induced with -estradiol and 
immunoprecipitated with PE2 antibody, relative to all other treatments. Therefore, EBNA-2 
binding occurred when the ChIP-qPCR value was found to be above the background level for 
each region in cells that were induced for EBNA-2 expression. ChIP-qPCR results indicate 
that type 1 ER-EBNA-2 bound to CXCR7 positions 1, 3, 5, 8 and 10 across the gene locus 
(Figure 4.9), consistent with ChIP-seq data (see section 4.2.2.1, Figure 4.3). These gene 
regions were found to be more abundant when type 1 ER-EBNA-2 nuclear lysates were 
immunoprecipitated with the PE2 antibody and were also above the background level (Figure 
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4.9). The moderate increase of type 1 ER-EBNA-2 binding at CXCR7 position 6 reported in 
the previous experiment (Figure 4.8) was found to not be significant when the assay was 
repeated (Figure 4.9). Type 1 ER-EBNA-2 binding still occurs at CXCR7 position 8 (Figure 
4.9), which was found to be the EBNA-2-regulated TSS of CXCR7 by 5 RACE (Figure 4.2). 
Binding of type 1 ER-EBNA-2 is greatest at CXCR7 position 3 (Figure 4.9). This was not 
surprising as ChIP-seq experiments revealed this CXCR7 region to have the biggest and 
broadest MACS peak of EBNA-2-binding in Mutu III BL cells [369] (see section 4.2.2.1, 
Figure 4.3). 
 
Type 2 ER-EBNA-2 showed no binding across the CXCR7 locus, except at position 3 
(Figure 4.9), the broadest of the EBNA-2 MACS peaks at CXCR7 in the Mutu III cell line 
(Figure 4.3), consistent with the previous experiment in the Daudi cell background (Figure 
4.8). There was no type 2 ER-EBNA-2 binding at CXCR7 position 6 when ChIP-qPCR 
assays were repeated (Figure 4.9). The moderate increase in type 2 EBNA-2 binding at 
CXCR7 position 10 previously reported (Figure 4.8) was not demonstrated when the 
experiment was repeated (Figure 4.9). Again, the CXCR7 TSS at position 8 was found to not 
be bound by type 2 ER-EBNA-2 (Figure 4.9). There was also no binding of either EBNA-2 
type at the control gene PPIA (Figure 4.9) 
 
Taken together, the results show that type 1 and type 2 ER-EBNA-2 bind differentially at 
CXCR7 promoter elements. Type 1 ER-EBNA-2 binds at higher levels to these regulatory 
elements of CXCR7 compared to type 2. In fact, type 2 ER-EBNA-2 only binds to CXCR7 
position 3 although at a lower level than that of type 1 EBNA-2 (Figure 4.9). 
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Figure 4.9. Type 1 and type 2 ER-EBNA-2 differentially bind to specific promoter elements of the CXCR7 
gene. Daudi:ER-EBNA-2 type 1 (T1) and type 2 (T2) cells were treated with (+) and without (-) -estradiol for 
12 h to activate ER-EBNA-2 proteins. Immunoprecipitations were performed with antibodies for EBNA-2 
(PE2) and mouse immunoglobulin (IgG) as a control. Inputs were taken so that qPCR products could be assayed 
and quantified by the standard curve method. qPCR experiments were performed in triplicate using primers 
specific for regions of CXCR7, which showed both T1 EBNA-2 binding and non-binding in ChIP-seq 
experiments in Mutu III BL cells [369] (Figure 4.3), and PPIA. Raw data were first normalised for the amount 
of EBNA-2 protein immunoprecipitated by the PE2 antibody in all experiments and plotted on the same graph to 
indicate relative EBNA-2-binding. qPCR values for PE2 immunoprecipitations performed on nuclear lysates 
where type 1 (dark blue) and type 2 (red) ER-EBNA-2 were induced are shown. Histograms indicate the mean 
of ChIP-qPCR data from at least 4 independent experiments and error bars show standard deviations. p-values: 
*<0.05, **<0.01, ***<0.005. 
 
 
4.2.2.4 Type 1 and type 2 ER-EBNA-2 binding at ADAMDEC1, another differentially 
regulated gene 
 
As EBNA-2 proteins were demonstrated to bind differentially to specific promoter elements 
of CXCR7, type 1 and type 2 EBNA-2 binding at another differentially regulated gene using 
the same ChIP-qPCR assay was investigated. 
 
195 
 
The cellular gene ADAMDEC1 was chosen to further explore type 1 and type 2 EBNA-2 
binding at the chromatin level of gene regulatory elements. ADAMDEC1 was previously 
demonstrated to be differentially regulated by EBNA-2 [210]. ChIP-seq experiments 
performed in Mutu III BL cells revealed a single MACS peak of EBNA-2 binding (Figure 
4.10A) [369]. Therefore, it was expected that gene regulation of ADAMDEC1 by EBNA-2 
was more simplistic than that of CXCR7 which has numerous EBNA-2 binding sites at its 
promoter [369] (Figure 4.3). It was thought that understanding EBNA-2 binding at 
ADAMDEC1 could inform our investigation of the mechanism of differential regulation of 
EBNA-2 target genes. 
 
qPCR primers were designed for the single EBNA-2 binding site of ADAMDEC1 and a non-
binding region (marked as positions (1) and (2) respectively in Figure 4.10). qPCR was then 
performed with immunoprecipitated DNA from previous experiments in order to determine 
the difference between type 1 and type 2 ER-EBNA-2 binding at these sites. Binding was 
again defined as an increase in ChIP-qPCR value when cells induced to express ER-EBNA-2 
proteins were immunoprecipitated with PE2, relative to the IgG control. There were no 
differences found in qPCR values between all cell types, treatments and 
immunoprecipitations at ADAMDEC1 position 1 (Figure 4.10B). Therefore, ER-EBNA-2 
proteins did not bind at this position in this assay, consistent with ChIP-seq results that 
indicated this region to show no EBNA-2-binding (Figure 4.10A) [369]. There was a 
moderate, approximately two-fold increase in qPCR value when samples were assayed at 
ADAMDEC1 position 2 in cells expressing type 1 ER-EBNA-2 and immunoprecipitated with 
PE2 antibody (Figure 4.10C). This result indicates that type 1 ER-EBNA-2 was bound to this 
specific region of ADAMDEC1, in agreement with ChIP-seq data (Figure 4.10A) [369]. 
There was no difference in ADAMDEC1 position 2 when type 2 ER-EBNA-2 was expressed 
in cells (Figure 4.10C) indicating the inability of type 2 ER-EBNA-2 to bind to this 
regulatory element. Therefore, EBNA-2 binding was again shown to be differential at a 
specific promoter site in this differentially regulated gene. 
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Figure 4.10. Differential binding of ER-EBNA-2 proteins at the ADAMDEC1 gene in Daudi:ER-EBNA-2 
cell lines. (A) ChIP-seq analysis of type 1 EBNA-2 binding sites at the ADAMDEC1 gene locus in the Mutu III 
BL cell line [369]. The single EBNA-2 binding site, defined as such by a MACS algorithm, is represented as a 
black box. ENCODE data for H3K27 acetylation is also shown. Specific regions along the CCL3 locus 
numbered 1 (red, non-binding) and 2 (black, EBNA-2-binding) were assayed in subsequent ChIP-qPCR 
experiments. (B and C) ER-EBNA-2 proteins were activated by treating Daudi:ER-EBNA-2 type 1 (T1) and 
type 2 (T2) cells with (+) or without (-) -estradiol for 12 h. Immunoprecipitations were performed with EBNA-
2 (PE2) and mouse monoclonal immunoglobulin (IgG) antibodies. Inputs samples were taken and included in 
the assay to quantify qPCR products by the standard curve method. qPCR was performed in triplicate using 
primers for regions of ADAMDEC1 which showed (A) no binding and (B) EBNA-2 binding in ChIP-seq 
experiments [369]. qPCR values are shown for PE2 ChIP (black) and IgG control (white) relative to ChIP input 
(%) based on a total of 4 independent experiments. p-values: *<0.05. 
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4.2.2.5 Nuclear import of type 1 and type 2 ER-EBNA-2 proteins 
 
To ensure that the effect observed in ChIP-qPCR assays was not influenced by the duration 
EBNA-2 proteins were present in the nucleus, the rate of their nuclear import was tested. 
Daudi:ER-EBNA-2 cell lines expressing type 1 and type 2 EBNA-2 fused to the ER, were 
induced and uninduced with -estradiol over a 12 h time-course experiment. Cells were 
fractionated at each time point using the sucrose density gradient centrifugation method and 
cytoplasmic and nuclear fractions analysed by Western blot (Figure 4.11). GAPDH was 
assayed as a loading control for cytoplasmic fractions (Figure 4.11A) and histone H1 for 
nuclear fractions (Figure 4.11B). As expected, most EBNA-2 was found in the cytoplasm 
when cells were not induced (0 h and - lanes) with -estradiol (Figure 4.11A). Type 1 and 
type 2 ER-EBNA-2 were trafficked to the nucleus as early as 2 h after -estradiol activation 
(Figure 4.11B), consistent with the reduction of ER-EBNA-2 in cytoplasmic fractions 
(compare 0 and 2 h lanes, Figure 4.11A). Both type 1 and type 2 ER-EBNA-2 were 
increasingly trafficked to nucleus over the 12 h treatment with -estradiol (Figure 4.11B). 
More type 2 ER-EBNA-2 was present in the nucleus compared to type 1 protein (Figure 
4.11B) but this may be reflective of the greater expression of type 2 ER-EBNA-2 (see section 
4.2.2.2, Figure 4.4A) rather than due to a difference in the rate of nuclear import of EBNA-2 
types. 
 
 
 
 
 
 
 
 
198 
 
 
 
 
 
 
Figure 4.11. Nuclear import of type 1 and type 2 ER-EBNA-2 occurs at a similar rate. Daudi:ER-EBNA-2 
type 1 (T1) and type 2 (T2) cells were induced with -estradiol (est) for 2, 4, 8 and 12 hours (h) or left 
uninduced (0 h and -). Cells were fractionated using sucrose gradients and (A) cytoplasmic and (B) nuclear 
fractions were analysed by Western blot, probing for EBNA-2 expression (PE2 antibody). (A) GAPDH was 
probed in cytoplasmic fractions as a loading control whereas (B) histone H1 was used for nuclear fractions. 
Taken together, the data suggest that despite a similar rate of type 1 and type 2 ER-EBNA-2 
nuclear import, type 1 ER-EBNA-2 binds more strongly to specific gene promoter elements 
in comparison to the type 2 protein. Therefore, reduced binding of type 2 ER-EBNA-2 at 
these sites may contribute to its impaired activation of specific viral and cell genes. These 
effects could result in the lower growth-transforming ability of type 2 EBNA-2. 
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4.2.3 Comparing wildtype type 1, type 2 and type 2 S442D EBNA-2 binding 
at promoter elements of genes relevant to B cell proliferation by chromatin 
immunoprecipitation (ChIP) 
 
In all previous ChIP experiments, chromatin binding by EBNA-2 proteins was studied in the 
context of ER-EBNA-2. In the Daudi cell lines used, type 2 EBNA-2 expressed as a fusion 
protein with ER was much more abundantly expressed and immunoprecipitated by the PE2 
antibody. In order to compare ChIP-qPCR results from type 1 and type 2 cell lines, the 
amount of protein precipitated in all experiments was first quantified by LI-COR and applied 
to qPCR raw data for normalisation. Therefore, a system with equal expression of inducible 
wildtype type 1, type 2 and type 2 S442D EBNA-2 proteins was established (see section 
4.2.3.2, Figure 4.17). 
 
4.2.3.1 Generating Daudi cell lines to express equal amounts of wildtype type 1, type 2 
and type 2 S442D EBNA-2 
 
Daudi cell lines expressing wildtype type 1 and type 2 EBNA-2 from a pHEBo vector under 
the control of a metallothionein (MT) promoter were generated by Claudio Elgueta in the 
laboratory as described (see section 2.3.3.16.2). After the result of the mutational EBNA-2 
analysis had become clear, I generated a Daudi cell line expressing type 2 S442D EBNA-2. 
 
Type 2 S442D pHEBoMT-EBNA-2 was generated by SDM of the type 2 vector (Figure 
4.14) but cloning involving pBS, pSG5 and pBK-CMV-MT vectors was initially attempted. 
BstXI/NotI digestion was used to clone the RG–C-terminus-spanning fragment of type 2 
EBNA-2 into the pSG5:E2T2 vector also cut with BstXI and NotI (Figure 4.12A). 
Transformants were screened by BstXI/NotI digestion to check for correct ligation and 
cloning (Figure 4.12B). 
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Figure 4.12. Cloning of type 2 S442D EBNA-2 into the pSG5 vector. (A) BstXI and NotI restriction enzymes 
were used to clone type 2 S442D EBNA-2 from the pBS vector (E2T2 S442D) into pSG5:E2T2. Fragments 
from a BstXI/NotI digestion were gel-extracted and separated on a 1% agarose gel stained with ethidium 
bromide. (B) Representative BstXI/NotI digest of pSG5:E2T2 S442D transformants. Approximately 100 ng 
DNA was cut with BstXI and NotI restriction enzymes generating two products including the C-terminal region 
of the EBNA-2 allele from the RG domain (approximately 1.2 kb). pSG5:E2T2 was used as a control (ctrl). 
100 bp and 1 kb markers (M) were used as appropriate. 
 
 
HindIII and BglII restriction enzymes were used to digest pSG5:E2T2 S442D and clone into 
HindIII/BamHI-cut pBK-CMV-MT. Despite repeated attempts with different insert:vector 
ratios in ligation reactions, successful cloning of pBK-CMV-MT:E2T2 S442D proved 
unsuccessful. SDM was therefore used to insert the S442D mutation into the pBK-CMV-
MT:E2T2 plasmid. SDM products were digested with DpnI and transformed into competent 
cells, before DNA was purified and digested with BstXI (Figure 4.13A). Primers spanning the 
whole of the EBNA-2 allele were used to sequence E2T2 S442D in the pBK-CMV-MT 
vector. Another point mutation was present in the EBNA-2 sequence but this was found to be 
silent and not alter the amino acid sequence. As the pBK-CMV-MT vector contained a 
promoter able to express the EBNA-2 allele in eukaryotic cells, HEK 293 cells were 
transfected with pBK-CMV-MT:EBNA-2 plasmids using lipofectamine and induced to 
express EBNA-2 with cadmium chloride (CdCl2) for 24 h. Western blot analysis revealed 
correct expression of the type 2 S442D EBNA-2 from this plasmid (Figure 4.13B).  
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Figure 4.13. Cloning the S442D mutation into a pBK-CMV-MT vector carrying the type 2 EBNA-2 allele. 
(A) Representative BstXI digest of approximately 200 ng DNA of pBK-CMV-MT:E2T2 S442D plasmid. pBK-
CMV-MT:E2T2 was also digested as a control (ctrl) and run on a 1% agarose gel stained with ethidium 
bromide. (B) Western blot analysis of HEK 293 cells transfected with pBK-CMV-MT vectors expressing type 2 
(ctrl) and type 2 S442D (E2T2 S442D) EBNA-2. Expression of EBNA-2 was induced for 24 h with CdCl2 and 
probed with the PE2 antibody and -actin was used as a loading control. 
 
 
The MT-E2T2 S442D fragment from the pBK-CMV-MT vector was used to clone into a 
pHEBo vector (where a BamHI site had been modified to a second NotI site) by NotI 
digestion. Meanwhile, an attempt was made to generate the type 2 S442D pHEBoMT-EBNA-
2 plasmid by SDM. For this, type 2 pHEBoMT-EBNA-2 was used in a SDM reaction and the 
product was digested with DpnI and transformed into E. coli XL1 Blue cells (Agilent 
Technologies). The resultant transformants were screened by NotI digestion (Figure 4.14A). 
The whole of the EBNA-2 allele was sequenced and found to contain no additional 
mutations, even in the nucleotide sequence. Since the expression plasmid (pHEBoMT-E2T2 
S442D) for use in Daudi cells had been generated, it was first tested in HEK 293 cells by 
transfection with lipofectamine for 24 h followed by a further 24 h CdCl2 treatment to induce 
EBNA-2 protein expression (Figure 4.14B). Western blot analysis of cell lysates revealed that 
type 2 S442D EBNA-2 was expressed correctly from this plasmid (Figure 4.14B). 
 
202 
 
 
 
 
Figure 4.14. Expression of correctly cloned type 2 S442D EBNA-2 from the pHEBoMT vector in HEK 
293 cells. (A) Representative NotI digest of approximately 200 ng DNA of pHEBoMT vectors expressing type 2 
(used as a control, ctrl) or type 2 S442D (E2T2 S442D) EBNA-2. Digested DNA was run with a 1 kb marker 
(M) on a 1% agarose gel stained with ethidium bromide. (B) Western blot analysis of HEK 293 cells transfected 
with pHEBoMT vectors expressing type 2 (ctrl) and type 2 S442D (E2T2 S442D) EBNA-2. EBNA-2 
expression was induced for 24 h with CdCl2 and probed with PE2. -actin was used as a loading control. 
 
 
The type 2 S442D pHEBoMT-EBNA-2 plasmid was subsequently used to transfect Daudi 
cells. 2x10
6 
Daudi cell lines were stably transfected with the pHEBo plasmid carrying the 
cadmium-responsive metallothionein (MT) promoter and type 2 S442D EBNA-2 expression 
cassette using the Neon transfection method (see section 2.2.6.3). Approximately 3-4 weeks 
post-transfection and hygromycin selection, the Daudi:pHEBoMT-E2T2 S442D cell line had 
grown out and was induced for 24 h with CdCl2 (Figure 4.15). Western blot analysis revealed 
that EBNA-2 was only expressed when cells were treated with CdCl2 (Figure 4.15).  
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Figure 4.15. The Daudi:pHEBoMT-E2T2 S442D cell line inducibly expresses type 2 S442D EBNA-2 when 
treated with CdCl2. After cell line outgrowth and hygromycin selection, a number of clones were treated (+) 
with CdCl2 or left untreated (-) for 24 h. Type 2 (T2) was used as a control. EBNA-2 expression was probed 
with PE2 and -actin was used as a loading control. 
 
 
Western blot analysis of Daudi:pHEBoMT cell lines expressing type 2 S442D EBNA-2 also 
revealed that, even for cells transfected with the same plasmid, EBNA-2 expression was not 
equal (Figure 4.15, upper panel). Optimisation of EBNA-2 expression such that it would be 
equal between type 1, type 2 and type 2 S442D EBNA-2 Daudi:pHEBoMT cell lines was 
therefore required (Figure 4.16) and this took a considerable amount of experimentation to 
achieve. Time-course experiments were performed over 48 hours with proteins extracted 
every 4 hours. This was repeated for each CdCl2 concentration and cell line so that equal 
expression of all EBNA-2 proteins was finally achieved (see section 4.2.3.2, Figure 4.17). 
 
As Daudi:pHEBoMT cell lines expressing wildtype type 1 and type 2 EBNA-2 proteins were 
first established, equal expression of these EBNA-2 proteins was initially optimised. Type 1 
and type 2 Daudi:pHEBoMT-EBNA-2 cell lines were first treated with 5 μM CdCl2 but type 
2 EBNA-2 was again more abundantly expressed compared to the type 1 protein (Figure 
4.16A). In these constructs, the length of the EBNA-2 polyproline repeat (PPR) was 
equalised in the type 1 and type 2 EBNA-2 alleles to generate EBNA-2 proteins of almost the 
same size (Figure 4.16). Treatment with a lower concentration (only 1 μM) of CdCl2 failed to 
induce EBNA-2 expression (Figure 4.16B). A higher concentration of CdCl2 (10 μM) was 
then used in another experiment resulting in a greater induction of type 1 EBNA-2, compared 
to the amount induced with 1 and 5 μM, but still lower than that of type 2 EBNA-2 at the 
same CdCl2 concentration (Figure 4.16C). When testing the inducibility of the type 2 S442D 
EBNA-2 Daudi:pHEBoMT cell line previously (Figure 4.15), the cells were treated with 
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5 μM CdCl2 and showed type 2-like levels of protein expression. The type 2 S442D EBNA-2 
Daudi:pHEBoMT cell line was therefore treated with a CdCl2 titration (3-5 μM) and 
increasing amounts of type 2 S442D EBNA-2 were found to be expressed (Figure 4.15D). 
Finally, type 1, type 2 and type 2 S442D Daudi:pHEBoMT-EBNA-2 cell lines were treated 
with 10, 5 and 5 μM respectively for 24 h (Figure 4.15E). All EBNA-2 proteins were found 
to be equally induced and expressed. 
 
 
 
 
 
Figure 4.16. Optimisation of Daudi:pHEBoMT-EBNA-2 cell lines so that type 1, type 2 and type 2 S442D 
EBNA-2 proteins are equally expressed. Daudi:pHEBoMT-EBNA-2 cell lines were treated with differing 
amounts of CdCl2 for 24 h. Cells expressing type 1 (T1) and type 2 (T2) EBNA-2 were induced with (A) 5 μM, 
(B) 1 μM and (C) 10 μM. Daudi:pHEBoMT cells expressing type 2 S442D EBNA-2 were treated with a (D) 
CdCl2 titration (3-5 μM). (E) T1, T2 and T2 S442D EBNA-2 from Daudi:pHEBoMT cell lines were induced 
with 10, 5 and 5 μM CdCl2 respectively. EBNA-2 expression was probed with the PE2 antibody. The EBNA-2 
proteins in these cell lines are of almost the same size (approximately 72 kDa) as the polyproline repeat (PPR) 
region was equalised in all EBNA-2 alleles. -actin was used as a loading control. 
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4.2.3.2 Differential regulation of LMP-1 and CXCR7 in Daudi cells expressing type 1, 
type 2 and type 2 S442D EBNA-2 
 
In previous ChIP experiments (see section 4.2.2), chromatin binding by EBNA-2 was studied 
in the context of ER-EBNA-2 proteins whose expression and immunoprecipitation differed 
greatly. A system, where equal expression of inducible wildtype type 1, type 2 and type 2 
S442D EBNA-2 proteins in Daudi cell lines, was then established (see section 4.2.3.1). 
 
Different amounts of cadmium chloride (CdCl2) were used to induce approximately equal 
expression of all EBNA-2 proteins for 24 h (Figure 4.17, upper panel). The effect of type 1, 
type 2 and type 2 S442D EBNA-2 induction on LMP-1 expression at the protein level was 
also assessed. Following 24 h CdCl2 induction and EBNA-2 expression, the endogenous 
LMP-1 gene in the Daudi EBV genome was much more strongly activated by type 1 EBNA-
2 at the protein level compared to type 2 EBNA-2 (Figure 4.17, middle panel). Type 2 S442D 
EBNA-2 was also found to induce LMP-1 protein expression as efficiently as type 1 EBNA-2 
in this Daudi cell system (Figure 4.17, middle panel), consistent with its growth-promoting 
properties in the EREB2.5 trans-complementation assay (Figures 3.14 and 3.17). 
 
 
      
 
 
Figure 4.17. Differential expression of LMP-1 protein in stable Daudi cell lines inducibly expressing equal 
amounts of wildtype type 1, type 2 or type 2 S442D EBNA-2 proteins. Type 1 (T1), type 2 (T2) and type 2 
S442D (SD) EBNA-2-expressing Daudi cells were induced (+) and uninduced (-) for 24 h with 10, 5 and 5 µM 
cadmium chloride (CdCl2) respectively. Whole cell lysates were prepared and analysed by Western blotting for 
EBNA-2 (PE2 antibody) and LMP-1 (CS 1-4 antibody) expression. -actin was used as a loading control. 
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Differential regulation of LMP-1 by type 1 and type 2 EBNA-2 in Daudi:pHEBoMT-EBNA-
2 cell lines was further supported by qRT-PCR analysis (Figure 4.18A). Cells were induced 
with CdCl2 in a time course experiment lasting up to 48 h. Upon induction, type 1 EBNA-2 
caused a markedly higher level LMP-1 mRNA expression compared to type 2 EBNA-2 
(Figure 4.18A). The type 2 S442D EBNA-2 mutant was also as effective as type 1 EBNA-2 
at inducing LMP-1 transcription (Figure 4.18A). Taken together, the results indicate that type 
1 and type 2 S442D EBNA-2 induce LMP-1 more strongly at both the protein and mRNA 
level, as previously observed in the EREB2.5 cell line (see section 3.2.8, Figure 3.17).  
qRT-PCR analysis was also performed with CXCR7 primers to detect the level of CXCR7 
mRNA in the same experiment (Figure 4.18B). CXCR7 mRNA levels were found to be much 
higher in type 1 EBNA-2 cells induced with CdCl2 (Figure 4.18B). Again, the type 2 S442D 
EBNA-2 mutant was able to induce CXCR7 mRNA expression at type 1 EBNA-2 levels, or 
even higher, compared to the weak induction by type 2 EBNA-2 in these cells (Figure 
4.18B). This observation further demonstrated the type 1-like phenotype of the type 2 S442D 
EBNA-2 mutant. 
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Figure 4.18. Differential expression of LMP-1 and CXCR7 mRNA in stable Daudi cell lines expressing 
inducible type 1, type 2 and type 2 S442D EBNA-2. Type 1 (T1), type 2 (T2) and type 2 S442D (T2 S442D) 
cell lines were treated with CdCl2 for 12, 24, 36 and 48 hours. Total cell RNA was extracted and retro-
transcribed into cDNA. qPCR analysis was performed to quantify (A) LMP-1 and (B) CXCR7 mRNA levels. 
Each data point shows the gene of interest/GAPDH mRNA ratio relative to T1 cells after 48 hours induction, for 
each transfection. A mean of qRT-PCR results from at least 3 independent experiments is shown with error bars 
to represent standard deviations. 
 
 
 
 
208 
 
4.2.3.3 Nuclear import of type 1, type 2 and type 2 S442D EBNA-2 proteins in the new 
Daudi:pHEBoMT cell lines 
 
The rate of nuclear import of wildtype type 1 and type 2 EBNA-2 as well as the type 2 
S442D mutant was then investigated. Daudi:pHEBoMT-EBNA-2 cell lines expressing type 1, 
type 2 and type 2 S442D EBNA-2 were induced and uninduced with CdCl2 over another 48 h 
time-course experiment. Cells were fractionated at each time point using the sucrose density 
gradient centrifugation method and nuclear fractions only were analysed by Western blot 
with histone H1 as a loading control (Figure 4.19). In this experiment, analysis of whole cell 
lysates (w.c.l) harvested and prepared 24 h post-induction showed that total expression of 
EBNA-2 proteins was approximately equal at this time point (Figure 4.19, left panel). EBNA-
2 proteins were induced, expressed and trafficked to the nucleus as early as 12 h post-
induction in all cell lines (Figure 4.19). Increasing amounts of EBNA-2 were transported to 
the nucleus by 24 h post-induction but the level of EBNA-2 proteins present in the nucleus 
remained approximately equal at all subsequent time points (Figure 4.19). In fact, the amount 
of all EBNA-2 proteins in nuclear fractions was found to be equal at all time points (Figure 
4.19). These results indicate that type 1, type 2 and type 2 S442D EBNA-2 have an equal rate 
of nuclear import as expected. 
 
 
         
 
 
Figure 4.19. Nuclear import of type 1, type 2 and type 2 S442D EBNA-2 occurs at a similar rate. 
Daudi:pHEBoMT-EBNA-2 type 1 (T1), type 2 (T2) and type 2 S442D (SD) cells were induced with cadmium 
chloride (CdCl2) for 12, 24, 36 and 48 hours (h) or left uninduced (0 h). Whole cell lysates were prepared at 24 h 
post-induction. Nuclear fractions were prepared at the given time points using sucrose gradient centrifugation 
and protein expression was analysed by Western blot. Amounts of EBNA-2 proteins were probed using the PE2 
antibody and immunoblotting for histone H1 acted as a loading control. 
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4.2.3.4 ChIP-sequencing (ChIP-seq) in the GM12878 LCL reveals stronger EBNA-2 
binding at a specific CXCR7 promoter element 
 
A collaborating laboratory recently used chromatin immunoprecipitation-sequencing (ChIP-
seq) to determine the EBNA-2 binding sites across the genome in the GM12878 LCL, as well 
as the previously characterised Mutu III BL cell line [369]. This revealed much stronger 
binding of type 1 EBNA-2 at a specific site of the CXCR7 locus (marked as CXCR7 position 
12 and MACS peak 16 in Figure 4.20) which was not previously investigated in the 
Daudi:ER-EBNA-2 cell lines (see section 4.2.2, Figures 4.3 and 4.9), relative to other 
CXCR7 regulatory elements (Figure 4.20). The number of sequence reads for CXCR7 
promoter elements from ChIP-seq experiments in GM12878 LCL and Mutu III BL cell lines 
may have varied but the EBNA-2 binding profile at this position was still markedly different 
between the cell types (Figure 4.20). In comparison to other sites of the CXCR7 locus in 
Mutu III cells which showed a much greater association with EBNA-2 (Figure 4.20, lower 
panel), CXCR7 position 12 did not seem an important EBNA-2 chromatin-binding site and 
was therefore not included in the original study (see section 4.2.2). However, EBNA-2 
binding was found to be greatest at this position in the GM12878 LCL (Figure 4.20, upper 
panel) and was therefore included with other regulatory elements in subsequent ChIP-qPCR 
assays (Figure 4.21). Regions defined as EBNA-2 binding peaks by the MACS algorithm are 
much sharper in GM12878 LCLs (Figure 4.20). In the GM12878 LCL ChIP-seq experiment, 
there were was a lower signal and less background, resulting in 10 MACS peaks across the 
CXCR7 locus in GM12878 LCLs, compared to 17 found in the Mutu III BL cell line (Figure 
4.20). 
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Figure 4.20. A comparison of EBNA-2 binding at the CXCR7 gene locus in GM12878 LCLs and Mutu III 
BL cells. ChIP-seq analysis of type 1 EBNA-2 binding sites at the CXCR7 gene locus in the GM12878 LCL 
and Mutu III BL cell lines. There are EBNA-2 binding sites 50 kb up- and downstream of the CXCR7 TSS. 
EBNA-2 binding is shown by green peaks and defined as such by a MACS algorithm (black boxes numbered 
from left to right with MACS peaks 13 and 16 shown). Specific regions along the CXCR7 locus are numbered 
1-12 and defined as EBNA-2-binding (black) or non-binding (red), based on ChIP-seq MACS peaks in the Mutu 
III BL cell line [369]. These regions were assayed in previous (see section 4.2.2.3) and subsequent ChIP-qPCR 
experiments. Some sites defined as MACS peaks in Mutu III BL cell line show no binding of EBNA-2 in 
GM12878 LCLs, including CXCR7 position 6. Adapted from [378]. 
 
 
4.2.3.5 Type 1, type 2 and type 2 S442D EBNA-2 bind differentially at CXCR7, LMP-1 
and CCL3 promoter elements in Daudi:pHEBoMT cell lines 
 
The ability of type 1, type 2 and type 2 S442D EBNA-2 to bind to chromatin in the new 
Daudi:pHEBoMT cell lines was investigated (Figure 4.21). All cell lines were induced or 
uninduced with CdCl2 for 24 h and four experiments were performed. Nuclear lysates were 
prepared and immunoprecipitations performed for EBNA-2 (PE2 antibody) and IgG as a 
negative control (Figure 4.21). ChIP samples were analysed with the PE2 antibody on a 
Western blot (Figure 4.21A) and EBNA-2 expression was found to be approximately equal in 
all induced cell lines (Figure 4.21A, upper panel). As expected, the IgG control antibody did 
not bind to any EBNA-2 proteins (Figure 4.21A, middle panel). Approximately equal 
amounts of type 1, type 2 and type 2 S442D EBNA-2 were immunoprecipitated with the PE2 
antibody (Figure 4.21A, lower panel), unlike the type 1 and type 2 ER-EBNA-2 proteins (see 
section 4.2.2.2, Figure 4.4B) in the cell lines used previously. 
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ChIP DNA samples were purified following immunocomplex washing and treatment with 
proteinase K to remove all proteins. qPCR experiments were subsequently carried out to 
determine the amount of specific regions of the cellular genes CXCR7, ADAMDEC1 and 
CCL3 bound to by EBNA-2 (Figure 4.21B). Primers specific to regions of LMP-1 known to 
be bound and not bound by EBNA-2 [240, 241, 244, 254, 394] were also used and thus LMP-
1 was assayed in this investigation (Figure 4.21B). PPIA was again used as negative control 
as EBNA-2 does not bind to any of its regulatory elements [369]. ChIP-qPCR results were 
compared for immunoprecipitations with PE2 and IgG antibodies and in cells that were 
induced and uninduced for EBNA-2 expression. EBNA-2-binding was defined as an increase 
in qPCR value, relative to ChIP input, at any given promoter element in cells induced with 
CdCl2 and immunoprecipitated with PE2 antibody, compared to all other treatments. 
 
Type 1 EBNA-2 was found to be significantly enhanced at specific sites along the CXCR7 
locus, at positions 1, 3, 5, 8, 10 and 12 (Figure 4.21B). This was expected as each of these 
regions gave significant EBNA-2-binding MACS peaks in ChIP-seq experiments with both 
the Mutu III and GM12878 cell lines (Figure 4.20). Of particular significance was CXCR7 
position 8 (which gave an EBNA-2 MACS peak of 13 and 7 in Mutu III and GM12878 cell 
lines respectively) as this was found to be the EBNA-2-regulated CXCR7 TSS (Figure 4.2). 
ChIP-qPCR values for CXCR7 positions 1 and 12 were demonstrated to be the highest, 
relative to ChIP input (approximately 0.2%) (Figure 4.21B) for type 1 EBNA-2, consistent 
with strong EBNA-2 binding observed in ChIP-seq experiments (Figure 4.20). Conversely, 
there was no type 1 EBNA-2 binding at CXCR7 positions 2, 4, 7, 9 and 11 (Figure 4.21B), as 
was also demonstrated in Mutu III and GM12878 cell lines by ChIP-seq which showed no 
EBNA-2 binding at these regions (Figure 4.20). In this investigation, there was also no 
significant binding of type 1 EBNA-2 at CXCR7 position 6 (Figure 4.21B) in contrast to the 
Daudi:ER-EBNA-2 cell line (Figure 4.8). This region of the CXCR7 locus had given an 
EBNA-2 binding peak in the Mutu III BL cell line (MACS peak 12) but not in the GM12878 
LCL (Figure 4.20) by ChIP-seq. Consistent with results from Daudi:ER-EBNA-2 cell lines, 
type 2 EBNA-2 was found to bind at CXCR7 position 3 (Figure 4.21B). Type 2 EBNA-2 was 
also shown to be enhanced at position 12 in the Daudi:pHEBoMT cell line (Figure 4.21B). At 
both these regions of CXCR7, type 2 EBNA-2-enrichment was found to be significantly 
lower compared to the type 1 EBNA-2 protein (Figure 4.21B). Type 2 EBNA-2 was not 
shown to bind to any other region of the CXCR7 locus (Figure 4.21B). Similar to type 2 
EBNA-2, the type 2 S442D mutant was also revealed to bind CXCR7 positions 3 and 12 only 
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(Figure 4.21B). Binding at CXCR7 position 3 was found to be lower than type 2 EBNA-2 but 
this was not significant (Figure 4.21B). In contrast, type 2 S442D EBNA-2 was significantly 
enhanced at CXCR7 position 12 compared to type 2 EBNA-2, but was still lower than the 
type 1 protein (Figure 4.21B). Interestingly, there was no type 2 S442D EBNA-2 association 
at CXCR7 position 8 which lies in the CXCR7 TSS regulated by EBNA-2 (Figure 4.21B). 
Since type 1 and type 2 S442D EBNA-2 show comparable levels of CXCR7 transcription, 
perhaps the contribution of EBNA-2-binding at CXCR7 position 12 is the most important for 
differential gene expression by EBNA-2. This will be discussed further in section 4.3. 
 
Chromatin-binding of EBNA-2 at the LMP-1 gene was also investigated (Figure 4.21B). This 
analysis was made easier as the sequence required for EBNA-2 activation of the LMP-1 
promoter had been extensively mapped previously and consisted of a single EBNA-2 binding 
site [240, 241, 244, 254, 394]. EBNA-2-binding and non-binding regions of LMP-1 
(respectively marked as LMP-1 (1) and LMP-1 (2) in Figure 4.21B) were analysed. A higher 
ChIP-qPCR value was observed in all samples immunoprecipitated with the PE2 antibody 
and treated with CdCl2, in comparison to cells treated similarly and lysates 
immunoprecipitated with the IgG control antibody (Figure 4.21B). Therefore, all EBNA-2 
proteins were found to significantly bind at LMP-1 position 1 (Figure 4.21B). There was no 
binding observed for any EBNA-2 protein at LMP-1 position 2 (Figure 4.21B), further 
indicating the specificity of EBNA-2-binding within the LMP-1 gene promoter. In this assay, 
type 2 S442D EBNA-2-binding at the LMP-1 promoter was significantly stronger than type 2 
EBNA-2 but also significantly lower than that of type 1 EBNA-2 (Figure 4.21B). A similar 
EBNA-2 binding profile was observed at CXCR7 position 12. Interestingly, type 1 and type 2 
S442D EBNA-2 both induce approximately equal levels of LMP-1 and CXCR7 expression. 
These data suggest that the promoters of the viral LMP-1 and cellular CXCR7 genes are 
similar and allow for differential regulation by EBNA-2 proteins. This will be discussed 
further in section 4.3. 
 
EBNA-2-binding at ADAMDEC1, another cell gene differentially regulated by EBNA-2 
types [210], was also analysed. ChIP-seq revealed regions of ADAMDEC1 that were bound 
and not bound by EBNA-2 [369] (marked as ADAMDEC1 (2) and ADAMDEC1 (1) 
respectively in Figure 4.21B). No EBNA-2-binding was observed at ADAMDEC1 position 1 
(Figure 4.21B). A moderate increase in type 1 EBNA-2 binding occurred at ADAMDEC1 
position 2, but this was not true for the type 2 or type 2 S442D proteins. A similar profile of 
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EBNA-2 binding was found at CXCR7 position 8. Only one EBNA-2 MACS peak was 
reported for the ADAMDEC1 gene in Mutu III BL cells [369]. However, since the ability of 
type 2 S442D EBNA-2 to induce ADAMDEC1 has not been tested in this study, it is difficult 
to speculate on the contribution of differential EBNA-2 promoter-binding to gene expression. 
 
The levels of the equally regulated CCL3 and negative control PPIA genes were also assayed 
in ChIP-DNA samples taken from the same experiment (Figure 4.21B). EBNA-2-binding and 
non-binding regions of CCL3 revealed by ChIP-seq [369] (respectively marked as CCL3 (2) 
and CCL3 (1) in Figure 4.21B) were analysed. There were no significant differences in qPCR 
values at CCL3 position 1 between immunoprecipitations with PE2 and α-IgG for cells 
treated in the same way, indicating no EBNA-2 binding as expected (Figure 4.21B). 
However, when cells were treated with CdCl2, type 1, type 2 and type 2 S442D EBNA-2 
proteins were found to bind to CCL3 position 2 at approximately equal levels (Figure 4.21B). 
This indicated that the differential chromatin and promoter-binding of EBNA-2 types 
previously reported was indeed gene and promoter element-specific. Additionally, there was 
no EBNA-2 binding at the PPIA gene promoter (Figure 4.21B), further indicating the 
specificity of the assay. 
 
The data therefore suggest that type 1 EBNA-2 binds to promoter elements of differentially 
regulated genes more efficiently than type 2 EBNA-2. It is possible that this reduced gene-
specific binding of type 2 EBNA-2 contributes to the impaired activation of viral LMP-1 and 
cellular CXCR7 genes by type 2 EBNA-2. This effect, in combination with the lower 
transactivation ability [378] discussed in section 3.3, could result in the impaired growth 
transforming function of type 2 EBNA-2. Further evidence for this is provided by the S442D 
mutation in type 2 EBNA-2 which restores transactivation function and partially rescues the 
reduced promoter-specific binding of differentially regulated genes observed for type 2 
EBNA-2 [378]. 
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Figure 4.21. Type 1, type 2 and type 2 S442D EBNA-2 binding at CXCR7, LMP-1, ADAMDEC1 and 
CCL3 promoter elements in Daudi:pHEBoMT cell lines. Cells expressing type 1 (T1), type 2 (T2) and type 2 
S442D (SD) EBNA-2 were induced (+) and uninduced (-) with cadmium chloride (CdCl2) for 24 hours. 
Immunoprecipitations were performed with the EBNA-2 PE2 antibody and a mouse monoclonal 
immunoglobulin (IgG) antibody as a negative control. ChIP samples were analysed by (A) Western blot and (B) 
qPCR. (A) Nuclear lysates and immunoprecipitated samples were immunoblotted for EBNA-2 with the PE2 
antibody. One representative immunoblot from at least 3 experiments shown. (B) qPCR using primers specific 
to regions of CXCR7 (positions 1-12), LMP-1 (regions 1 and 2), ADAMDEC1 (regions 1 and 2) and CCL3 
(regions 1 and 2) known to be bound and not bound by type 1 EBNA-2 in ChIP-seq [369] was performed in 
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triplicate on DNA samples purified from the immunocomplex of ChIP experiments. Input samples were taken to 
quantify qPCR values by the standard curve method and are given relative to ChIP input (%). qPCR values for 
EBNA-2 PE2 ChIP (black) and IgG control ChIP (white) are shown. Results are presented as histograms 
depicting the mean of ChIP-qPCR data  standard deviations from at least 3 independent ChIP experiments. p-
values: ns=not significant, *<0.05, **<0.01, ***<0.005. 
 
 
4.2.3.6 p300 ChIP revealed no difference in p300 association at EBNA-2 binding sites of 
gene-specific promoter elements in Daudi:pHEBoMT cell lines induced for EBNA-2 
expression 
 
In previous assays, it was seen that type 1 EBNA-2 binds more efficiently than type 2 EBNA-
2 at specific promoter elements of genes that it activates more strongly than the type 2 
protein. The type 2 S442D EBNA-2 mutant was also found to bind to some of these 
regulatory sites although to a lesser extent than type 1 EBNA-2. However, it is unclear how a 
mutation in the amino acid sequence of the transactivation domain can have an effect on 
specific promoter-binding. A possible hypothesis for the differential effect observed at 
specific promoters is that type 1, type 2 and type 2 S442D EBNA-2 proteins interact 
differently with certain co-activators and cofactors. Here, the interaction of EBNA-2 proteins 
with the coactivator E1A binding protein p300 (p300) at sites relevant to EBNA-2 binding 
was investigated. The contribution of histone H3 acetylation to EBNA-2 promoter-specific 
binding was also explored in section 4.2.3.7. 
 
p300 is encoded by the EP300 gene in humans [395]. It belongs to the p300-CBP family of 
coactivator proteins that are also histone acetyltransferases (HATs) and interact with 
numerous transcription factors to increase the expression of their target genes [396, 397]. The 
HAT activity of p300 has been shown to be important for its coactivating effects [398-400]. 
Moreover, p300 has been reported to specifically interact with the acidic transactivation 
domain (TAD) of EBNA-2, and that this interaction is important for activation of the LMP-1 
promoter [255]. The ability of p300 to bind to EBNA-2 types in the context of EBNA-2 
target gene expression was investigated (Figure 4.22). 
 
As an initial experiment, the ability of p300 to bind at the specific promoter elements 
differentially bound by type 1, type 2 and type 2 S442D EBNA-2 in cells induced for EBNA-
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2 expression was tested (Figure 4.22). Chromatin from a previous experiment was used. p300 
expression was assayed and found to be at comparable levels in all cell lines and CdCl2 
treatments (Figure 4.22A). qPCR experiments were then performed to determine the amount 
of specific regions of CXCR7, LMP-1, ADAMDEC1 and CCL3 bound to by p300 (Figure 
4.22B). CXCR7 positions 4-7 were not assayed in this experiment as there was not enough 
DNA purified from the ChIP samples and they either showed no or minimal binding by 
EBNA-2 in ChIP-seq and previous ChIP-qPCR experiments (Figures 4.8, 4.9 and 4.21).  
 
There was no real difference in p300-binding at any CXCR7 promoter element when cells 
were induced or induced for expression of each EBNA-2 type (Figure 4.22B). A small 
decrease in p300 binding occurred when cells expressing type 2 EBNA-2 were induced 
(Figure 4.22B), indicating no role in type 2 EBNA-2 induction of CXCR7. A small increase 
in p300-binding was found at CXCR7 positions 3 and 10 for cells induced for type 1 EBNA-
2 expression, but this did not occur in type 2 or type 2 S442D cells (Figure 4.22B). Moreover, 
at both sites, the level of p300 was lower in the type 1 EBNA-2 induced cells than in the type 
2 EBNA-2 cells (Figure 4.22B). At CXCR7 position 12, which was previously found to be 
differentially bound by EBNA-2 types, there was no change in p300 association in any of the 
cell types (Figure 4.22B). 
 
p300 association at the EBNA-2 binding regions of the differentially regulated genes LMP-1 
and ADAMDEC1 was also assayed. There was no difference in p300 binding at the EBNA-
2-binding site of LMP-1 (marked as LMP-1 (1) in Figure 4.22B) apart from a small decrease 
in CdCl2-treated type 2 S442D EBNA-2 cells (Figure 4.12B). A small reduction of p300 was 
also recorded at LMP-1 (2) for type 2 S442D EBNA-2 cells (Figure 4.22B), but this was not 
deemed significant as this is a region not bound by EBNA-2. No change in p300-binding was 
observed at the ADAMDEC1 locus, apart from a small increase in type 1 and type 2 S442D 
EBNA-2-induced cells, relative to non-induced cells at ADAMDEC1 position 1 (Figure 
4.22B). However, this was at a sequence not bound by EBNA-2 and type 2 EBNA-2 cells 
still showed greater p300 binding, irrespective of EBNA-2 induction (Figure 4.22B). 
 
The binding of p300 at the genes previously used as controls, CCL3 and PPIA, was then 
investigated. Very small, if any, changes in p300 association between cell lines were 
observed along the CCL3 locus (Figure 4.22B). A very moderate increase in p300 binding 
occurred at CCL3 position 2 when each cell line was induced for EBNA-2 expression (Figure 
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4.22B). Interestingly, this was the EBNA-2 binding site for CCL3 where type 1, type 2 and 
type 2 S442D EBNA-2 were demonstrated to bind equally (Figure 4.21B). No differences in 
p300-binding were found when cells were induced, or not, for EBNA-2 expression (Figure 
4.22B). 
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Figure 4.22. p300 binding at EBNA-2 binding sites of CXCR7, LMP-1, ADAMDEC1 and CCL3 gene 
promoters. Cells were induced (+) and uninduced (-) with cadmium chloride (CdCl2) for 24 hours to express 
type 1 (T1), type 2 (T2) and type 2 S442D (SD) EBNA-2. (A) Whole cell lysates were prepared and samples 
analysed by Western blot for p300 expression with the C-20 antibody (Santa Cruz) and -actin as a loading 
control. (B) Nuclear lysates were prepared and immunoprecipitations performed with the p300 C-20 antibody. 
ChIP samples were analysed in triplicate by qPCR. Primers specific to CXCR7 (region 1-3 and 8-12), LMP-1 
(regions 1 and 2), ADAMDEC1 (regions 1 and 2), CCL3 (regions 1 and 2) and PPIA were used in ChIP-qPCR 
assays. Input samples were taken before immunoprecipitation to quantify qPCR values by the standard curve 
method. qPCR values for uninduced (white) and induced (black) cells from one experiment are shown. 
 
 
Overall, the results indicate that p300-binding was not significantly different between cell 
lines and CdCl2 induction of EBNA-2 expression. This suggests that CdCl2 treatment and 
type of EBNA-2 protein induced did not have a significant effect on p300 binding at 
promoter elements which displayed differential EBNA-2-binding. The comparative ability of 
type 1, type 2 and type 2 S442D EBNA-2 to bind p300 in vitro was therefore not 
investigated. It cannot be excluded that the p300 antibody did not work in this assay in this 
cell background since a positive control for p300-binding was not performed. However, the 
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p300 antibody has previously been used successfully in ChIP assays performed in B cells 
[401]. Taken together, the results suggest that there is no increase in p300 coactivation of 
EBNA-2 at promoter elements that were previously found to be differentially bound by type 
1, type 2 and type 2 S442D EBNA-2. 
 
 
4.2.3.7 Histone H3 acetylation (H3ac) at EBNA-2-regulated genes is not altered by 
CdCl2 treatment and expression of EBNA-2 types in Daudi:pHEBoMT cell lines 
 
It was previously found that there were no differences in p300 association at EBNA-2 
binding sites of EBNA-2 differentially regulated genes in Daudi:pHEBoMT cell lines. p300 
however is only one of many coactivators which displays histone acetyltransferase (HAT) 
activity. For example, CBP and PCAF HATs have also been shown to interact with EBNA-2 
and potentiate upregulation of LMP-1 expression [255]. Hence, the contribution of histone 
H3 acetylation at EBNA-2 promoter-specific binding sites was investigated. 
 
Histone acetylation causes changes in gene expression such that acetylation at lysine residues 
of histone molecules is associated with transcriptional activation [402]. The regulatory 
mechanism thought to be involved is two-fold – lysine residues lose their positive charge 
when acetylated thus weakening the DNA-histone interaction and providing a more open 
chromatin state which can subsequently be accessed by transcriptional machinery [402]. In 
addition, this posttranslational modification provides a recognition site for transcription 
factors that activate gene expression by interacting with acetylated histone tails through their 
bromodomains [403, 404]. Since EBNA-2 interacts with HATs [255] and histone H3 
acetylation has been demonstrated at specific sites in EBV-positive Mutu III BL cells [369] 
(Figure 4.3), it is clear how this histone modification may have a role in EBNA-2 target gene 
regulation. Histone H3 acetylation may affect the expression of EBNA-2 target genes but also 
the binding of EBNA-2 and other coactivators and cofactors at specific promoter elements. 
Therefore, the histone H3 acetylation state at promoter elements differentially bound by 
EBNA-2 was investigated (Figure 4.23). 
 
Chromatin from a previous experiment in which Daudi:pHEBoMT cell lines were treated for 
24 h with CdCl2 to induce EBNA-2 expression, or left untreated, was used. 
Immunoprecipitations were performed using a histone H3 acetylation antibody. Any DNA 
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fragments that were bound by acetylated histone H3 proteins were purified and assayed by 
qPCR. The amount of bound specific regions of CXCR7, LMP-1, ADAMDEC1 and CCL3 
was compared in cells treated for type 1, type 2 and type 2 S442D EBNA-2 expression 
(Figure 4.23). 
 
There were no significant differences in histone H3 acetylation across the CXCR7 locus 
when cells were induced or uninduced for EBNA-2 expression (Figure 4.23). Small 
differences were observed between cell lines, but these were not relevant as they either 
occurred at gene regions not bound by EBNA-2 or the level of histone H3 acetylation was 
found to be similar in cells that were not induced for EBNA-2 expression (Figure 4.23). 
CXCR7 position 12, although previously shown to be bound differentially by EBNA-2 types, 
maintained a similar level of histone H3 acetylation in the different cell lines, irrespective of 
EBNA-2 expression (Figure 4.23). 
 
Acetylated histone H3 association was also monitored at EBNA-2 binding and non-binding 
sites of the LMP-1, ADAMDEC1, CCL3 and PPIA genes (Figure 4.23). Acetylated histone 
H3 association across gene loci and between EBNA-2 cell lines and EBNA-2 expression was 
found to be comparable (Figure 4.23). A reduced amount of CCL3 position 1, LMP-1 
position 2 and PPIA was immunoprecipitated (Figure 4.23), but these were all regions not 
bound to by EBNA-2. 
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Figure 4.23. Acetylated histone H3 binding at EBNA-2 binding sites of CXCR7, LMP-1, ADAMDEC1 
and CCL3 gene promoters. Daudi:pHEBoMT cell lines were induced (+) and uninduced (-) to express type 1 
(T1), type 2 (T2) and type 2 S442D (SD) EBNA-2 with cadmium chloride (CdCl2) for 24 hours. Nuclear lysates 
were prepared from one experiment and immunoprecipitations performed with the H3ac antibody. CXCR7 
(regions 1-3 and 8-12), LMP-1 (regions 1 and 2), ADAMDEC1 (regions 1 and 2) and CCL3 (regions 1 and 2) 
were analysed in triplicate in ChIP-qPCR assays. qPCR values for uninduced (white) and induced (black) 
samples were quantified by the standard curve method using input samples taken before immunoprecipitation. 
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The results indicate that histone H3 acetylation is not affected by CdCl2 treatment of cells and 
EBNA-2 expression. Irrespective of EBNA-2 type and expression, the level of acetylated 
histone H3 remained similar. For example, there were no CXCR7 promoter elements which 
showed a significantly greater association for acetylated histone H3 in cells induced for 
EBNA-2 expression than without (Figure 4.23). This is unsurprising at the CXC7 locus, 
given that Daudi cells express a low endogenous level of CXCR7 mRNA prior to EBNA-2 
induction [211, 293, 299] and the chromatin is therefore likely to already be in an open, 
transcriptionally active state. Subsequently, induction of type 1, type 2 or type 2 S442D 
EBNA-2 proteins seems to play no role in acetylated histone H3 association at EBNA-2-
regulated promoter elements. Similarly to the p300 ChIP assay (Figure 4.22), a positive 
control for the acetylated histone H3 antibody was not performed and so an inability to bind 
in this assay cannot be excluded. However, this antibody has also previously been used 
successfully in a ChIP assay in a Burkitt’s lymphoma cell line [405]. 
 
Overall, the results demonstrate that histone H3 acetylation is unlikely to play a role in 
differential EBNA-2 binding at gene promoter elements. However, it is possible that other 
coactivators and cofactors may bind differentially to EBNA-2 types to mediate the 
differential effects of EBNA-2 on its target genes. Indeed, ChIP-seq and ENCODE data has 
revealed the increasing complexity of transcriptional regulation. 
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4.3 Discussion 
 
The experiments and results presented in this chapter aimed to determine whether differences 
in the binding of type 1 and type 2 EBNA-2 to gene regulatory elements at the chromatin 
level influenced the increased activation of CXCR7 and LMP-1 by type 1 EBNA-2. ChIP-
qPCR analysis was performed with ER-EBNA-2 proteins initially (see section 4.2.2) and then 
with newly generated Daudi cell lines stably transfected with plasmids that inducibly 
expressed wildtype type 1, type 2 or type 2 S442D EBNA-2 (see section 4.2.3.5). This 
inducible expression was mediated by a cadmium-responsive metallothionein (MT) promoter 
and, in these constructs, the EBNA-2 polyproline repeat (PPR) length was equalised in all 
EBNA-2 alleles in order to generate EBNA-2 proteins of almost identical size. In the new 
Daudi cell lines, the superior activation of the endogenous LMP-1 gene in the Daudi EBV 
genome in addition to the induction of CXCR7 mRNA was demonstrated (Figure 4.18). 
Consistent with its growth-promoting properties in the EREB2.5 LCL assay, type 2 S442D 
EBNA-2 induced LMP-1 and CXCR7 as effectively as the type 1 protein (Figures 4.17 and 
4.18). In this chapter, Daudi cell lines expressing wildtype or ER-fused EBNA-2 proteins 
were tested in ChIP assays to identify and compare EBNA-2-binding at promoter elements of 
genes known to be important for B cell proliferation (see sections 4.2.2 and 4.2.3). ChIP-
qPCR analysis detected significantly increased binding of type 1 EBNA-2 compared to type 2 
EBNA-2 at positions 1, 3, 5, 6 (ER-EBNA-2 only), 8, 10 and 12 (Figures 4.8 and 4.21). 
There was also an increased amount of type 1 EBNA-2, compared to the type 2 protein, at 
position 1 of the LMP-1 promoter (Figure 4.21). In contrast, there was equal binding of both 
type 1 and type 2 EBNA-2 to a site at the equally regulated CCL3 gene (Figures 4.7 and 
4.21), and no binding at the non-regulated PPIA gene (Figures 4.6 and 4.21), indicating that 
EBNA-2 binding is gene-specific. When the binding of type 2 S442D EBNA-2 was assayed, 
it was found to bind to the LMP-1 promoter EBNA-2 binding site and at position 12 of the 
CXCR7 locus (Figure 4.21). At these sites, type 2 S442D EBNA-2 binding was stronger than 
type 2 EBNA-2 but lower than that of type 1 EBNA-2 (Figure 4.21). 
 
The experiments performed in this chapter have identified the specific CXCR7 transcript that 
is expressed in response to EBNA-2 activity. This laboratory had previously used RT-PCR to 
confirm the induction of CXCR7 when both AK31:EBNA-1/ER-EBNA-2 and EREB2.5 cells 
were activated with oestrogen [210]. Two known splice variants involving CXCR7 leading 
228 
 
exons were observed and a novel splice variant was also identified [210]. These RT-PCR 
assays however were performed with total RNA isolated following oestrogen-activation of 
these cell lines. Here, 5 RACE was successfully used to identify the true EBNA-2-regulated 
TSS of CXCR7 (Figure 4.2). When the ChIP-qPCR assay was performed for this position of 
CXCR7, only type 1 EBNA-2 binding was detected in contrast to type 2 and type 2 S442D 
EBNA-2 (Figures 4.8, 4.9 and 4.21). 
 
Nuclear import of EBNA-2 proteins was also investigated to ensure this did not play a role in 
differential promoter element-binding by EBNA-2 proteins. In both Daudi cell lines which 
expressed ER-fused or inducible wildtype EBNA-2 proteins including the type 2 S442D point 
mutant, the rate of EBNA-2 nuclear import was found to be equal (Figures 4.11 and 4.19). 
This is unsurprising as type 1 and type 2 EBNA-2 proteins share a very conserved C-terminus 
including the nuclear localisation signal (NLS) (see section 1.3.2, Figure 1.4). An NLS 
typically consists of one or more short sequences of positively charged lysine or arginine 
residues exposed on the protein surface. In fact, the proposed consensus sequence K-K/R-X-
K/R for monopartite NLSs [406] is present as an identical KRPR sequence in both type 1 and 
type 2 EBNA-2 (see section 1.3.2, Figure 1.4). Therefore, differences identified in promoter 
element binding were due to EBNA-2 protein-specific effects, rather than their rate of nuclear 
import. 
 
ChIP analysis was initially performed with Daudi cell lines that expressed type 1 or type 2 
ER-EBNA-2 proteins (see section 4.2.2). Significantly more type 1 EBNA-2 was found at 
CXCR7 positions 1, 3, 5, 6, 8 and 10 (Figure 4.8) but equal binding was reported at the 
equally regulated CCL3 gene (Figures 4.7) and no binding at the non-regulated PPIA gene 
(Figures 4.6). These results indicated that EBNA-2 binding was gene-specific and the assay 
could be used to confidently compare type 1 and type 2 EBNA-2 binding. However, these 
Daudi cell lines expressed the EBNA-2 proteins as fusions with the ER. These ER-EBNA-2 
proteins were also expressed (Figure 4.4) and immunoprecipitated (Figure 4.5) at 
significantly different levels. Therefore, in order to compare ChIP-qPCR results from type 1 
and type 2 ER-EBNA-2 cell lines, the amount of protein precipitated in all experiments was 
first quantified by LI-COR and applied to qPCR raw data for normalisation.  
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A system where Daudi cells were inducible for equal expression of wildtype type 1 and type 
2 EBNA-2 proteins was then established. This enabled a more direct comparison of the 
ability of wildtype EBNA-2 proteins to bind and interact with specific promoter elements at 
the chromatin level. This analysis also included a Daudi cell line expressing type 2 S442D 
EBNA-2 as the EBNA-2 mutation study had been completed at this time. When ChIP 
analysis was performed with these cell lines, an increase in type 1 EBNA-2 binding, 
compared to the type 2 protein, was detected at CXCR7 positions 1, 3, 5, 8, 10 and 12 (Figure 
4.21) and at position 1 of the LMP-1 promoter (Figure 4.21). Type 2 EBNA-2 was only able 
to bind to CXCR7 positions 3 and 12 and LMP-1 position 1 in this assay and at a 
significantly lower level than type 1 EBNA-2 (Figure 4.21). Type 2 S442D EBNA-2 showed 
stronger binding at these sites compared to type 2 EBNA-2 but still lower than that of the 
type 1 protein (Figure 4.21). Again, the regulatory element at the equally regulated CCL3 
gene demonstrated equal binding by all EBNA-2 types and no EBNA-2 protein was found to 
bind to PPIA (Figure 4.21). 
 
In the ChIP experiments performed in this chapter with the Daudi:pHEBoMT-EBNA-2 cell 
lines, EBNA-2 proteins were induced with CdCl2 for 24 hours. This length of EBNA-2 
induction was chosen as the time-course induction experiment (Figure 4.18) revealed that this 
was the optimum time to observe differential binding of type 1, type 2 and type 2 EBNA-2. 
At this specific time point, LMP-1 and CXCR7 were both induced at a low level by type 1 
and type 2 S442D EBNA-2, but not by the type 2 protein suggesting that type 2 EBNA-2, 
unlike the type 1 and type 2 S442D proteins, had not interacted with promoter elements of 
target genes at this time point. This may also be reflective of what occurs during EBV 
infection of primary B cells in vitro. A previous study by this laboratory revealed that 
uninfected primary B cells already contain CXCR7 mRNA [211], an observation consistent 
with other reports [293, 299]. A more detailed investigation then showed that, upon EBV 
infection, there is an initial rapid drop of CXCR7 mRNA levels followed by re-induction of 
CXCR7 [378] (Figure 4.24). This re-induction is thought to be EBNA-2-mediated since 
EBNA-2 protein expression is first detected between 12 and 16 h after infection [50]. 
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Figure 4.24. CXCR7 mRNA is rapidly degraded upon EBV infection and is then re-induced by EBNA-2.  
(A) Primary B cells were infected with type 1 B95-8 EBV or with UV-inactivated B95-8 EBV (UV B95-8), 
exposed to supernatant remaining after pelleting the EBV virus by ultracentrifugation (SUP) or treated with 
TPA (TPA). RNA was extracted after 1 or 3 days, cDNA prepared and qPCR performed for CXCR7. CXCR7 
mRNA level was normalised to GAPDH and is shown relative to the mock infection day 0 value. Error bars 
represent standard deviations from at least 3 independent experiments. (B) Primary B cells were infected with 
B95-8 EBV or treated with TPA as in part A but analysed for CXCR7 mRNA after 4 or 8 hours. (C) Primary B 
cells were infected as in part A and protein extracts 1, 2 and 3 days post-infection were tested for EBNA-2 
expression by Western blot. β-actin was used as a loading control. Adapted from [378]. 
 
 
CXCR7 mRNA level was reduced at 1 day post-infection with type 1 B95-8 EBV but, by 3 
days post-infection, the level increased to exceed that of non-infected cells (Figure 4.24A). 
The initial degradation of CXCR7 mRNA appears to result from signal transduction upon 
viral infection because UV-inactivated EBV caused a similar reduction at day 1 to untreated 
EBV but was unable to re-induce CXCR7 to the level of non-infected cells at day 3 (Figure 
4.24A). Furthermore, the supernatant left after pelleting the EBV from the virus preparation 
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by ultracentrifugation did not reduce CXCR7 levels. Therefore, it appears to be the virus 
infection that caused CXCR7 mRNA degradation. The initial reduction in CXCR7 mRNA 
levels following EBV infection was even more pronounced at 4 and 8 hours post-infection 
(Figure 4.24B). This suggests that the CXCR7 mRNA level 1 day post-infection is already 
increasing again, consistent with the expression of EBNA-2 at this time (Figure 4.24C). 
Further evidence for regulation by signal transduction came from a rapid and dramatic 
reduction in CXCR7 mRNA levels when B cells were treated with TPA but without EBV 
(Figure 4.24A and B). Previous analysis performed in this laboratory using B95-8 EBV from 
a BAC, rather than the EBV induced from B95-8 cells used in this experiment, showed a 
slightly more rapid re-induction of CXCR7 [211] but this most likely reflects the different 
amounts of infectious virus used in the experiments. Importantly, however, the CXCR7 
mRNA level was consistently lower in type 2 infections compared to that of type 1 virus-
infected cells [211]. Hence, the difference in CXCR7 regulation by type 1 and type 2 EBV 
upon infection of primary B cells seems to lie in a delayed and weaker re-induction of 
CXCR7 after infection by type 2 EBV. The ChIP assay established in this study therefore 
reflects the initial effects and EBNA-2 binding events when it is first expressed after EBV 
infection. 
 
Interestingly, in ChIP experiments performed with Daudi:pHEBoMT-EBNA-2 cell lines, 
type 2 and type 2 S442D EBNA-2 were unable to bind to CXCR7 position 8 (defined as 
MACS peak 13 on Figure 4.20) which was revealed to be the CXCR7 transcription start site 
(TSS) that is regulated by EBNA-2. Since type 2 EBNA-2 can induce CXCR7 expression 
albeit at a slower rate than the type 1 protein (Figure 4.18), it is clear that EBNA-2-binding at 
this site is not critical to CXCR7 expression. Further highlighting this is the type 2 S442D 
EBNA-2 protein that, despite not binding to the CXCR7 TSS, induces CXCR7 mRNA to a 
similar level as type 1 EBNA-2 (Figure 4.18). Therefore, EBNA-2 binding to the TSS is not 
critical for type-specific effects of EBNA-2 on CXCR7. This is unsurprising given that recent 
ChIP-sequencing analyses of EBNA-2 binding sites in the Mutu III BL cell line and in LCLs 
(IB4 and GM12878) have shown that most EBNA-2 binding sites in the human genome are 
located at distances up to 100 kb up- or downstream from the TSSs of genes [368, 369, 378]. 
Indeed, CXCR7 position 12 (marked as MACS peak 16 in Figure 4.10) is approximately 
40 kb downstream of the CXCR7 TSS. This CXCR7 EBNA-2 binding site is likely to be 
involved in EBNA-2 regulation of CXCR7, since, unlike position 8 and the TSS, all EBNA-2 
proteins tested bind to this element albeit at different levels (Figure 4.21).  
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The sequences required for EBNA-2 activation of the LMP-1 promoter are much closer to the 
transcription start site and have been mapped in detail in previous studies [240, 241, 244, 
254, 394]. The EBNA-2 binding site in the LMP-1 promoter was included in this analysis and 
was found to be bound much more strongly by type 1 compared to type 2 EBNA-2 as 
expected (LMP-1 position 1 in Figure 4.21B). The association of type 2 S442D EBNA-2 to 
the regulatory element in the LMP-1 promoter was stronger than that of type 2 EBNA-2 but 
weaker than that of type 1 EBNA-2 (Figure 4.21). The amount of EBNA-2 association was 
reflective of the ability of the EBNA-2 protein to induce LMP-1 expression (Figure 4.18) and 
was dependent on aspartate-442 in the TAD. 
 
Since both LMP-1 and CXCR7 are differentially regulated by EBNA-2 types and these 
specific promoter elements (position 1 of LMP-1 and position 12 (MACS peak 16) of 
CXCR7) are bound to in the same way, this must occur via a similar mechanism. ChIP signal 
however is not solely dependent on the binding of EBNA-2 proteins to promoter elements. 
This signal can also be affected by the stability of the EBNA-2-chromatin interaction and 
other cofactors and coactivators that might be involved in a transcriptional protein complex. 
Indeed, ChIP is limited in its ability to detect transient DNA-protein interactions and type 2 
EBNA-2-binding cannot be completely excluded. In addition, the comparative ability of the 
PE2 antibody to immunoprecipitate type 1 and type 2 EBNA-2 is unknown although they are 
equally recognised in Western blot [210]. The coactivator p300 may also play a role as it had 
previously been shown to interact with EBNA-2 in the activation of the LMP-1 promoter 
[255]. The ability of p300 to differentially bind at EBNA-2 binding sites in Daudi cells 
induced to express type 1, type 2 or type 2 S442D EBNA-2 was tested (Figure 4.22). 
However, no significant differences in p300-binding were detected across the CXCR7 or 
LMP-1 promoters (Figure 4.22). This indicates that the mechanism of differential regulation 
of EBNA-2 target genes does not involve preferential association of p300 with type 1 EBNA-
2. Since p300 is one of many coactivators which displays HAT activity and others such as 
CBP and PCAF HATs have also been shown to interact with EBNA-2 and activate LMP-1 
expression [255], the contribution of histone H3 acetylation at EBNA-2 promoter-specific 
binding sites was also investigated. Again, there were no significant differences in histone H3 
acetylation across the CXCR7 and LMP-1 loci when cells were induced or uninduced for 
EBNA-2 expression (Figure 4.23). 
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To further investigate the differential binding of EBNA-2 types at specific promoter elements 
of differentially regulated genes, EBNA-2 binding sites were characterised in greater detail. It 
is known that EBNA-2 does not bind directly to DNA in a sequence-specific manner rather it 
accesses DNA binding sites by associating with a cellular partner protein. Although RBP-Jκ 
is the best characterised of these cofactors, EBNA-2 has also been shown to interact with 
PU.1 in vitro and pull down the protein from extracts [240]. In fact, in addition to an RBP-Jκ 
site, binding sites for PU.1 and EBF1 in the LMP-1 promoter (Figure 1.6) are also required 
for efficient EBNA-2-mediated activation of LMP-1 expression [240, 241, 368]. Therefore, 
to identify sequences that might characterise the EBNA-2 response elements (E2REs) of 
genes that are more strongly induced by type 1 EBNA-2 compared to type 2 EBNA-2, 
colleagues at the University of Sussex used MEME-ChIP to perform unbiased motif 
searching on EBNA-2 binding peaks identified from ChIP-seq experiments carried out in 
Mutu III BL cells [369, 378] (Table 4.1). 
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Table 4.1. 31 binding sites found by MEME in the EBNA-2 binding regions of genes differentially 
regulated by type 1 and type 2 EBNA-2 that contribute to the enriched consensus motif. * EBNA-2 
binding sites identified by ChIP-seq analysis in the Mutu III BL line with MACS <10-7 annotated by peak 
number across the gene locus [369]. # (+) indicates the sequence motif is found in the DNA sequence provided 
and (-) indicates it is found in the reverse complement of the sequence. † The p-value of a site is computed from 
the match score of the site with the position specific scoring matrix for the enriched motif. ‡ The LMP-1 
promoter sequence from +1 to -320 was also included in the sequence set. Adapted from [378]. 
 
 
For this analysis, significant EBNA-2 binding peaks around a set of nine previously identified 
[210] differentially regulated genes (CXCR7, ADAMDEC1, IL1B, MARCKS, CCL3L3, 
HES1, ZAP70, FCRL2, IL4) and nine equally regulated genes (GCET2, CD69, BATF, 
FCRL3, CCR7, HEY1, CCL3, RUNX3, DTX1) were identified. The LMP-1 promoter region 
from +1 to -320 was included in the analysis of the differentially regulated gene regulatory 
elements (Table 4.1). Astonishingly, this unbiased motif search analysis returned only one 
significantly-enriched motif in the EBNA-2 binding sites from differentially regulated genes 
(Figure 4.25) and no enriched motifs for the equally regulated gene binding sites [378]. 
 
 
 
 
 
Figure 4.25. The enriched motif generated by MEME-ChIP analysis of EBNA-2 binding sites. Nine 
differentially regulated cell genes and the EBV LMP-1 promoter were included in the MEME-ChIP analysis to 
identify the enriched motif in EBNA-2 binding sites. The enriched motif is shown in standard form (left) and as 
the reverse complement (right). The overlapping PU.1 (ETS) and interferon regulatory factor (IRF) motifs that 
constitute an ETS-IRF composite element (EICE) are indicated. Details of the matching sites are shown in Table 
4.1. Adapted from [378]. 
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Remarkably, this unbiased analysis identified a consensus motif (Figure 4.25) that occurs 31 
times in the set of EBNA-2 binding sites analysed from differentially regulated genes, 
including one occurrence in the LMP-1 promoter (Table 4.1). The 30 examples of the 
consensus motif in the EBNA-2 binding regions of differentially regulated cell genes were 
distributed as follows: MARCKS (11), FCRL2 (4), ADAMDEC1 (1), CCL3L3 (1), HES1 
(2), ZAP70 (1), CXCR7 (10). The 10 motifs that were identified at the CXCR7 locus 
distributed across seven of the EBNA-2 binding peaks identified by ChIP-seq analysis 
(Figure 4.20 and Table 4.1). Importantly, this included the consensus motif in MACS peak 16 
of CXCR7 that was analysed as position 12 in the ChIP experiment shown in Figure 4.21. In 
fact, the GGAA motif was previously found in the LMP-1 promoter and was shown to be the 
site of PU.1 binding, to which another factor previously termed LBF4 could also bind [240] 
(Table 4.1). The consensus enriched motif consisted of overlapping binding sites for E26 
transformation-specific (ETS) TFs (e.g. PU.1 of the SPI subfamily) and interferon regulatory 
factors (IRFs). This element is termed an ETS-IRF composite element (EICE), the best 
known example of which is located in the IgL λ enhancer (5′-AAAAGGAAGTGAAACCA-
3′) [407]. These EICE motifs consist of a GGAA sequence which represents a core ETS 
binding site and an overlapping IRF site (AAXXGAAA). The enriched motif identified in our 
analysis (Figure 4.25) closely resembles the IgL λ enhancer site [407]. This EICE is enriched 
in EBNA-2 binding sites of genes that are differentially regulated by EBNA-2 types. 
Furthermore, the GGAA ETS motif is present in both the LMP-1 promoter and the MACS 
peak 16 region of CXCR7 (Table 4.1). The data therefore suggest that the reduced ability of 
type 2 EBNA-2 to activate gene expression via this EICE motif may be a key factor that leads 
to the reduced transforming ability of type 2 EBV. 
 
The results presented in this chapter indicate that EBNA-2 regulation of the differentially 
regulated cell promoters is likely to be similar to that of LMP-1 and involve regulation 
through an EICE motif that includes a binding site for ETS family members such as PU.1 and 
IRF proteins. The greater binding of type 1 EBNA-2 at specific gene regulatory elements and 
interaction with cell factors that may mediate increased binding is likely to play a role in the 
increased expression of these genes and superior growth of cells containing type 1 EBNA-2 
compared to the type 2 protein. This is also likely to involve aspartate-442 as it at least 
partially rescues type 1-like binding of type 2 EBNA-2 at EBNA-2 sites of differentially 
regulated genes that are enriched for the EICE motif. Although PU.1 is able to bind the PU.1 
site found in the LMP-1 promoter [240], there is no direct evidence that PU.1 is the cell 
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factor which mediates EBNA-2 binding at cell genes with motifs similar to the one present in 
the LMP-1 promoter. It is possible that EBNA-2 interacts directly with PU.1 since a GST-
type 1 EBNA-2 fragment (amino acids 310-376) was found to bind to in vitro translated 
mouse PU.1 and was also able to deplete PU.1 from a human B cell extract [240]. However, 
the 310-376aa region (from type 1 EBNA-2) was not required in the mutant EBNA-2 
EREB2.5 growth assays (see section 3.2.5.2, Figure 3.14). This region, whether type 1 or 
type 2 in sequence (in type 1 and type 2 S442D EBNA-2 proteins respectively), mediated the 
same growth-promoting phenotype in the EREB2.5 trans-complementation assay (Figure 
3.14). If PU.1 binding was only dependent on this region (amino acids 310-376 of type 1 
EBNA-2), then EBNA-2-PU.1 association would likely be equal in all EBNA-2 types. 
However, other regions of EBNA-2 such as the TAD that includes aspartate-442 in type 1 
EBNA-2 could indirectly contribute to the interaction with PU.1. 
 
Aspartate-442 could also contribute to the binding of type 1 EBNA-2 to another factor that 
can also activate gene expression via EBNA-2 binding sites such as an IRF protein that binds 
to the composite element, or another member of the ETS family. This would be unsurprising 
since some protein interactions of EBNA-2 have already been mapped to the TAD region as 
described above (see section 3.3). These include amino acids 448-471 which mediate the 
interaction between type 1 EBNA-2 and the Tfb1/p62 subunit of TFIIH [256, 388] and W458 
of B95-8 type 1 EBNA-2 (equivalent to W454 of the W91 isolate [230]) which is also 
required for interaction with p300 and PCAF [255]. It is also possible that the presence of an 
additional acidic amino acid in the TAD of type 1 EBNA-2 could contribute to the 
characteristic relatively non-specific protein-protein interaction function of TADs. This 
would result in the stabilisation of the assembly of transcription complexes with coactivators 
such as histone acetyl transferases (HATs) and the transcription machinery. The specific 
involvement of the EICE motif identified (Figure 4.25) could reflect a particular need for the 
binding and assembly of a stable ETS/IRF complex at the LMP-1 promoter and at cell genes 
that are activated less well by type 2 EBNA-2 which lacks the aspartate-442 residue. PU.1 is 
known to be an important pioneer factor in opening up chromatin sites [408], so there may be 
specific features of the chromatin around these genes that would explain a higher dependency 
on the factors that associate with EICEs.  
 
It would be interesting to mutate the EICE motifs identified in some of the cell gene 
promoters to test directly whether they mediate the differential regulation of gene expression 
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observed by type 1 and type 2 EBNA-2. This might be done using new clustered regularly 
interspaced short palindromic repeat (CRISPR) or transcription activator-like effector 
nuclease (TALEN) techniques [409]. The fact that a large number of EBNA-2 binding sites 
have been identified at many of the target gene loci and the strong possibility of redundancy 
in these elements made these techniques too lengthy and technically challenging to undertake 
and perform in this study. Nevertheless, the data presented in this chapter indicate that the 
greater ability of type 1 EBNA-2 to activate gene expression via an ETS-IRF composite 
element (EICE) may play a key role in the greater transforming ability of type 1 EBV, 
compared to type 2 strains. 
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5 Final discussion: summary and future work 
 
This study further investigated the mechanism which underlies the functional difference 
between type 1 and type 2 EBV, namely the greater transforming ability in vitro of type 1 
EBV strains compared to type 2. Previous reports in the laboratory [210, 211] showed that 
this greater transforming activity of type 1 EBV correlated with a stronger and more rapid 
induction of viral LMP-1 and cellular CXCR7, genes that are both required for EBV-LCL 
growth, during infection of primary B cells with EBV-BAC recombinant viruses and also 
confirmed in oestrogen-regulated BL cell lines. A functional assay which can distinguish 
between type 1 and type 2 EBNA-2-induced EBV-LCL proliferation based on the EREB2.5 
cell line was used to determine that the C-terminal region of type 1 EBNA-2 was sufficient to 
complement type 2 deficiency [211], despite sequence differences between EBNA-2 types 
being more common in the N-terminal region of the protein. Although the RG, CR7 and TAD 
domains of type 1 EBNA-2 were previously shown to be the minimum sequences required 
for this phenotype, this study has revealed the key role of aspartate-442 of type 1 EBNA-2 in 
the differential regulation of EBNA-2 target genes. Remarkably, a single S442D point 
mutation in the TAD of type 2 EBNA-2 was able to rescue the proliferative effects of the 
protein in EBV-LCLs and induced type 1-like levels of LMP-1 and CXCR7, whereas the 
reverse mutation in the type 1 protein had the opposite effect. It was unclear why only 
specific promoters of EBNA-2-regulated genes were affected and so the mechanism of 
differential regulation of EBNA-2 target genes was investigated using a ChIP-based 
approach. Type 1 EBNA-2 was found to interact more strongly with specific promoter 
elements of the differentially regulated genes LMP-1 and CXCR7 compared to the type 2 
protein. The S442D point mutation in type 2 EBNA-2 was shown to partially restore the 
reduced gene-specific binding observed for type 2 EBNA-2 at some of these promoter 
elements. These sites were analysed further to identify motifs that might allow type 1 EBNA-
2 and aspartate-442 to mediate a stronger interaction at the chromatin level. An ETS-IRF 
composite element (EICE) was found in the EBNA-2 binding site for LMP-1 and at the 
region of the CXCR7 locus that had the greatest ChIP-seq peak of EBNA-2 binding in an 
LCL. The results presented in this thesis indicate that EBNA-2-mediated regulation of 
differentially regulated cell promoters is likely to be similar to that of LMP-1 and involve 
regulation via a motif that includes a binding site for ETS family members such as PU.1 and 
IRF proteins. Therefore, a combination of the higher TAD activity mediated by aspartate-442 
240 
 
in type 1 EBNA-2, the greater binding of type 1 EBNA-2 at specific gene regulatory elements 
and interaction with cell factors that may mediate increased EBNA-2-binding at those 
specific elements is likely to result in the increased expression of the differentially regulated 
genes and superior growth and transformation of B cells with type 1 EBNA-2. 
 
The finding that type 2 EBNA-2 cannot restore growth to oestrogen-depleted EREB2.5 cells 
is surprising since type 2 EBV strains are able to establish LCLs upon primary B cell 
infection eventually, although with very low efficiency [211, 363]. In previous infection 
studies which demonstrated the difference in transforming phenotype between type 1 and 
type 2 EBV, cell dilution was shown to be a critical factor for wildtype and recombinant 
type 2 EBNA-2 viruses to growth-transform B cells [132, 363]. However, cell concentration 
did not affect the null growth phenotype of type 2 EBNA-2 in experiments performed with 
EREB2.5 cells in this laboratory [210]. Therefore, the difference between the growth 
phenotype of primary B cells infected with type 2 EBV and the null growth of EREB2.5 cells 
with type 2 EBNA-2 could be attributed to additional factors involved in the interaction 
between the B cell and the virus during the infection process. These could affect events such 
as viral cell attachment, gp350/220-CD21 binding-induced signalling, viral cell entry, B cell 
activation, cell cycle entry, EBV genome circularisation, EBV genome amplification in 
infected cells, promoter switching and clonal expansion finally resulting in the immortalised 
state of the LCL [12]. These early events of the initial stages of EBV infection may act as 
compensatory mechanisms for the inferior ability of type 2 EBNA-2 to induce proliferation 
of B cells. For example, most established LCLs usually express low levels of a single isoform 
of EBNA-LP, whereas several EBNA-LP species are expressed and at very high levels during 
initial EBV infection of naive B cells which may complement the low transactivation activity 
of type 2 EBNA-2. Furthermore, LCL outgrowth following initial infection of resting B cells 
by EBV is a stochastic event such that only a few cells are selected and clonally expanded if 
the genes required for B cell proliferation (LMP-1, CXCR7) are expressed at a high enough 
level. It seems likely therefore that the slower and lower type 2 EBNA-2-driven induction of 
both LMP-1 and CXCR7 during the initial stages of infection results in the lower 
transforming activity of type 2 EBV strains. However, once a few type 2 EBV-infected cells 
eventually express the required level of LMP-1 and CXCR7, they are selected and amplified 
in order to establish an LCL. This hypothesis is supported by the fact that type 1 and type 2 
EBV-LCLs were reported to express approximately similar levels of LMP-1 and CXCR7 
[210]. 
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Strain variability comparable to the EBV EBNA-2 gene is also found in other herpesviruses. 
For example, the KSHV K1 gene encodes a transforming signalling protein functionally 
comparable to LMP-1 of EBV and has a very divergent sequence when compared to other 
regions of the KSHV genome. Similarly to EBNA-2, 4 major subtypes of KSHV (A, B, C 
and D) have been characterised and are defined by their K1 gene sequence [410, 411]. Unlike 
EBNA-2 alleles however, the K1 gene of KSHV shows high divergence even among 
individual isolates of the same subtype and at least 13 variants have been identified [412]. 
Almost 85% of nucleotide changes are non-synonymous in K1 variants indicating a highly 
selective biological mechanism at the protein level which is likely to be host immune 
pressure that drives KSHV subtype evolution. Interestingly, KSHV subtypes also display 
specific patterns of geographical distribution and subtype B is almost exclusively found in 
Central and Southern Africa similar to type 2 EBV [413]. In contrast to EBV however, 
phenotypic differences between KSHV subtypes have not been reported despite the important 
role of K1 in cell transformation [33, 410].  
 
The sequence variation of the Stp gene also defines the subtypes (A, B or C) of HVS. Strains 
of subgroups A and C can immortalise common marmoset lymphocytes but in vitro assays 
have shown that subgroup B strains are immortalisation-incompetent [414]. Stp can therefore 
be considered as similar to EBV EBNA-2 since HVS viral subtype and in vitro transforming 
phenotype are defined by its sequence polymorphism. Similarly to KSHV K1 but in contrast 
to EBV EBNA-2, the HVS type 2 Stp gene shows a considerable amount of heterogeneity at 
the amino acid level (up to 15%) among different isolates [414]. KSHV K1 and HVS Stp 
genes are found at the 5 end of their respective viral genomes and in close proximity to 
terminal repeats where mutations by homologous recombination occur frequently due to the 
presence of repetitive sequences [33]. There is also clear evidence for inter-typic 
recombination of EBV based on polymorphisms distributed along the EBV genome [415-
417]. In fact, a comparison of the EBV B95-8, GD1 and AG876 sequences led to a 
theoretical proposal of the minimum number of recombination events that would be required 
to generate the current genome arrangements of those virus strains [418]. Although points of 
variation within type 1 EBNA-2 have been studied extensively [344], recombination events 
within EBNA-2 are prevented since the DNA sequences of type 1 and type 2 EBNA-2 DNA 
sequence are sufficiently different. Therefore, it is not necessary for all amino acid 
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differences of EBNA-2 to be selected for to maintain characteristic type 1 and type 2 EBNA-
2 sequences and a point mutation (e.g. S442D) would persist in the population. 
 
The biological significance of type 1 and type 2 EBV however is still not understood. Similar 
to type 1 and type 2 EBV, two viral types of rhesus lymphocryptoviruses (LCVs) have been 
identified. The genetic polymorphism in the EBNA-2 genes of rhesus LCV strains and type 1 
and type 2 EBV are very comparable (approximately 40% and 56% amino acid identity). 
Furthermore, the first two LCV isolates were from B cell lymphoma biopsies of rhesus 
monkeys indicating the oncogenic potential of LCV types. In fact, one cell line derived from 
the type 2 rhesus LCV strain grew very slowly in cell culture and its viral progeny displayed 
very poor immortalisation efficiency of rhesus monkey primary B cells, similar to the 
phenotype of type 2 EBV [419]. It is unknown whether this in vitro growth phenotype is 
indicative of type 2 LCV strains since only a single isolate of each type was compared in the 
analysis performed. Moreover, the type 2 rhesus LCV isolate grown in cell culture also had a 
deletion of the EBNA-2 C-terminus and its reduced in vitro growth phenotype could be 
explained by the lack of an EBNA-2 NLS rather than a growth-promoting deficiency of the 
type 2 EBNA-2 gene sequence. Nevertheless, type 1 and type 2 EBV strains in humans and 
LCV strains in non-human primates have evolved similarly, suggesting that type-specific 
EBNA-2 polymorphisms are not random and that each allele confers a selective advantage in 
vivo. There appears to be a common selective pressure in human and non-human primate 
hosts therefore for the evolution of two distinct EBV/LCV types. Since EBV has also co-
evolved with its host like all herpesviruses, a host-specific selective pressure is likely to be 
driving the evolution of the two viral subtypes, as suggested in the evolution of KSHV 
subtypes described above. Candidate host factors that might provide this selection pressure 
include SNPs in host genes, HLA-DR alleles and MHC selection, co-infection with other 
pathogens, nutrition and immune system status. 
 
Factors that affect in vivo selection of viral variants could include immune surveillance which 
would be expected to correlate with MHC type since functional epitopes vary according to 
presentation on MHC. Since predominant MHC types differ geographically and between 
racial groups, this could play a major role in EBV variation worldwide. Many epitopes for 
cytotoxic T lymphocyte (CTL) surveillance have been mapped in EBV antigens and 
correlated with MHC type and there is already some clear evidence for epitope selection 
based on immune surveillance [338, 420-426]. Some evidence also suggests that EBV 
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variation might be important for the immune detection of the virus although this has not yet 
been clearly linked to tumourigenesis in vivo so far. The EBNA-3 proteins are the major 
determinant of MHC class I CTL responses [427] and, in individuals with the HLA A11 
haplotype, CTL responses are predominantly directed against two specific epitopes in EBNA-
3B (amino acid sequences 399-408 and 416-424 which are both variable in type 1 and type 2 
sequences) [336, 428, 429]. Interestingly, the A11 haplotype is rare in Caucasians and 
African populations and EBNA-3B epitopes are conserved in the viral strains of these 
specific populations. In Southern China and Papua New Guinea, however, where the A11 
haplotype is common, the resident EBV strains lack the immunodominant A11-restricted 
CTL epitopes [429]. An alanine-to-serine mutation (from type 1 B95-8-specific amino acid to 
the residue found in type 2 AG876 EBV) in the first EBNA-3B epitope (amino acids 399-
408) causes a loss of the immunodominant epitope. This suggests that viral strains that have a 
type 2 sequence in the EBNA-3B allele might become dominant within a specific population 
as a consequence of immune pressure [336, 429]. It is also possible that EBNA-2 allele 
variability has evolved in order to mimic or avoid a particular HLA-DR repertoire which 
might allow preferential viral entry and survival in genetically-appropriate host cells only. In 
fact, EBNA-2 can also elicit EBV-specific CTL responses [427, 430]. One report also 
showed that cytotoxic T cells prepared from type 1 virus carriers are able to lyse both type 1-
EBV LCLs and type 2 EBV-transformed target cells in vitro equally well. This indicates that 
the amino acid sequence differences between the EBNA-2 proteins are not the dominant 
antigen for induction of EBV-specific CTL responses [430]. In contrast, another study 
reported that EBV-specific T cell clones obtained from type 1 EBV-seropositive donors were 
able to kill only type 1, but not type 2, autologous targets efficiently in vitro [431] suggesting 
an ability to discriminate type 1 of type 2 EBV-transformed B lymphocytes. It is therefore not 
yet fully understood whether variation between type 1 and type 2 EBNA-2 influences the 
outcome of host CTL responses. 
 
So what might be the selective advantage that type 2 EBNA-2 confers to type 2 EBV strains? 
Another explanation for the persistence of type 2 EBV despite its lower transformation 
efficiency of B cells may lie in its ability to infect other cell types. It is not uncommon for 
herpesviruses of the same genus or species to differ with respect to their cell tropisms. The 
African (A) and non-African (B) subgroups of HHV-6 are classified based on sequence 
variability of the nuclear regulatory protein IE1 (63% nucleotide identity) and the 
glycoproteins gB and gH [432, 433], and are now considered as distinct herpesvirus species 
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[434]. These HHV-6 subgroups are closely related yet distinct from both biological and 
molecular aspects. They differ based on cell and host signalling pathway interactions, DNA 
sequence, epidemiology and cell tropism [433, 435, 436]. In fact, HHV-6 A strains are much 
more efficient than subtype B strains at infecting cytotoxic effector cells [437]. Although the 
main target for EBV infection is B lymphocytes, it is known that EBV can also infect 
epithelial, T, NK and smooth muscle cells. It has very recently been reported that type 2 EBV 
is able to infect T cells and perhaps more efficiently than type 1 strains [personal 
communication, R Rochford]. Therefore, some of the sequence differences between type 1 
and type 2 EBV may relate to phenotypes that are not apparent in the B cell system studied in 
this thesis. However, this remarkable difference in B cell growth transformation efficiency 
remains the clearest example of functional variation in Epstein-Barr virus types. 
 
The peculiar geographical distribution of type 2 EBV can also be used to hypothesise why 
type 2 strains have evolved and how they establish a persistent infection despite their poor 
transformation ability. Type 2 EBV is only widespread in specific parts of the world (e.g. 
sub-Saharan Africa) which suggests an additional factor in these areas that aids successful 
type 2 EBV infection and persistence. Interestingly, type 2 EBV is detected where 
holoendemic malaria, a mosquito-borne disease caused by the parasite Plasmodium 
falciparum, is also common [438]. Furthermore, P. falciparum is highly prevalent in children 
below the age of 5 [438] when primary EBV infection is also most likely to occur. EBV and 
P. falciparum malaria have been identified as co-factors in endemic Burkitt’s lymphoma 
(eBL) aetiology and they are believed to interact at the B cell level thus contributing to BL 
pathogenesis [200]. It has been reported that chronic P. falciparum malaria infection induces 
a constant stimulation of B cells thus promoting their infection by EBV [200]. Several studies 
have also revealed the role of P. falciparum as a B cell mitogen and promoting in vitro 
proliferation of B cells [439-444]. Furthermore, when cultured P. falciparum extracts are 
administered to peripheral blood lymphocytes ex vivo, the spontaneous establishment of 
EBV-LCLs is enhanced [444]. In addition, during an episode of acute P. falciparum malaria 
in children, the number of EBV-infected B cells increases [445]. Other epidemiological data 
also show that, in the Western world, type 2 EBV strains are detected at much higher 
frequency in HIV-positive patients (approximately 30%) than in healthy carriers 
(approximately 3%) [345, 355, 356]. There is also some evidence to suggest that type 1 EBV 
strains are better at transforming resting B cells than activated B cells [446]. Taken together, 
these observations suggest that other microbial agents present during EBV infection may 
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have an effect on EBV-induced B cell transformation. It is possible that type 2 EBV is more 
successful at infecting host cells only in the presence of other microbial infections when 
patients have a compromised immune system and the B cell pool is chronically stimulated. 
Therefore, a difference in EBNA-2 could allow persistence of type 2 EBV in populations 
with a chronically-activated immune system. The ability of type 2 EBV strains to infect 
activated B cells in vitro could be investigated in future work and this would help to address 
the significance of EBV types in vivo. 
 
Other work that could be carried out in the future to further investigate the mechanism of 
differential regulation of target genes important for LCL proliferation by type 1 and type 2 
EBNA-2 could include extensive mapping of the LMP-1 promoter binding sites required for 
EBNA-2 regulation. The expression of a luciferase reporter gene under the control of the 
LMP-1 promoter in the Daudi:pHEBoMT-EBNA-2 cell lines could be assayed and 
transactivation of the LMP-1 promoter, altered at TF and cofactor binding sites, measured to 
determine the differential effects of EBNA-2 proteins. Cofactors and/or binding sites 
important for the differential regulation of LMP-1 could then be identified and applied to 
experiments devised to investigate the regulation of the CXCR7 promoter. Since there are 
EBNA-2 binding sites at the CXCR7 gene that span approximately 80 kb, it would not be 
possible to carry out reporter assays for the whole CXCR7 locus. Instead, specific binding 
sites (e.g. EICE motifs) similar to those demonstrated as being important for differential 
regulation of the LMP-1 promoter could be individually mutated to test whether they mediate 
differential regulation by EBNA-2 types. This could be done using CRISPR or TALEN 
techniques [409] as described above. Biotinylated oligonucleotide pulldowns could also be 
performed using short sequences of the LMP-1 promoter (and of other differentially regulated 
genes). Labelled DNA would be captured with magnetic streptavidin beads and then 
incubated with extracts of induced type 1, type 2 or type 2 S442D Daudi:pHEBoMT-EBNA-
2 cells. The binding of specific EBNA-2 proteins to cofactor binding sites and EICE motifs 
could then be tested by Western blotting of the eluted samples. It is envisaged that type 1 
EBNA-2 binds to both RBP-Jκ and PU.1 (or other ETS/IRF) sites whereas the type 2 protein 
can only bind to RBP-Jκ. If the PU.1 binding motif (or EICE) of a gene promoter is deleted, 
type 1 EBNA-2 would also only interact with the promoter at the RBP-Jκ site. It would be 
interesting to investigate whether, in this scenario, type 1 and type 2 EBNA-2 induce equal 
expression of the target gene. 
246 
 
Since the EBNA-2 TAD is thought to facilitate transcriptional transactivation by acting as an 
adaptor molecule, a combination of co-immunoprecipitation (CoIP) and electrophoretic shift 
mobility (EMSA) assays could be used to investigate the proteins and transcription factors 
that it interacts with. If a specific TF family or binding motif from further promoter analysis 
is determined, this would make the search for proteins that associate with EBNA-2 a less 
lengthy undertaking. Specific antibodies for ETS and IRF proteins could be used to identify 
which proteins may act as cofactors for EBNA-2. These techniques could also be used to 
further probe and map the interaction between EBNA-2 and EBNA-LP and to establish 
whether aspartate-442 is required. Further structural determination of the EBNA-2 protein, 
not just the TAD [388], by NMR spectroscopy or X-ray crystallography could demonstrate 
the functions of other EBNA-2 domains in protein interactions. 
 
The ChIP assay used in this study was a powerful tool to compare the binding of type 1, type 
2 and type 2 S442D EBNA-2 at specific promoter elements. The experiment was performed 
in a way that was reflective of the initial EBNA-2 binding events when EBNA-2 is first 
expressed after EBV infection. It would be interesting to perform a time course experiment to 
determine whether type 2 EBNA-2 binding increases the longer EBNA-2 is induced for. This 
could be used to test whether the binding of type 2 EBNA-2 also reaches type 1-like levels at 
promoter sites of differentially regulated genes since expression of LMP-1 eventually reaches 
steady-state levels [210, 211]. A ChIP-seq experiment with cells expressing type 2 EBNA-2 
would also identify the binding of the type 2 protein across the whole genome which could 
then be compared directly against type 1 EBNA-2. 
 
Finally, the effects of the S442D mutation in a type 2 EBV virus have yet to be determined. A 
recombinant EBV-BAC virus expressing a type 2 S442D EBNA-2 protein might be 
generated in future work to test its affect on the in vivo properties of B cell infection, 
immortalisation and LCL establishment. Furthermore, previous infection studies performed 
in this laboratory [211] have used a recombinant type 1 EBV-BAC that expressed a type 2 
EBNA-2 protein. A type 2 EBV-BAC could be produced from AG876 EBV and used in 
primary B lymphocyte infection in order to compare the in vivo properties and functional 
differences of wildtype type 1 and type 2 EBV. 
  
In summary, this thesis has shown that by changing a single amino acid from serine in type 2 
EBNA-2 to the aspartate found in type 1 EBNA-2 at the corresponding position (S442D) 
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confers a type 1 growth phenotype in the EREB2.5-LCL trans-complementation growth 
assay. This amino acid is located in the TAD of type 1 EBNA-2 and results in a greater and 
more rapid induction of the differentially regulated genes, viral LMP-1 and cellular CXCR7. 
ChIP assays were also used to show that aspartate-442 confers increased binding to a specific 
sequence element that is enriched in the EBNA-2 binding regions of the LMP-1 promoter and 
cell promoters which are differentially regulated by the EBNA-2 types but not in EBNA-2 
binding sites of genes that are regulated equally. This motif includes a PU.1 (Spi-1) and IRF 
binding sequence and closely resembles the ETS-IRF composite element (EICE) in the 
IgL() gene enhancer and a similar sequence that mediates PU.1 activation of the LMP-1 
promoter. In combination with the higher TAD activity mediated by aspartate-442, the 
greater binding of type 1 EBNA-2 at these differentially regulated gene loci and a potential 
influence on cell factors that interact with EICEs that may mediate the greater binding is 
likely to determine the increased expression of these genes and superior growth of cells 
infected with viruses containing type 1 EBNA-2. 
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